

ABILIFY MYCITE

Products Affected

- Abilify Mycite Maintenance Kit
- Abilify Mycite Starter Kit

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	The following criteria applies to members who newly start on the drug: documentation of the medical necessity of tracking compliance with the prescribed treatment regimen.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

ACTEMRA

Products Affected

- Actemra INJ 162MG/0.9ML
- Actemra Actpen

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Rheumatoid arthritis (RA) renewal: improved functioning and/or improvement in tender joint count and swollen joint count. 2) Juvenile idiopathic arthritis (JIA) renewal: improved functioning and/or greater improvement in tender joint count and swollen joint count. 3) Lung disease with systemic sclerosis, renewal: documentation of a reduction in decline in pulmonary function.
Age Restrictions	N/A
Prescriber Restrictions	RA, JIA, temporal arteritis: rheumatologist. Lung disease: pulmonologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	RA initial: failure of methotrexate and at least one other DMARD such as leflunomide, sulfasalazine, or hydroxychloroquine. Polyarticular juvenile idiopathic arthritis initial: failure of an 8 week trial of methotrexate.

ACTHAR HP

Products Affected

- Acthar

- Cortrophin INJ 80UNIT/ML

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Use of corticotropin intravenously. Corticotropin should not be used in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or active peptic ulcer disease, congestive heart failure, uncontrolled hypertension, or sensitivity to proteins of porcine origin. Corticotropin is contraindicated in patients under the age of 2 with suspected congenital infections and for patients who also have adrenocortical insufficiency or adrenocortical hyperfunction.
Required Medical Information	Medical record documentation of one of the following conditions: 1) Infantile spasms, 2) Acute exacerbation of multiple sclerosis, 3) Exacerbation of rheumatic disorders including psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, 4) Exacerbation of or maintenance for collagen diseases including systemic lupus erythematosus, systemic dermatomyositis, 5) Dermatologic diseases including severe erythema multiforme, Stevens-Johnson Syndrome, 6) Allergic states such as serum sickness, 7) Ophthalmic diseases including keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation, 7) Respiratory diseases such as symptomatic sarcoidosis or 8) Edematous condition from nephrotic syndrome or lupus erythematosus.
Age Restrictions	For infantile spasms: age less than 2 years.
Prescriber Restrictions	N/A
Coverage Duration	Infantile spasms: until two years of age. All others: 1 month.

Other Criteria	For steroid responsive conditions, conditions number 2 to 7 listed in the Required Medical Information section: medical record documentation of failure of corticosteroid therapy in the last 30 days or reason why corticosteroids cannot be used.
-----------------------	---

ACTIMMUNE

Products Affected

- Actimmune INJ 100MCG/0.5ML

PA Criteria	Criteria Details
Indications	All FDA-approved Indications, Some Medically accepted Indications.
Off-Label Uses	T-cell lymphoma
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	Prior authorization criteria does not apply to members already established on Actimmune for the treatment of T-cell lymphoma. 1. The use of Actimmune for T-cell lymphoma must be supported by Micromedex, AHFS-Drug Information, NCCN Compendium, Clinical Pharmacology, Lexi-Drugs, or acceptable medical journals.

ADALIMUMAB

Products Affected

- Adalimumab-aaty 1-pen Kit
- Adalimumab-aaty 2-pen Kit
- Adalimumab-aaty 2-syringe Kit
- Adalimumab-aaty Cd/uc/hs Starter
- Adalimumab-adbm
- Adalimumab-adbm Crohns/uc/hs Starter
- Adalimumab-adbm Psoriasis/uveitis Starter
- Adalimumab-adbm Starter Package For Crohns Disease/uc/hs
- Adalimumab-adbm Starter Package For Psoriasis/uveitis
- Humira INJ 10MG/0.1ML, 20MG/0.2ML, 40MG/0.4ML, 40MG/0.8ML
- Humira Pediatric Crohns Disease Starter Pack INJ 0, 80MG/0.8ML
- Humira Pen
- Humira Pen-cd/uc/hs Starter
- Humira Pen-pediatric Uc Starter Pack
- Humira Pen-ps/uv Starter

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A

Required Medical Information	1) Crohn's disease (CD) renewal: a decrease in symptoms, reduction in enterocutaneous fistulas or clinical remission. 2) Rheumatoid arthritis (RA) renewal: improved functioning and/or improvement in tender joint count and swollen joint count. 3) Psoriasis with arthropathy (PsA) renewal: improved functioning and/or greater improvement in tender joint count and swollen joint count. 4) Ankylosing spondylitis (AS) renewal: improved functioning and/or signs and symptoms of AS. 5) Juvenile idiopathic arthritis (JIA) renewal: improved functioning and/or greater improvement in tender joint count and swollen joint count. 6) Plaque psoriasis (PsO) initial: involvement of at least 3% of body surface area or hand, foot, face, scalp, or genital involvement. PsO renewal: improvement in affected BSA, plaque severity and/or functioning. 7) Ulcerative Colitis (UC) renewal: medical record documentation of treatment response such as decrease in bloody stools per day, elimination of signs of toxicity, or clinical remission. 8) Hidradenitis suppurativa (HS) initial: moderate to severe disease evident by documentation of Hurley Stage II or III and at least 3 abscesses or inflammatory nodules. HS renewal: medical record documentation of a reduction in nodules or abscesses. 9) Uveitis initial: documentation of non-infectious, intermediate, posterior or panuveitis. Renewal: documentation that treatment response is being monitored for the following development of new inflammatory chorioretinal and/or inflammatory retinal vascular lesions, anterior chamber cell grade or vitreous haze, or visual acuity.
Age Restrictions	N/A
Prescriber Restrictions	Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis: rheumatologist. Psoriatic arthritis: dermatologist or rheumatologist. Plaque psoriasis or hidradenitis suppurativa: dermatologist. Crohn's disease and ulcerative colitis: Gastroenterologist. Uveitis: Ophthalmologist
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	RA initial, failure of one of the following: methotrexate, leflunomide, sulfasalazine, or hydroxychloroquine. AS initial: failure of one non-steroidal anti-inflammatory drug such as meloxicam, ibuprofen, naproxen or diclofenac. JIA initial: failure of an 8 week trial of methotrexate. PsO Initial: failure of 1) one topical agent such as a corticosteroid (i.e. betamethasone or clobetasol), calcipotriene, tacrolimus, or tazarotene (requires prior authorization), and 2) methotrexate or cyclosporine.

ADBRY

Products Affected

- Adbry

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Atopic dermatitis initial (AD): body surface area involvement of at least 10% at baseline. 2) AD renewal criteria: medical record documentation of a positive treatment response such as a reduction in body surface area involvement, improvement in itching, improvement in functional ability, reduction in the Investigator Global Assessment or Eczema Area and Severity Index from baseline.
Age Restrictions	N/A
Prescriber Restrictions	Prescribing restricted to a dermatologist, allergist, or immunologist or in consultation with.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Atopic dermatitis: failure of or contraindication to 1) one of the following very high potency topical steroids: augmented betamethasone, clobetasol or halobetasol and 2) tacrolimus ointment,

ADEMPAS

Products Affected

- Adempas

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial criteria: 1) For patients with WHO Group 4 pulmonary arterial hypertension - chronic thromboembolic pulmonary arterial hypertension: failure of surgical treatment or would not be a candidate for surgical treatment.
Age Restrictions	N/A
Prescriber Restrictions	Pulmonologist or cardiologist
Coverage Duration	Lifetime
Other Criteria	Initial criteria for patients with WHO Group 1 pulmonary arterial hypertension: Medical record documentation of failure of or would be a poor candidate for the following: 1) A phosphodiesterase type 5 (PDE-5) inhibitor such as sildenafil or tadalafil and 2) An endothelin receptor antagonist such as ambrisentan or bosentan.

AGAMREE

Products Affected

- Agamree

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: genetic testing results confirming a diagnosis of Duchenne muscular dystrophy. Renewal criteria: documentation of a positive treatment response (e.g. pulmonary function, muscle strength, functional ability, walk tests).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or a specialist in Duchenne Muscular Dystrophy or neuromuscular disorders.
Coverage Duration	12 months
Other Criteria	Failure of prednisone and deflazacort (requires PA).

AIMOVIG

Products Affected

- Aimovig

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial criteria: 1) Episodic migraine: 4-14 headache days per month, 2) Chronic migraines: 15 or more headache days per month with at least 8 days of migraines for 3 months. Migraine renewal criteria: documentation of treatment response including decrease in the number of migraine days, less migraine episodes, decreased abortive medication usage, or emergency room visits related to migraine.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: Lifetime
Other Criteria	1) Episodic Migraine prophylaxis and chronic migraine prophylaxis: failure of propranolol and topiramate.

ALDURAZYME

Products Affected

- Aldurazyme

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of 1) Diagnostic confirmation by presence of glycosaminoglycans (GAG) in the urine, deficiency in a-L-iduronidase enzyme activity, or genetic testing, and 2) Objective, measurable treatment goals. Renewal: Medical record documentation of stabilization of disease progression, such as improvement in percent predicted FVC, improvement in 6-minute walk test, reduction in urinary GAG levels, or reduction in liver size.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: Lifetime.
Other Criteria	Dosing consistent with product label: 0.58 mg/kg IV once weekly.

ALOSETRON

Products Affected

- Alosetron Hydrochloride

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	1) Constipation. 2) Intestinal obstruction, stricture, toxic megacolon, GI perforation and/or adhesions. 3) Ischemic colitis, impaired intestinal circulation. 4) Severe hepatic impairment. 5) Diverticulitis. 6) Hypercoaguable state. 6) Thrombophlebitis. 7) Crohn's disease or ulcerative colitis. 8) Concomitant use with apomorphine or fluvoxamine.
Required Medical Information	Initial: Medical record documentation of predominant symptom is severe diarrhea lasting at least 6 months and defined as frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, or disability or restriction of daily activities due to IBS. Renewal: Medical record documentation of a significant reduction in diarrhea frequency and abdominal pain and/or improvement in quality of life during the 8 week trial.
Age Restrictions	Age at least 18 years.
Prescriber Restrictions	N/A
Coverage Duration	Initial: 8 weeks. Renewal: Lifetime.
Other Criteria	Failure of loperamide and dicyclomine.

ALYFTREK

Products Affected

- Alyftrek

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of a diagnosis of cystic fibrosis with at least one F508del mutation or has a mutation that is responsive to the drug confirmed using an FDA-cleared cystic fibrosis mutation test. Renewal: Medical record documentation of treatment response such as an improvement in FEV1, reduction in pulmonary exacerbation, or improvement in respiratory symptoms.
Age Restrictions	6 years of age and older.
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Initial: Trial of Trikafta in patients with at least one F508del mutation or a Trikafta-responsive mutation.

AMBRISENTAN

Products Affected

- Ambrisentan

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Pregnancy
Required Medical Information	Documentation of WHO Class II-IV.
Age Restrictions	N/A
Prescriber Restrictions	Pulmonologist or Cardiologist
Coverage Duration	Lifetime
Other Criteria	N/A

APOKYN

Products Affected

- Apomorphine Hydrochloride INJ

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Renewal: Documentation that the patient's off time has been reduced with apomorphine.
Age Restrictions	N/A
Prescriber Restrictions	Neurologist
Coverage Duration	Initial: 3 months. Renewal: Lifetime.
Other Criteria	Initial: Documentation of failure of maximum tolerable doses of oral levodopa/carbidopa and one of the following: selegiline, ropinirole, pramipexole, tolcapone and entacapone.

AQNEURSA

Products Affected

- Aqneursa

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: a) confirmation of a diagnosis of Niemann-Pick disease type C (NPC) by genetic testing, b) documentation of neurologic symptoms due to NPC, and c) documentation of weight at least 15kg.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist or neurologist.
Coverage Duration	Lifetime.
Other Criteria	N/A

ARALAST

Products Affected

- Aralast Np INJ 1000MG, 500MG

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) documented ZZ or Z/null AAT deficiency and 2) AAT serum level less than or equal to 11 micromoles/L or 50mg/dL and 3) moderate emphysema and/or FEV1 less than 80% and 4) the provider has outlined specific, measurable treatment goals such as slowing of FEV1 decline or lack of disease progression. Renewal: documentation patient is meeting treatment goals such as slowing FEV1 decline or lack of disease progression.
Age Restrictions	N/A
Prescriber Restrictions	Pulmonologist
Coverage Duration	Initial: 3 months. Renewal: 12 months.
Other Criteria	N/A

ARCALYST

Products Affected

- Arcalyst

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Deficiency of Interleukin-1 Receptor Antagonist (DIRA) renewal: documentation of positive clinical response, such as low disease activity or improvement in signs and symptoms. 2) Recurrent pericarditis, renewal: documentation that pericarditis has not recurred. 3) All others indications: Renewal criteria: Medical record documentation of significant improvements in signs and symptoms.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 3 months. Renewal: 12 months.
Other Criteria	For Deficiency of Interleukin-1 Receptor Antagonist (DIRA): failure of Kineret (requires PA).

ARIKAYCE

Products Affected

- Arikayce

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Documentation that Arikayce will be used as part of combination antibacterial drug regimen, and either positive sputum culture or lack of clinical signs of improvement (such as anemia, fever, or lack of reduction in nodule size).
Age Restrictions	Age at least 18 years
Prescriber Restrictions	Infectious disease specialist, HIV specialist or pulmonologist
Coverage Duration	6 months
Other Criteria	Failure of at least 6 consecutive months of a multidrug regimen (such as combination of the following agents: azithromycin or clarithromycin, ethambutol, rifabutin, clofazimine).

ARISTADA

Products Affected

- Aristada
- Aristada Initio

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	The following criteria applies to members who newly start on the drug: documentation that the patient is currently taking oral Abilify and prescriber wishes to switch to the injection to improve compliance.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

ARMODAFINIL

Products Affected

- Armodafinil

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Renewal: documentation of significant improvement in daytime sleepiness and functioning.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 3 months. Renewal: lifetime.
Other Criteria	N/A

ASTAGRAF

Products Affected

- Astagraf XL

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	To prevent or treat an organ transplant rejection, Part B versus D determination will be made to determine coverage. If the drug is to be covered by Part D and the patient is newly started on Astagraf, failure of tacrolimus immediate release or reason why tacrolimus immediate release cannot be used is required.

ATTRUBY

Products Affected

- Attruby

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation confirming the diagnosis of either wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTRwt-CM or hATTR-CM).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist.
Coverage Duration	Lifetime
Other Criteria	N/A

AUSTEDO

Products Affected

- Austedo

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Excluded in patients with suicidality, hepatic impairment, inadequately treated depression, concomitant use of MAOIs and reserpine.
Required Medical Information	Renewal criteria: 1) For Huntington's disease (HD): medical record documentation of a clinical response such as improvement in chorea, ability to perform activities of daily living, reduction in falls, and increase in quality of life. 2) For tardive dyskinesia (TD): medical record documentation of treatment response such as a reduction in the AIMS score from baseline, improvement in involuntary movement, or improvement in functional ability
Age Restrictions	For tardive dyskinesia (TD): 18 years and older
Prescriber Restrictions	HD: prescribed by or in consultation with a neurologist. TD: prescribed by or in consultation with a neurologist, movement disorder specialist or a psychiatrist.
Coverage Duration	HD Initial: 3 months. TD Initial: 6 months. Renewal for HD and TD: 12 months.
Other Criteria	Initial criteria for HD: failure of or contraindication to tetrabenazine (requires prior authorization). Initial criteria for TD: failure of or contraindication to tetrabenazine and Ingrezza (both require prior authorization).

AUVELITY

Products Affected

- Auvelity

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on Auvelity: medical record documentation of failure of a) bupropion and b) an SSRI or SNRI such as sertraline, fluoxetine, escitalopram, paroxetine, venlafaxine, duloxetine.

BENLYSTA

Products Affected

- Benlysta

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Severe active CNS lupus or used in combination with other biologics or IV cyclophosphamide
Required Medical Information	A) Systemic lupus erythematosus initial criteria: 1) Medical record documentation of a diagnosis of systemic lupus erythematosus (SLE) and is auto-antibody positive as defined as Antinuclear antibody (ANA titer) greater than or equal to 1:80 or anti-double stranded DNA antibody (Anti-dsDNA) greater than or equal to 30 IU/ml. 2) Receiving standard therapy including NSAIDs, antimalarials, corticosteroids or immunosuppressants. Renewal criteria: medical record documentation of treatment response such as an improvement in the SELENA-SLEDAI score or no worsening of disease activity. B) Active lupus nephritis initial criteria: 1) Medical record documentation of a diagnosis of active lupus nephritis. 2) Receiving standard therapy including corticosteroids or immunosuppressants. Renewal: medical record documentation of treatment response such as stabilization of eGFR or no worsening of disease activity.
Age Restrictions	N/A
Prescriber Restrictions	Rheumatologist or nephrologist
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

BENZNIDAZOLE

Products Affected

- Benznidazole

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of Chagas disease caused by T. cruzi confirmed by detection of T. cruzi trypomastigotes on microscopy, detection of T. cruzi DNA by PCR assay, or 2 positive diagnostic serologic tests using two different techniques and antigens showing IgG antibodies to T. cruzi.
Age Restrictions	Age at least 2 to 12 years
Prescriber Restrictions	Prescribed by or in consultation with an infectious disease specialist or cardiologist
Coverage Duration	60 days
Other Criteria	N/A

BEXSERO

Products Affected

- Bexsero INJ 0.5ML

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Age 10-25 years
Prescriber Restrictions	N/A
Coverage Duration	Series of 2 doses in 2 months.
Other Criteria	N/A

BOSENTAN

Products Affected

- Bosentan

- Tracleer TBSO

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	1) Concomitant administration with cyclosporine A or glyburide. 2) Pregnancy.
Required Medical Information	Documentation of New York Heart Association (NYHA) Class II-IV.
Age Restrictions	N/A
Prescriber Restrictions	Pulmonologist or Cardiologist
Coverage Duration	Lifetime
Other Criteria	The following does not apply to pediatric members with idiopathic/congenital pulmonary arterial hypertension: Failure of or contraindication to sildenafil or tadalafil (both require prior authorization).

BOTULINUM TOXIN

Products Affected

- Botox

- Xeomin

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Chronic migraine (For Botox only): a) Initial: at least 15 days of headache lasting 4 hours a day or longer. b) Renewal: documentation of treatment response including decrease in the number of migraine days, less migraine episodes, decreased abortive medication usage, or emergency room visits related to migraine. 2. Urinary incontinence (For Botox only) renewal criteria: documentation of treatment response including a decrease in the number of incontinence episodes or frequency. 3. Chronic sialorrhea: Renewal criteria (For Xeomin only): documentation of treatment response such as an improvement in drooling severity, drooling frequency, or improvement in the Global Impression of Change Scale. 4) Renewal criteria for all other diagnoses: documentation of treatment response including a decrease in the severity of dystonia, decrease in pain, or decrease in disability.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Xeomin (chronic sialorrhea): 12 months, 3 dose series. All other diagnoses: 12 months, 4 dose series
Other Criteria	1) Migraine prophylaxis (For Botox only): failure of propranolol and topiramate. 2) Urinary incontinence (For Botox only): failure of two oral anticholinergics such as oxybutynin, tolterodine, or solifenacin.

BRIVIACT

Products Affected

- Briviact

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on Briviact tablets or suspension. For tabs: medical record documentation of failure of 1) levetiracetam and 2) one of the following: carbamazepine, phenytoin, topiramate, divalproex, felbamate, tiagabine, lamotrigine, gabapentin, oxcarbazepine, lacosamide, or zonisamide. For suspension: 1) medical record documentation of failure of a) levetiracetam suspension and b) one of the following suspensions or solutions: carbamazepine, phenytoin, felbamate, oxcarbazepine, gabapentin, or lacosamide, and 2) inability to swallow oral dosage forms.

BRONCHITOL

Products Affected

- Bronchitol

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Failure of bronchitol tolerance test.
Required Medical Information	Initial: confirmation of a diagnosis of cystic fibrosis.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist
Coverage Duration	Lifetime
Other Criteria	N/A

BUPHENYL

Products Affected

- Sodium Phenylbutyrate POWD 3GM/TSP
- Sodium Phenylbutyrate TABS

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Use as emergency treatment of acute hyperammonemia.
Required Medical Information	Initial: Medical record documentation of diagnostic confirmation by plasma quantitative amnio acid analysis or urinary orotic acid testing or enzyme activity from a liver biopsy or genetic testing. Renewal: Medical record documentation of stabilization of disease progression.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: Lifetime.
Other Criteria	Dosing consistent with product label: Usual total daily dose is 450-600mg/kg/day in patients weighing less than 20kg, or 9.9-13.0 G/m2/day in larger patients. Maximum dose is 20 G/day.

BUPRENORPHINE PATCH

Products Affected

- Buprenorphine PTWK

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	Failure of morphine sulfate ER.

BYLVAY

Products Affected

- Bylvay
- Bylvay (pellets)

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of pruritis associated with progressive familial intrahepatic cholestasis or associated with Alagille syndrome. Renewal: Medical record documentation of clinical benefit such as decrease in pruritis or improvement in quality of life.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months
Other Criteria	N/A

CABLIVI

Products Affected

- Cablivi

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) Medical record support of a diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP). 2) Documentation that Cablivi will be used in combination with plasma exchange. Renewal: Documented signs of persistent underlying disease such as suppressed ADAMTS13 activity levels remain present.
Age Restrictions	N/A
Prescriber Restrictions	Hematologist
Coverage Duration	Initial: 90 days. Renewal-receiving plasma exchange: 90 days. Renewal-post plasma exchange: 58 days.
Other Criteria	N/A

CAMZYOS

Products Affected

- Camzyos

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) medical record documentation of NYHA class II or III obstructive hypertrophic cardiomyopathy and 2) documentation of left ventricular ejection fraction of greater than or equal to 55%. Renewal: 1) documentation of left ventricular ejection fraction of greater than 50% and 2) improvement in symptoms or functioning.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a cardiologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

CANCER DRUGS

Products Affected

- Abiraterone Acetate
- Abirtega
- Abraxane
- Akeega
- Alecensa
- Aliqopa
- Alunbrig
- Augtyro
- Avastin
- Avmapki Fakzynja Co-pack
- Ayvakit
- Balversa
- Bavencio
- Beleodaq
- Bendamustine Hydrochloride INJ 100MG, 25MG
- Besremi
- Bexarotene
- Bortezomib INJ 3.5MG
- Bosulif
- Braftovi CAPS 75MG
- Brukinsa
- Busulfan
- Cabometyx
- Calquence
- Caprelsa
- Carmustine INJ 100MG
- Clofarabine
- Cometriq
- Copiktra
- Cotellic
- Cynamza
- Dacarbazine INJ 200MG
- Dactinomycin
- Danziten
- Darzalex
- Darzalex Faspro
- Dasatinib
- Daunorubicin Hydrochloride INJ 20MG/4ML
- Daurismo
- Docetaxel INJ 160MG/16ML, 160MG/8ML, 20MG/2ML, 20MG/ML, 80MG/4ML, 80MG/8ML
- Doxorubicin Hcl INJ 2MG/ML
- Doxorubicin Hydrochloride INJ 10MG
- Doxorubicin Hydrochloride Liposomal
- Empliciti
- Erbitux INJ 100MG/50ML
- Eribulin Mesylate
- Erivedge
- Erleada
- Erlotinib Hydrochloride TABS
- Everolimus TABS 10MG, 2.5MG, 5MG, 7.5MG
- Everolimus TBSO
- Exkivity
- Firmagon INJ 120MG/VIAL, 80MG
- Fluorouracil INJ 1GM/20ML, 2.5GM/50ML, 500MG/10ML, 5GM/100ML
- Folotyn
- Fotivda
- Fruzaqla
- Fulvestrant
- Gavreto
- Gefitinib
- Gilotrif
- Gomekli
- Ibrance
- Iclusig
- Idarubicin Hcl
- Idarubicin Hydrochloride
- Idhifa
- Imatinib Mesylate TABS
- Imbruvica CAPS
- Imbruvica SUSP
- Imbruvica TABS 280MG, 420MG, 560MG
- Imfinzi
- Inlyta

- Inqovi
- Itovebi
- Iwilfin
- Jakafi
- Jaypirca
- Jevtana
- Keytruda INJ 100MG/4ML
- Kisqali
- Kisqali Femara 200 Dose
- Kisqali Femara 400 Dose
- Kisqali Femara 600 Dose
- Koselugo
- Krazati
- Kyprolis
- Lapatinib Ditosylate
- Lazcluze
- Lenalidomide
- Lenvima 10 Mg Daily Dose
- Lenvima 12mg Daily Dose
- Lenvima 14 Mg Daily Dose
- Lenvima 18 Mg Daily Dose
- Lenvima 20 Mg Daily Dose
- Lenvima 24 Mg Daily Dose
- Lenvima 4 Mg Daily Dose
- Lenvima 8 Mg Daily Dose
- Libtayo
- Lonsurf
- Lorbrena
- Lumakras
- Lumoxiti
- Lynparza TABS
- Lytgobi
- Mekinist
- Mektovi
- Melphalan Hydrochloride
- Mitomycin INJ 20MG, 40MG, 5MG
- Mutamycin
- Mylotarg
- Nelarabine
- Nilotinib Hydrochloride
- Ninlaro
- Nipent
- Nubeqa
- Odomzo
- Ogsiveo
- Ojemda
- Ojjaara
- Onureg
- Opdivo INJ 100MG/10ML, 240MG/24ML, 40MG/4ML
- Orserdu
- Oxaliplatin INJ 100MG, 100MG/20ML
- Paclitaxel Protein-bound Particles INJ 900MG; 100MG
- Pazopanib Hydrochloride
- Pemazyre
- Pemetrexed INJ 100MG, 500MG
- Pemetrexed Disodium
- Perjeta
- Piqray 200mg Daily Dose
- Piqray 250mg Daily Dose
- Piqray 300mg Daily Dose
- Pomalyst
- Proleukin
- Qinlock
- Retevmo
- Revlimid
- Revuforj
- Rezlidhia
- Romidepsin INJ 10MG
- Romvimza
- Rozlytrek CAPS
- Rubraca
- Rydapt
- Scemblix
- Sorafenib
- Sorafenib Tosylate TABS
- Stivarga
- Sunitinib Malate
- Synribo
- Tabrecta
- Tafenlar
- Tagrisso
- Talzenna
- Tassigna

- Tazverik
- Tecentriq
- Tecentriq Hybreza
- Temsirolimus
- Tepmetko
- Tevimbra
- Thiotepa INJ 15MG
- Tibsovo
- Toremifene Citrate
- Trelstar Mixject
- Tretinoin CAPS
- Truqap
- Truseltiq
- Tukysa
- Turalio
- Valchlor
- Vanflyta
- Vectibix INJ 100MG/5ML
- Venclexta
- Venclexta Starting Pack
- Verzenio
- Vitrakvi
- Vizimpro
- Vonjo
- Voranigo
- Vyxeos
- Welireg
- Xalkori
- Xospata
- Xpovio
- Xpovio 60 Mg Twice Weekly
- Xpovio 80 Mg Twice Weekly
- Xtandi
- Yervoy
- Yondelis
- Yonsa
- Zaltrap
- Zanosar
- Zejula
- Zelboraf
- Zolinza
- Zydelig
- Zykadia TABS

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of the diagnosis.
Age Restrictions	N/A
Prescriber Restrictions	Must be prescribed by or in consultation with an oncologist or in certain conditions a hematologist, endocrinologist or neurologist. For chronic graft versus host disease, a transplant specialist. For systemic mast cell disease, an allergist or immunologist.

Coverage Duration	Lifetime
Other Criteria	<p>Drug must be prescribed for a FDA approved indication. If prescribed for non-cancer indication that is not FDA approved, the off-label use of the drug must be for a medically accepted indication that is supported by AHFS (American Hospital Formulary Service) Drug Information or Micromedex DrugDex. If prescribed for a cancer indication that is not FDA approved, the off-label use of the drug must be supported by NCCN (National Comprehensive Cancer Network) guidelines, AHFS (American Hospital Formulary Service) Drug Information, Micromedex DrugDex, Clinical Pharmacology, Lexi-Drugs, or research found in peer reviewed medical literature in accordance with Chapter 15 of the Medicare Benefit Policy Manual.</p>

CAPLYTA

Products Affected

- Caplyta

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: For treatment of schizophrenia: failure of two of the following: Latuda, Rexulti (requires PA for new starts), Vraylar (requires step therapy for new starts), Fanapt (requires step therapy for new starts). For treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression): failure of two of the following: lithium, divalproex sodium, Latuda, quetiapine or olanzapine.

CARBAGLU

Products Affected

- Carglumic Acid

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	A) For hyperammonemia type III, Initial: 1) Diagnosis confirmed by DNA testing and 2) Objective, measurable treatment goals are provided. B) For hyperammonemia due to propionic acidemia or methylmalonic acidemia, Initial: medical record documentation of the diagnosis. Renewal for all indications: Medical record documentation of stabilization of disease progression such as stabilization of neurologic impairments or seizures.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 3 months. Renewal: 12 months.
Other Criteria	N/A

CAYSTON

Products Affected

- Cayston

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of 1) FEV1 between 25% and 90% predicted and 2) Pseudomonas aeruginosa infection.
Age Restrictions	Age at least 7 years
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Documentation of failure of or resistance to tobramycin (TOBI).

CERDELGA

Products Affected

- Cerdelga

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of 1) Diagnostic confirmation by one of the following: a) biochemical assay showing decreased glucocerebrosidase activity in white blood cells or skin fibroblasts or b) genotyping revealing 2 pathogenic mutations of the glucocerebrosidase gene, and 2) Signs and symptoms that are severe enough to result in one or more of the following conditions: moderate-to-severe anemia, thrombocytopenia with bleeding tendency, bone disease, or significant hepatomegaly or splenomegaly, and 3) Documentation from a FDA-cleared test that the patient is an extensive, intermediate or poor CYP2D6 metabolizer and 4) Objective, measurable treatment goals. Renewal: Medical record documentation of stabilization of disease progression, such as 1) Improvement in hematologic markers, such as increased hemoglobin, hematocrit, or platelet counts or 2) Reduction in spleen or liver volume, or biochemical markers, such as chitotrisidase, ACE, acid phosphatase tartrate resistant (TRAP), or skeletal markers, such as DEXA scan, bone pain, bone age (for patient age 14 years or less).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	For CYP2D6 extensive and intermediate metabolizers, the dose should not exceed 84mg twice daily. For CYP2D6 poor metabolizers, the dose should not exceed 84mg daily.

CEREZYME

Products Affected

- Cerezyme

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of 1) Diagnostic confirmation by one of the following: a) biochemical assay of glucocerebrosidase activity in WBCs or skin fibroblasts is less than or equal to 30% of normal activity or b) genotyping revealing 2 pathogenic mutations of the glucocerebrosidase gene, and 2) Signs and symptoms that are severe enough to result in one or more of the following conditions: moderate-to-severe anemia, thrombocytopenia with bleeding tendency, bone disease, or significant hepatomegaly or splenomegaly, and 3) Objective, measurable treatment goals. Renewal: Medical record documentation of stabilization of disease progression, such as 1) Improvement in hematologic markers, such as increased Hgb/Hct and/or platelet counts or 2) Reduction in spleen or liver volume, or biochemical markers, such as chitotrisidase, ACE, acid phosphatase tartrate resistant (TRAP), or skeletal markers, such as DEXA scan, bone pain, bone age (for patient age 14 years or less).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Dosing consistent with product label. Dose range: 2.5/kg IV 3 times weekly to 60 units/kg IV every 2 weeks. Usual dosage is 60 units/kg IV every 2 weeks.

CHENODAL

Products Affected

- Chenodal

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation that the patient is not a candidate for laparoscopic cholecystectomy.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Failure of ursodiol.

CHOLBAM

Products Affected

- Cholbam

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Bile acid synthesis defect, initial: medical record documentation of a bile acid synthesis disorder. First renewal after 4 months of initiating treatment: medical record documentation of liver function improvement and lack of complete biliary obstruction. Ongoing renewal criteria: lack of complete biliary obstruction. 2) Peroxisomal disorders, initial: Medical record documentation that Cholbam will be used adjunctively, and that there are liver disease manifestations, steatorrhea, or complications due to decreased absorption of fat soluble vitamins. First renewal after 4 months of initiating treatment: medical record documentation of liver function improvement and lack of complete biliary obstruction. Ongoing renewal criteria: lack of complete biliary obstruction.
Age Restrictions	N/A
Prescriber Restrictions	Hepatologist or gastroenterologist
Coverage Duration	Initial: 4 months. Renewal: 12 months.
Other Criteria	N/A

CIMZIA

Products Affected

- Cimzia

- Cimzia Starter Kit

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Rheumatoid arthritis (RA) renewal: improved functioning and/or improvement in tender joint count and swollen joint count. 2) Psoriasis with arthropathy (PsA) renewal: improved functioning and/or improvement in tender joint count and swollen joint count. 3) Plaque psoriasis (PsO) initial: involvement of at least 3% of body surface area or hand, foot, face, scalp or genital involvement. PsO renewal: improvement in affected BSA, plaque severity and/or functioning. 4) Ankylosing spondylitis (AS) renewal: improved functioning and/or signs and symptoms of AS. 5) Crohn's Disease (CD) renewal: medical record documentation of a decrease in symptoms, reduction in enterocutaneous fistulas or clinical remission. 6) Active non-radiographic axial spondyloarthritis renewal: improved functioning and/or signs and symptoms of active non-radiographic axial spondyloarthritis. 7) polyarticular juvenile idiopathic arthritis (pJIA) renewal: improved functioning and/or improvement in tender joint count and swollen joint count.
Age Restrictions	N/A
Prescriber Restrictions	Plaque psoriasis: dermatologist. PsA: dermatologist or rheumatologist. RA, pJIA, Ankylosing spondylitis, and nonradiographic spondyloarthritis: rheumatologist. Crohn's disease: gastroenterologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.

Other Criteria	<p>RA initial: Failure of or contraindication to two of the following: adalimumab (Humira or adalimumab-adbm), Enbrel, Simponi, Actemra, Orencia, Rinvoq, or Xeljanz (IR or XR). All require prior authorization.</p> <p>PsO initial: Failure of or contraindication to two of the following: adalimumab (Humira or adalimumab-adbm), Enbrel, Otezla, Cosentyx, Skyrizi, Stelara.</p> <p>PsA initial: Failure of or contraindication to two of the following: adalimumab (Humira or adalimumab-adbm), Enbrel, Simponi, Orencia, Otezla, Cosentyx, Skyrizi, Stelara, Rinvoq, or Xeljanz (IR or XR).</p> <p>AS initial: Failure of or contraindication to two of the following: adalimumab (Humira or adalimumab-adbm), Enbrel, Simponi, Cosentyx, or Xeljanz (IR or XR). All have prior authorization.</p> <p>CD initial: Failure of adalimumab (Humira or adalimumab-adbm) and Stelara with prior authorization.</p> <p>Active non-radiographic axial spondyloarthritis initial: failure of one non-steroidal anti-inflammatory drug such as meloxicam, ibuprofen, naproxen or diclofenac.</p>
-----------------------	--

CINRYZE

Products Affected

- Cinryze

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Documentation of hereditary angioedema Type 1 and II confirmed by genetic testing, or complement studies of C4, C1INH antigenic and C1INH functional levels supporting the diagnosis. For hereditary angioedema Type III, documentation of diagnosis confirmed by genetic testing, normal complement studies combined with clinical features of angioedema or family history. Renewal criteria for long term prevention: Documentation of a reduction in the number of angioedema attacks, improvement in the severity and duration of attacks or clinical documentation of functional improvement
Age Restrictions	Age at least 6 years.
Prescriber Restrictions	Hematologist, allergist or immunologist
Coverage Duration	Short term prevention: 1 procedure. Long term prevention initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

CITALOPRAM 40MG

Products Affected

- Citalopram Hydrobromide TABS 40MG

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Not covered for members age 60 years and older who newly start on citalopram and using more than 20mg of citalopram per day.
Required Medical Information	N/A
Age Restrictions	Prior Authorization applies to members who newly start on citalopram and are 60 years or older.
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

CLOBAZAM

Products Affected

- Clobazam SUSP 2.5MG/ML

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Age at least two.
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: documentation of an inability to swallow solid dosage forms.

COBENFY

Products Affected

- Cobenfy
- Cobenfy Starter Pack

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of a diagnosis of schizophrenia.
Age Restrictions	Age of at least 18 years
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug. Failure of two of the following: lurasidone, aripiprazole, risperidone, olanzapine, quetiapine, ziprasidone.

COLONY STIMULATING FACTORS

Products Affected

- Fulphila
- Fylnetra
- Granix
- Leukine INJ 250MCG
- Neulasta
- Nyvepria
- Rolvedon
- Stimufend
- Udenyca
- Udenyca Onbody
- Zarxio
- Ziextenzo

PA Criteria	Criteria Details
Indications	All FDA-approved Indications, Some Medically accepted Indications.
Off-Label Uses	1) AIDS Neutropenia (Leukine) and 2) Myelodysplastic Syndromes (Leukine)
Exclusion Criteria	N/A
Required Medical Information	Documentation of one the following: a) receiving myelosuppressive chemotherapy for a non-myeloid malignancy, receiving chemotherapy for AML, post-induction chemotherapy for AML (Leukine only), or acute exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome) (for Neulasta and Leukine only), or b) BMT (allogeneic or autologous) or c) autologous peripheral blood progenitor cell (PBPC) transplant or d) severe chronic neutropenia and not on interferon-ribavirin based Hepatitis C treatment or e) AIDS or f) myelodysplastic syndromes.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	N/A

CORLANOR

Products Affected

- Corlanor SOLN

- Ivabradine Hydrochloride

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Adults with chronic heart failure: medical record documentation of the following: 1) Ejection fraction of 35% or less and 2) In sinus rhythm with a resting heart rate of at least 70 beats per minute.
Age Restrictions	Stable symptomatic heart failure due to dilated cardiomyopathy (DCM): at least 6 months of age to less than 19 years of age.
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	1) Receiving maximally tolerated doses of a beta blocker or there is a medical reason why a beta blocker cannot be used and 2) failure of a) an angiotensin receptor enzyme inhibitor or angiotensin receptor blocker or b) a mineralcorticoid receptor antagonist. 3) For oral solution only: Documentation of an inability to swallow solid dosage forms.

CORTROPHIN

Products Affected

- Cortrophin

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Use of corticotropin intravenously. Corticotropin should not be used in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or active peptic ulcer disease, congestive heart failure, uncontrolled hypertension, or sensitivity to proteins of porcine origin. Corticotropin is contraindicated in patients under the age of 2 with suspected congenital infections and for patients who also have adrenocortical insufficiency or adrenocortical hyperfunction.
Required Medical Information	Medical record documentation of one of the following conditions: 1) Infantile spasms, 2) Acute exacerbation of multiple sclerosis, 3) Exacerbation of rheumatic disorders including psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, 4) Exacerbation of or maintenance for collagen diseases including systemic lupus erythematosus, systemic dermatomyositis, 5) Dermatologic diseases including severe erythema multiforme, Stevens-Johnson Syndrome, 6) Allergic states such as serum sickness, 7) Ophthalmic diseases including keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation, 7) Respiratory diseases such as symptomatic sarcoidosis or 8) Edematous condition from nephrotic syndrome or lupus erythematosus.
Age Restrictions	For infantile spasms: age less than 2 years.
Prescriber Restrictions	N/A
Coverage Duration	Infantile spasms: until two years of age. All others: 1 month.
Other Criteria	For steroid responsive conditions, conditions number 2 to 7 listed in the Required Medical Information section: medical record documentation of failure of corticosteroid therapy in the last 30 days or reason why corticosteroids cannot be used.

COSENTYX

Products Affected

- Cosentyx INJ 125MG/5ML, 150MG/ML
- Cosentyx Sensoready Pen
- Cosentyx Unoready

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Plaque psoriasis (PsO) initial: involvement of at least 3% of body surface area or hand, foot, face, scalp, or genital involvement. PsO renewal: improvement in affected body surface area, plaque severity and/or functioning. 2) Psoriatic arthritis renewal: improved functioning and/or improvement in tender joint count and swollen joint count. 3) Ankylosing spondylitis renewal: improved functioning and/or signs and symptoms of AS. 4) Active non-radiographic axial spondyloarthritis renewal: improved functioning and/or signs and symptoms of active non-radiographic axial spondyloarthritis. 5) Enthesitis-related arthritis (ERA) renewal: improved functioning and/or signs and symptoms of ERA. 6) Hidradenitis suppurativa (HS): initial: moderate to severe disease evident by documentation of Hurley Stage II or III and at least 3 abscesses or inflammatory nodules. HS renewal: reduction in nodules and abscesses.
Age Restrictions	N/A
Prescriber Restrictions	Plaque psoriasis and hidradenitis suppurativa: dermatologist. Psoriatic arthritis: dermatologist or rheumatologist. Ankylosing spondylitis, nonradiographic spondyloarthritis, enthesitis-related arthritis: rheumatologist
Coverage Duration	Initial: 6 months. Renewal: 12 months.

Other Criteria	<p>PsO initial: failure of 1) one topical agent such as a corticosteroid (i.e. betamethasone or clobetasol), calcipotriene, tazarotene (requires prior authorization), or tacrolimus and 2) methotrexate or cyclosporine.</p> <p>Ankylosing spondylitis, active non-radiographic axial spondyloarthritis and active enthesitis-related arthritis, initial: failure of one non-steroidal anti-inflammatory drug such as meloxicam, ibuprofen, naproxen or diclofenac.</p>
-----------------------	--

CRENESSITY

Products Affected

- Crenessity CAPS 100MG, 50MG
- Crenessity SOLN

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) Medical record and lab result confirmation of a diagnosis of classic congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. 2) Documentation that Crenessity will be used in combination with supraphysiologic glucocorticoid replacement. Renewal: Documentation of a reduction in daily glucocorticoid replacement dose.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	For oral solution only: documentation of an inability to swallow solid oral dosage forms.

CRESEMBA

Products Affected

- Cresemba CAPS 186MG
- Cresemba INJ

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 months
Other Criteria	For the treatment of invasive aspergillosis (not required for invasive mucormycosis): failure of voriconazole.

CTEXLI

Products Affected

- Ctexli

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: medical record documentation of a diagnosis of cerebrotendinous xanthomatosis (CTX) confirmed via either a) serum cholestanol and/or urine bile alcohol levels or b) genetic testing. Renewal: medical record documentation of improvements in the symptoms of CTX (such as reduction in diarrhea, decrease in spasticity or hyperreflexia, improvement in ataxia or dysarthria) or reduction in serum cholestanol levels or bile alcohol levels.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with an endocrinologist, metabolic specialist, or neurologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

CUVRIOR

Products Affected

- Cuvrior

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) Medical record documentation of stable Wilson's disease who are de-coppered and tolerant to penicillamine. 2) Renewal: medical record documentation of clinical benefit from treatment with Cuvrior.
Age Restrictions	At least 18 years of age
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Initial: Failure of or contraindication to penicillamine.

CYSTADANE

Products Affected

- Betaine Anhydrous

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of diagnostic confirmation such as by measurement of plasma and urine homocysteine levels. Renewal: Medical record documentation of stabilization of disease, such as decrease in plasma and urine homocysteine levels, improvement in neurological and neuromuscular function.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

CYSTEAMINE

Products Affected

- Cystadrops
- Cystaran

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial criteria: Medical record documentation of corneal cysteine crystal deposits. Renewal criteria: medical record documentation of a reduction in corneal crystal deposits.
Age Restrictions	N/A
Prescriber Restrictions	Doctor who specialize in genetic or metabolic disorders or ophthalmologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

DALFAMPRIDINE

Products Affected

- Dalfampridine Er

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	History of seizure or moderate or severe renal impairment defined as creatinine clearance less than or equal to 50 mL/min.
Required Medical Information	Initial criteria: medical record documentation of 1) Diagnosis of multiple sclerosis, and 2) Prior to initiation of therapy, the patient must have a timed 25-foot walk time to establish a baseline to evaluate treatment response. Renewal criteria: 1) Medical record documentation of an improvement in the timed 25-foot walk time compared to baseline maximum walk speed.
Age Restrictions	Age at least 18 years.
Prescriber Restrictions	Neurologist
Coverage Duration	Initial: 3 months. Renewal: Lifetime.
Other Criteria	If indicated, must be receiving concurrent therapy with a disease modifying agent such as Avonex, Betaseron, Extavia, glatiramer, Rebif, fingolimod, or dimethyl fumarate.

DAYBUE

Products Affected

- Daybue

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record confirmation of a diagnosis of Rett syndrome. Renewal: Medical record documentation of maintenance or improvement of symptoms.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a neurologist
Coverage Duration	Initial: 3 months. Renewal: 12 months.
Other Criteria	N/A

DEFLAZACORT

Products Affected

- Deflazacort

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: medical record documentation of genetic testing confirmation of Duchenne muscular dystrophy. Renewal criteria: documentation of a positive treatment response (e.g. pulmonary function, muscle strength, functional ability, walk tests)
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or a specialist in Duchenne Muscular Dystrophy or neuromuscular disorders.
Coverage Duration	12 months
Other Criteria	Failure of or adverse effects to prednisone.

DENG VAXIA

Products Affected

- Dengvaxia

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Medical record documentation of a laboratory confirmed previous dengue infection. 2) Documentation of residence in an endemic area.
Age Restrictions	Age between 9 and 16 years.
Prescriber Restrictions	N/A
Coverage Duration	3 doses over 6 months
Other Criteria	N/A

DIACOMIT

Products Affected

- Diacomit

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Medical record documentation of Dravet syndrome. 2) Documentation that Diacomit will be taken with clobazam.
Age Restrictions	N/A
Prescriber Restrictions	Neurologist
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: failure of or contraindication to Epidiolex (requires prior authorization).

DICLOFENAC 3% GEL

Products Affected

- Diclofenac Sodium GEL 3%

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	90 days
Other Criteria	Failure of or contraindication to imiquimod and topical 5-fluorouracil.

DICLOFENAC SODIUM SOLUTION

Products Affected

- Diclofenac Sodium EXTERNAL SOLN 1.5%

PA Criteria	Criteria Details
Indications	All FDA-approved Indications, Some Medically accepted Indications.
Off-Label Uses	1) Cancer-related pain
Exclusion Criteria	N/A
Required Medical Information	1) Cancer related pain, initial: medical record documentation of cancer-related pain. 2) Osteoarthritis of the knee, initial: medical record confirmation of osteoarthritis of the knee.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

DIFICID

Products Affected

- Dificid

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of an infection caused by clostridium difficile.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	10 days
Other Criteria	Failure of or intolerance to vancomycin. For oral powder for suspension only: documentation of an inability to swallow oral dosage forms.

DOJOLVI

Products Affected

- Dojolvi

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). Renewal: Documentation of improved muscle function, exercise tolerance, or health related quality of life.
Age Restrictions	N/A
Prescriber Restrictions	Genetic specialist
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

DOPTELET

Products Affected

- Doptelet

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Chronic immune thrombocytopenia (ITP): Initial criteria: Medical record documentation of platelet count less 30,000 per mm ³ . Renewal criteria: Medical record documentation of maintenance of platelet counts between 30,000 per mm ³ and 150,000 per mm ³ or an increase in platelet counts from baseline with resolution of bleeding episodes. 2) Chronic liver disease with thrombocytopenia: Platelets less than 50k.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a gastroenterologist, hepatologist, a hematologist, or a surgeon.
Coverage Duration	ITP: Initial 6 weeks, Renewal 24 weeks. Chronic liver disease with thrombocytopenia: 5 days.
Other Criteria	Chronic immune thrombocytopenia: insufficient response to systemic corticosteroids and immunoglobulin replacement. Chronic liver disease with thrombocytopenia: Documentation of upcoming procedure.

DRIZALMA

Products Affected

- Drizalma Sprinkle

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: documentation of an inability to swallow solid oral dosage forms.

DRONABINOL

Products Affected

- Dronabinol

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	The following criteria only applies to the treatment of nausea and vomiting associated with cancer chemotherapy: 1) failure of at least one of the following antiemetics: dimenhydrinate, meclizine, metoclopramide, promethazine, or prochlorperazine and 2) ondansetron.

DROXIDOPA

Products Affected

- Droxidopa

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Renewal criteria: medical record documentation of treatment response including decrease in lightheadedness, dizziness or falls.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

DUPIXENT

Products Affected

- Dupixent

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Atopic dermatitis initial (AD): body surface area involvement = 10% at baseline. 2) AD renewal criteria: medical record documentation of a positive treatment response such as a reduction in body surface area involvement, improvement in itching, improvement in functional ability, reduction in the Investigator Global Assessment or Eczema Area and Severity Index from baseline. 3) Moderate to severe asthma, eosinophilic phenotype initial: eosinophil count greater than or equal to 150 cells/mcL. 4) Moderate to severe asthma, oral corticosteroid dependent initial: documentation that chronic oral steroid use is required for asthma control. 5) Moderate to severe asthma, renewal: reduction in oral steroid use or in asthma symptoms. 6) Chronic rhinosinusitis with nasal polyposis (CR) initial: medical record documentation that 1) the condition is inadequately controlled and 2) that Dupixent will be used as add-on therapy. 7) CR renewal: documentation of treatment response such as reduction in steroid use or need for surgery. 8) Eosinophilic esophagitis (EE) initial: a) medical record documentation of a diagnosis of eosinophilic esophagitis confirmed by symptoms related to esophageal dysfunction and biopsy showing eosinophil-predominant inflammation (such as a peak value of $f \geq 15$ eosinophils per high power field (HPF) or 60 eosinophils per mm ² . b) weight of at least 15kg. 9) EE renewal: documentation of a clinical response, such as improvement in dysphagia or histologic remission. 10) Prurigo nodularis, renewal: documentation of a clinical response, such as an improvement in pruritis, a reduction in nodular lesions, or improvement in functioning. 10) eosinophilic type COPD initial: eosinophil count of at least 300 cells/mcL. Renewal: Improvement in symptoms or less exacerbations.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a dermatologist, pulmonologist, allergist, ENT, otolaryngologist, or immunologist. For EE: Gastroenterologist.

Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Atopic dermatitis: For patients 12 years of age or older: 1) failure of one of the following very high potency topical steroids: augmented betamethasone, clobetasol or halobetasol and 2) failure of tacrolimus ointment, OR documentation that topical prescription therapies are not appropriate or are contraindicated. Moderate to severe asthma, eosinophilic phenotype or oral corticosteroid dependent: trial and failure of an ICS+LABA combo such as fluticasone/vilanterol or fluticasone/salmeterol. Uncontrolled COPD, initial: exacerbations while on triple therapy with an ICS + LAMA + LABA combo such as Trelegy or Breztri.

DUVYZAT

Products Affected

- Duvyzat

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: a) genetic testing results confirming a diagnosis of Duchenne muscular dystrophy. b) medical record documentation of male gender. Renewal criteria: documentation of a positive treatment response (e.g. pulmonary function, muscle strength, functional ability, walk tests)
Age Restrictions	At least 6 years of age or older.
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or a specialist in Duchenne Muscular Dystrophy or neuromuscular disorders.
Coverage Duration	12 months
Other Criteria	N/A

EGRIFTA

Products Affected

- Egrifta Sv

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	1) Disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, or head irradiation or trauma, 2) malignancy, active (either newly diagnosed or recurrent), malignancies should be inactive and completely treated prior to initiating therapy, 3) Pregnancy, 4) Body mass index less than or equal to 20 kg/m ² . 5) Not approved for use in patients without HIV infection.
Required Medical Information	Initial criteria: 1) Lipodystrophy defined as a) For men: a waist circumference of greater than or equal to 95 cm or 37.5 inches or a waist-to-hip ratio of greater than or equal to 0.94 and b) For women: a waist circumference of greater than or equal to 94 cm or 37 inches or a waist-to-hip ratio of greater than or equal to 0.88. 2) Currently on anti-retroviral therapy. Renewal criteria: documentation of treatment response such as reduction in visceral adipose tissue as demonstrated from waist circumference or CT scan.
Age Restrictions	N/A
Prescriber Restrictions	Endocrinologist or HIV specialist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

ELAPRASE

Products Affected

- Elaprase

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of 1) Diagnostic confirmation of by such as presence of glycosaminoglycans (GAG) in the urine, deficiency in iduronate-2-sulfatase enzyme activity, or genetic testing, and 2) Objective, measurable treatment goals. Renewal: Medical record documentation of stabilization of disease progression, such as improvement in percent predicted FVC, improvement in 6-minute walk test, reduction in urinary GAG levels, or reduction in liver or spleen size.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Dosing consistent with product label: 0.5mg/kg IV once weekly.

ELMIRON

Products Affected

- Elmiron

PA Criteria	Criteria Details
Indications	All FDA-approved Indications, Some Medically accepted Indications.
Off-Label Uses	Hemorrhagic cystitis
Exclusion Criteria	N/A
Required Medical Information	Renewal criteria: medical record documentation of an improvement in symptoms such as a reduction in bladder pain.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: Lifetime.
Other Criteria	N/A

EMEND

Products Affected

- Aprepitant CAPS

- Emend SUSR

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Concomitant use of pimozide.
Required Medical Information	Confirmation of diagnosis and use as prophylaxis and not for established nausea and vomiting.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	PONV: one dose. Chemotherapy: 12 months.
Other Criteria	Chemotherapy: 1) Requires concurrent treatment with IV or oral Zofran (ondansetron) or Kytril (granisetron) or Aloxi (palonosetron) and dexamethasone. 2) Part B versus D determination will be made to determine coverage.

EMGALITY

Products Affected

- Emgality

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Episodic cluster headache: 1) Initial: medical record documentation of the diagnosis and that the patient has experienced at least 2 cluster periods from 7 to 365 days, separated by pain free periods lasting at least 3 months. 2) Renewal: documentation of treatment response including a reduction in headaches, decreased abortive medication use, or emergency room visits. 3) Not used in combination with another CGRP inhibitor. Migraines: 1) Initial: episodic migraine, 4-14 headache days per month. Chronic migraines, 15 or more headache days per month with at least 8 days of migraines for 3 months. 2) Renewal: documentation of treatment response including decrease in the number of migraine days, less migraine episodes, decreased abortive medication usage, or emergency room visits related to migraine.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: Lifetime.
Other Criteria	1) Episodic Migraine prophylaxis and chronic migraine prophylaxis: failure of propranolol and topiramate.

EMSAM

Products Affected

- Emsam

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	1) Concomitant use of the any of the following medications: SSRIs, SNRIs, TCAs, MAOIs, sympathomimetic amines including amphetamines, meperidine, tramadol, methadone, mirtazapine, bupropion, cyclobenzaprine, carbamazepine and oxcarbamazepine.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: Failure of or intolerance to at least 2 of the following: 1) a selective serotonin receptor reuptake inhibitor such as citalopram, escitalopram, fluoxetine, paroxetine, or sertraline, 2) an SNRI such as venlafaxine or duloxetine, 3) bupropion or 4) mirtazapine.

ENBREL

Products Affected

- Enbrel INJ 25MG/0.5ML, 50MG/ML
- Enbrel Mini
- Enbrel Sureclick

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Rheumatoid arthritis (RA) renewal: improved functioning and/or improvement in tender joint count and swollen joint count. 2) Psoriasis with arthropathy (PsA) renewal: improved functioning and/or improvement in tender joint count and swollen joint count. 3) Ankylosing spondylitis (AS) Renewal: Improved functioning and/or symptoms. 4) Plaque psoriasis (PsO initial: involvement of more than 3% of body surface area or hand, foot, face, scalp or genital involvement. PsO renewal: improvement in affected BSA, plaque severity and/or functioning. 5) Juvenile idiopathic arthritis (JIA) and juvenile psoriatic arthritis (JPsA) renewal: Improved functioning and/or improvement in tender joint count and swollen joint count.
Age Restrictions	N/A
Prescriber Restrictions	Rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis and juvenile psoriatic arthritis: rheumatologist. Plaque psoriasis: dermatologist. Psoriatic arthritis : rheumatologist or dermatologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	RA Initial: failure of methotrexate and at least one other DMARD such as leflunomide, sulfasalazine, or hydroxychloroquine. AS initial: failure of one oral non-steroidal anti-inflammatory drug such as meloxicam, ibuprofen, naproxen or diclofenac. PsO initial: Failure of 1) one topical agent such as a corticosteroid (i.e. betamethasone or clobetasol), calcipotriene, tazarotene (requires prior authorization), or tacrolimus and 2) methotrexate or cyclosporine. JIA and JPsA initial: failure of methotrexate for at least 8 weeks.

ENDARI

Products Affected

- L-glutamine PACK

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Renewal criteria: medical record documentation that the drug has been effective in reducing the number of sickle cell crisis.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Medical record documentation of failure of or intolerance to hydroxyurea. Failure defined as continued acute complications or pain crisis or continued need for blood transfusions while on hydroxyurea.

ENSPRYNG

Products Affected

- Enspryng

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of a diagnosis of anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder
Age Restrictions	N/A
Prescriber Restrictions	Neurologist or ophthalmologist
Coverage Duration	12 months
Other Criteria	N/A

ENTYVIO

Products Affected

- Entyvio Pen

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Ulcerative Colitis (UC) renewal: medical record documentation of treatment response such as decrease in bloody stools per day, elimination of signs of toxicity, or clinical remission. Crohn's disease (CD) renewal: a decrease in symptoms, reduction in enterocutaneous fistulas or clinical remission.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a gastroenterologist
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	UC Initial: Failure of two of the following: adalimumab (Humira or adalimumab-adbm), Stelara, Rinvoq, Simponi and Xeljanz. All require prior authorization. CD initial: Failure of two of the following: adalimumab (Humira or adalimumab-adbm), Stelara, Rinvoq, and Simponi. All require prior authorization.

EOHILIA

Products Affected

- Eohilia

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: medical record documentation of a diagnosis of eosinophilic esophagitis confirmed by symptoms related to esophageal dysfunction and biopsy showing eosinophil-predominant inflammation (such as a peak value of $f \geq 15$ eosinophils per high power field (HPF) or 60 eosinophils per mm ² . Renewal: documentation of a clinical response, such as improvement in dysphagia or histologic remission.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

EPIDIOLEX

Products Affected

- Epidiolex

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: 1) For all diagnoses: Epidiolix must be used as adjunctive treatment. 2) For Lennox-Gastaut Syndrome: failure of two of the following: clonazepam, valproate, topiramate, lamotrigine, felbamate or rufinamide.

EPRONTIA

Products Affected

- Eprontia

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to new starts only. Initial: Documentation of an inability to swallow oral dosage forms or contents of sprinkle capsules.

ERYTHROPOIESIS-STIMULATING AGENTS

Products Affected

- Aranesp Albumin Free INJ
100MCG/0.5ML, 100MCG/ML,
10MCG/0.4ML, 150MCG/0.3ML,
200MCG/0.4ML, 200MCG/ML,
25MCG/0.42ML, 25MCG/ML,
300MCG/0.6ML, 40MCG/0.4ML,
40MCG/ML, 500MCG/ML,
60MCG/0.3ML, 60MCG/ML
- Procrit
- Retacrit

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Anemia associated with chronic kidney disease (CKD): a) Hgb below 10 g/dL or Hct below 30% and b) ferritin at least 100 ng/mL and/or c) transferrin saturation at least 20%. 2) Anemia associated with cancer treatment for non-myeloid cancers: a) Hgb below 10 g/dL or Hct below 30% and b) ferritin at least 100 ng/mL and/or c) transferrin saturation at least 20%. 3) Anemia associated with Zidovudine therapy in HIV/AIDS: a) Hgb below 10 g/dL or Hct below 30% and b) transferrin saturation at least 20%, and c) endogenous erythropoietin below 500 IU/L, 4) Surgery: a) high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery and b) baseline Hgb greater than 10g/dL, but below 13g/dL. Renewal criteria for 1-3: transferrin saturation greater than 20%.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	CKD and HIV: 12 months. Cancer: 6 months. Surgery: 1 month.

Other Criteria	1) Anemia associated with zidovudine therapy: zidovudine dose less than 4200mg per week verified by claim history. 2) For end stage renal disease (ESRD) patients on dialysis, Part B versus Part D determination will be made to determine if the drug prescribed will be used for an ESRD-related condition. For ESRD-related conditions, the drug will be covered under Part B and provided by the dialysis center.
-----------------------	--

ESLICARBAZEPINE

Products Affected

- Eslicarbazepine Acetate

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: Failure of 1) oxcarbazepine and 2) One of the following: carbamazepine, phenytoin, topiramate, divalproex, felbamate, tiagabine, lamotrigine, gabapentin, zonisamide, lacosamide, levetiracetam.

EVENTITY

Products Affected

- Evenity

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	1) Stroke or myocardial infarction in the last 12 months. 2) Uncorrected hypocalcemia.
Required Medical Information	Medical record documentation of high risk or very high risk of fracture defined as a history of osteoporotic fracture, or multiple risk factors for fracture (such as bone mineral density less than -2.5, previous minimal trauma fracture as an adult, low weight or body mass index, history of hip fracture in a first degree relative, tall stature or use of tobacco), or failure of other available osteoporosis therapy. Very high risk of fracture is defined as recent fracture (within the past 12 months), fractures while on approved osteoporosis therapy, multiple fractures, fractures while on drugs causing skeletal harm such as long term steroids, very low T-score such as less than -3, high risk of falls or history of injurious falls, and very high fracture probability determined by the Fracture Risk Assessment Tool (FRAX).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months maximum. Use is not recommended for longer.
Other Criteria	Failure of or contraindication to 1) oral bisphosphonates and 2) Prolia. These criteria do not apply if considered very high risk for fracture.

EVRYSDI

Products Affected

- Evrysdi

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record confirmation of a diagnosis of spinal muscle atrophy (SMA) confirmed by genetic testing.
Age Restrictions	N/A
Prescriber Restrictions	Neurologist
Coverage Duration	12 months
Other Criteria	N/A

EXENATIDE

Products Affected

- Bydureon Bcise
- Byetta
- Exenatide

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of a diagnosis of type 2 diabetes.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

EXONDYS

Products Affected

- Exondys 51

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial criteria: Medical record documentation of a confirmed mutation of the Duchenne muscular dystrophy (DMD) gene that is amenable to exon 51 skipping. Renewal criteria: Documentation of an improvement in symptoms including distance that a patient can walk on a flat, hard surface in a period of 6 minutes and/or reduction in disease progression.
Age Restrictions	N/A
Prescriber Restrictions	Neurologist or in consultation with a neurologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

FABHALTA

Products Affected

- Fabhalta

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Paroxysmal nocturnal hemoglobinuria (PNH): medical record documentation of a diagnosis of paroxysmal nocturnal hemoglobinuria. PNH Renewal: medical record documentation of clinical benefit, such as increase in hemoglobin level from baseline. 2) Primary immunoglobulin A nephropathy (IgAN) initial: a) biopsy results confirming IgAN. b) laboratory results confirming proteinuria.
Age Restrictions	N/A
Prescriber Restrictions	PNH: Prescribed by, or in consultation with a hematologist or an oncologist. IgAN: Prescribed by, or in consultation with a nephrologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	IgAN: documentation of failure of or contraindication to Filspari (requires prior authorization).

FABRAZYME

Products Affected

- Fabrazyme

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of 1) For males, diagnostic confirmation of a-galactosidase levels (a- GAL) of less than 1.5 nmol/hr/ml on plasma or less than 4nmol/hr/mg in leukocytes. For females, diagnostic confirmation based on low leukocyte a- GAL A or family history of genetic mutation analysis of the a- GAL A gene or characteristic findings e.g., angiokeratomas, telangiectasias, severe neuropathic pain and organ involvement, and 2) Objective, measurable treatment goals. Renewal: Medical record documentation of stabilization or slowing of disease progression.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Dosing consistent with product label: 1 mg/kg IV infusion every 2 weeks.

FASENRA

Products Affected

- Fasenra

- Fasenra Pen

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Asthma initial criteria: 1) Medical record documentation of a diagnosis of severe asthma with eosinophilic phenotype and 2) Blood eosinophil levels greater than or equal to 150 cells/mcL in the last 4 weeks. Asthma renewal criteria: documentation of or claims history showing a reduction in the use of oral steroids or reduction in asthma symptoms. Eosinophilic granulomatosis with polyangiitis (EGPA) initial: 1) diagnosis confirmed by documentation of asthma, and 2) blood eosinophil level of 10% or an absolute count of greater than 1000 cells/mm3. EGPA renewal criteria: documentation of response to treatment such as achievement of remission, decrease in the use of steroids, decrease in the rate of relapses or improvement in asthma symptoms.
Age Restrictions	N/A
Prescriber Restrictions	Asthma: Prescribed by or in consultation with a pulmonologist, allergist, or immunologist. EGPA: prescribed by or in consultation with a rheumatologist, pulmonologist, immunologist or vasculitis specialist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Asthma, initial: failure of an inhaled corticosteroid and a long-acting beta agonist.

FETZIMA

Products Affected

- Fetzima

- Fetzima Titration Pack

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: Failure of 1) an SSRI such as sertraline or fluoxetine and 2) an SNRI such as venlafaxine and or duloxetine.

FILSPARI

Products Affected

- Filspari

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Immunoglobulin A nephropathy initial: 1) medical record documentation of biopsy confirmed primary immunoglobulin A nephropathy. Renewal: medical record documentation of a decrease in urine protein-to-creatinine ratio from baseline.
Age Restrictions	Age of at least 18 years
Prescriber Restrictions	Prescribed by, or in consultation with a nephrologist
Coverage Duration	Initial: 6 months. Renewal: Lifetime
Other Criteria	N/A

FILSUVEZ

Products Affected

- Filsuvez

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of genetic testing confirmation of junctional epidermolysis bullosa (JEB) or dystrophic epidermolysis bullosa (DEB). Renewal: medical record documentation of clinical response (i.e. wound healing).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a dermatologist.
Coverage Duration	Initial: 3 months. Renewal: 12 months.
Other Criteria	N/A

FINGOLIMOD

Products Affected

- Fingolimod Hydrochloride
- Gilenya CAPS 0.25MG

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	1) Unstable angina, transient ischemic attack, myocardial infarction, stroke, heart failure Class III/IV or decompensated heart failure requiring hospitalization within the last 6 months. 2) Concomitant Class Ia or Class III anti-arrhythmic drugs. 3) Mobitz type II second-degree, third-degree atrioventricular block, sick-sinus syndrome unless the patient has a functional pacemaker. 4) QTc interval at baseline 500 milliseconds or greater.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist.
Coverage Duration	Lifetime
Other Criteria	Documentation that fingolimod is being requested for monotherapy and is not intended to be used in combination with other disease modifying multiple sclerosis agents.

FINTEPLA

Products Affected

- Fintepla

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: Failure of or contraindication to Epidiolex (requires PA for new starts).

FIRDAPSE

Products Affected

- Firdapse

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	History of seizure
Required Medical Information	Initial: Confirmation of a diagnosis of Lambert-Eaton myasthenic syndrome via EMG or antibody testing. Renewal: Documentation of a treatment response such as a reduction in muscle weakness or functional impairment.
Age Restrictions	Age at least 6 years.
Prescriber Restrictions	Neurologist
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

FYCOMPA

Products Affected

- Fycompa

- Perampanel

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: For tablets and suspension: 1) For the treatment of partial-onset seizures: failure of two of the following: carbamazepine, oxcarbazepine, lacosamide, phenytoin, topiramate, divalproex, felbamate, tiagabine, lamotrigine, gabapentin, zonisamide, and levetiracetam. 2) For the treatment of primary generalized tonic-clonic seizures: failure of two of the following topiramate, lacosamide, lamotrigine, phenytoin, and levetiracetam. For suspension only: inability to swallow oral dosage forms.

GALAFOLD

Products Affected

- Galafold

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of 1) For males, diagnostic confirmation of a-galactosidase levels (a- GAL) of less than 1.5 nmol/hr/ml on plasma or less than 4nmol/hr/mg in leukocytes. For females, diagnostic confirmation based on low leukocyte a- GAL A or family history of genetic mutation analysis of the a- GAL A gene or characteristic findings e.g., angiokeratomas, telangiectasias, severe neuropathic pain and organ involvement, and 2) Objective, measurable treatment goals. Renewal: Medical record documentation of stabilization or slowing of disease progression.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

GARDASIL

Products Affected

- Gardasil 9 INJ 0.5ML

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Age 9-45 years
Prescriber Restrictions	N/A
Coverage Duration	Series of 3 doses in 12 months.
Other Criteria	N/A

GATTEX

Products Affected

- Gattex

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial criteria: Medical record documentation that the patient is dependent on parenteral support. Renewal criteria: Medical record documentation of a decrease in parenteral support such as a decrease in volume and/or frequency.
Age Restrictions	N/A
Prescriber Restrictions	Gastroenterologist or GI specialist
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

GEMTESA

Products Affected

- Gemtesa

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: for overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH), documentation that the member is receiving pharmacological therapy for BPH.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria does not apply to adult males with BPH: Failure of mirabegron.

GRANISETRON

Products Affected

- Granisetron Hcl INJ 1MG/ML
- Granisetron Hydrochloride

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Prevention or treatment of nausea and vomiting associated with cancer chemotherapy or radiation: documentation of current treatment with 1) moderately or highly emetogenic chemotherapy or 2) total body, upper hemi-body or abdominal irradiation.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Nausea and vomiting, cancer treatment: 12 months. Post-operative nausea and vomiting: one dose.
Other Criteria	1) Not receiving concurrent oral or IV Zofran, Kytril, Anzemet or Emend. 2) If granisetron is being used as part of a cancer chemotherapy regimen, Part B versus D determination will be made to determine coverage.

HAEGARDA

Products Affected

- Haegarda

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) Documentation of hereditary angioedema Type 1 and II confirmed by genetic testing or complement studies of C4, C1INH antigenic and C1INH functional levels supporting the diagnosis. 2) For hereditary angioedema Type III, documentation of diagnosis confirmed by genetic testing, normal complement studies combined with clinical features of angioedema or family history. Renewal criteria for long term prevention: Documentation of a reduction in the number of angioedema attacks, improvement in the severity and duration of attacks or clinical documentation of functional improvement.
Age Restrictions	N/A
Prescriber Restrictions	Prescribing restricted to or in consultation with a hematologist, allergist or an immunologist
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

HETLIOZ

Products Affected

- Hetlitz Lq

- Tasimelton

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	A) Non-24 hour sleep-wake cycle, initial: documentation of a diagnosis that meets the International Classification of Sleep Disorders diagnostic criteria. Renewal: documentation of an increase in nighttime sleeping and decrease in daytime napping. B) Dyssomnia due to Smith-Magenis syndrome, initial: medical record documentation of the diagnosis. Renewal: documentation of an improvement in sleep quality.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

HYFTOR

Products Affected

- Hyftor

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: medical record documentation of a confirmation of facial angiofibroma associated with tuberous sclerosis. Renewal: medical record documentation of a clinical response to therapy, such as improvement in size or redness of facial angiofibroma.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 12 weeks. Renewal: 12 months.
Other Criteria	N/A

IBTROZI

Products Affected

- Ibtrozi

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of the diagnosis.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist.
Coverage Duration	Lifetime
Other Criteria	1) Failure of, intolerance or contraindication to: a) Xalkori and 2) Rozyltrek. Both require prior authorization. 2) Drug must be prescribed for a FDA approved indication. If prescribed for non-cancer indication that is not FDA approved, the off-label use of the drug must be for a medically accepted indication that is supported by AHFS (American Hospital Formulary Service) Drug Information or Micromedex DrugDex. If prescribed for a cancer indication that is not FDA approved, the off-label use of the drug must be supported by NCCN (National Comprehensive Cancer Network) guidelines, AHFS (American Hospital Formulary Service) Drug Information, Micromedex DrugDex, Clinical Pharmacology, Lexi-Drugs, or research found in peer reviewed medical literature in accordance with Chapter 15 of the Medicare Benefit Policy Manual.

ICATIBANT

Products Affected

- Icatibant Acetate

- Sajazir

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Documentation of hereditary angioedema Type 1 and II confirmed by genetic testing or complement studies of C4, C1INH antigenic and C1INH functional levels supporting the diagnosis. For hereditary angioedema Type III, documentation of diagnosis confirmed by genetic testing, normal complement studies combined with clinical features of angioedema or family history. Renewal criteria for long-term prevention: Documentation of a reduction in symptoms such as abdominal pain, cutaneous pain and cutaneous swelling.
Age Restrictions	Age at least 18 years.
Prescriber Restrictions	Hematologist, allergist or immunologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

IMKELDI

Products Affected

- Imkeldi

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Medical record documentation of the diagnosis.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with an oncologist, or in certain conditions a hematologist, endocrinologist, neurologist, allergist or dermatologist.
Coverage Duration	Lifetime
Other Criteria	1) Documentation of an inability to swallow oral tablets. 2) Drug must be prescribed for an FDA approved indication, or if prescribed for non-cancer indication that is not FDA approved, the off-label use of the drug must be for a medically accepted indication that is supported by AHFS (American Hospital Formulary Service) Drug Information or Micromedex DrugDex, or if prescribed for a cancer indication that is not FDA approved, the off-label use of the drug must be supported by NCCN (National Comprehensive Cancer Network) guidelines, AHFS (American Hospital Formulary Service) Drug Information, Micromedex DrugDex, Clinical Pharmacology, Lexi-Drugs, or research found in peer reviewed medical literature in accordance with Chapter 15 of the Medicare Benefit Policy Manual.

IMPAVIDO

Products Affected

- Impavido

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record confirmation of a diagnosis of leishmaniasis.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with an infectious disease specialist
Coverage Duration	28 days
Other Criteria	Failure of amphotericin B or Ambisome.

INBRIJA

Products Affected

- Inbrija

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Renewal: Documentation that the patient's off time has been reduced with Inbrija.
Age Restrictions	N/A
Prescriber Restrictions	Neurologist
Coverage Duration	Initial: 3 month. Renewal: Lifetime.
Other Criteria	Initial: failure of maximum tolerable doses of oral levodopa/carbidopa and one of the following: selegiline, ropinirole, pramipexole, tolcapone and entacapone.

INCRELEX

Products Affected

- Increlex

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	1) Evidence of closure of epiphyseal plate. 2) Active or suspected neoplasia.
Required Medical Information	1) Primary IGF-1 Deficiency, Initial: a) Secondary causes have been ruled out, such as growth hormone deficiency, malnutrition, hypothyroidism, and chronic corticosteroid therapy, b) Height standard deviation score less than or equal to -3, c) basal IGF-1 standard deviation score of less than or equal to -3 and d) normal or elevated growth hormone, greater than or equal to 10ng/ml to at least two stimuli including insulin, levodopa, arginine, clonidine, or glucagon. Renewal criteria: documentation of clinical improvement, such as an increase in height velocity. 2) Growth Hormone Gene Deletion Initial: evidence of gene deletion and (+) neutralizing antibodies to growth hormone. Renewal criteria: documentation of clinical improvement, such as an increase in height velocity.
Age Restrictions	Age 2-18 years
Prescriber Restrictions	Endocrinologist
Coverage Duration	12 months
Other Criteria	N/A

INFLIXIMAB

Products Affected

- Avsola

- Inflectra

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	1) Moderate to severe heart failure, doses greater than 5mg/kg should not be administered
Required Medical Information	1) Crohn's disease (CD) renewal: a decrease in symptoms, reduction in enterocutaneous fistulas or clinical remission. 2) Rheumatoid arthritis (RA) renewal: improved functioning and/or improvement in tender joint count and swollen joint count. 3) Psoriasis with arthropathy (PsA) renewal: improved functioning and/or greater improvement in tender joint count and swollen joint count. 4) Ankylosing spondylitis (AS) renewal: improved functioning and/or signs and symptoms of AS. 5) Juvenile idiopathic arthritis (JIA) renewal: improved functioning and/or greater improvement in tender joint count and swollen joint count. 6) Plaque psoriasis (PsO) initial: involvement of more than 3% of body surface area or hand, foot, face, scalp or genital involvement. PsO renewal: improvement in affected BSA, plaque severity and/or functioning. 7) Ulcerative Colitis (UC) renewal: medical record documentation of treatment response such as decrease in bloody stools per day, elimination of signs of toxicity, or clinical remission. 8) Hidradenitis suppurativa (HS) initial: moderate to severe disease evident by documentation of Hurley Stage II or III and at least 3 abscesses or inflammatory nodules. HS renewal: medical record documentation of a reduction in nodules or abscesses. 9) Uveitis initial: documentation of non-infectious, intermediate, posterior or panuveitis. Renewal: documentation that treatment response is being monitored for the following development of new inflammatory chorioretinal and/or inflammatory retinal vascular lesions, anterior chamber cell grade or vitreous haze, or visual acuity.
Age Restrictions	N/A
Prescriber Restrictions	Plaque psoriasis: dermatologist. Psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis: rheumatologist. Crohn's disease and ulcerative colitis: gastroenterologist.

Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	RA initial: failure of methotrexate and at least one other DMARD such as leflunomide, sulfasalazine, or hydroxychloroquine. AS initial: failure of one non-steroidal anti-inflammatory drug such as meloxicam, ibuprofen, naproxen or diclofenac. JIA initial: failure of an 8 week trial of methotrexate. PsO Initial: failure of 1) one topical agent such as a corticosteroid (i.e. betamethasone or clobetasol), calcipotriene, tazarotene (requires prior authorization), or tacrolimus (requires prior authorization) and 2) methotrexate or cyclosporine.

INGREZZA

Products Affected

- Ingrezza

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Tardive dyskinesia, renewal: medical record documentation of treatment response such as a reduction in the Abnormal Involuntary Movement Scale (AIMS) score from baseline, improvement in involuntary movement, or improvement in functional ability. Chorea associated with Huntington's disease, renewal: medical record documentation of a clinical response such as improvement in chorea, ability to perform activities of daily living, reduction in falls, or increase in quality of life.
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist, movement disorder specialist or a psychiatrist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

INREBIC

Products Affected

- Inrebic

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of the diagnosis.
Age Restrictions	N/A
Prescriber Restrictions	Must be prescribed by or in consultation with an oncologist or a hematologist.
Coverage Duration	Lifetime
Other Criteria	1) Failure of Jakafi or the prescriber must provide a medical reason why Jakafi cannot be used. 2) Drug must be prescribed for an FDA approved indication or a medically accepted indication that is supported by AHFS (American Hospital Formulary Service) Drug Information or Micromedex DrugDex if for non-cancer use, or supported by NCCN Compendium, Clinical Pharmacology, Lexi-Drugs, and acceptable medical journals for cancer indication.

INTRAVENOUS IMMUNE GLOBULIN

Products Affected

- Atgam
- Bivigam INJ 10%, 5GM/50ML
- Flebogamma Dif INJ 10GM/100ML, 10GM/200ML, 2.5GM/50ML, 20GM/200ML, 20GM/400ML, 5GM/100ML, 5GM/50ML
- Gamastan
- Gammagard Liquid
- Gammagard S/d Iga Less Than 1mcg/ml
- Gammaked INJ 10GM/100ML, 1GM/10ML, 20GM/200ML, 5GM/50ML
- Gammaplex INJ 10GM/100ML, 10GM/200ML, 20GM/200ML, 20GM/400ML, 5GM/100ML, 5GM/50ML
- Gamunex-c
- Octagam INJ 10GM/100ML, 10GM/200ML, 1GM/20ML, 2.5GM/50ML, 20GM/200ML, 2GM/20ML, 30GM/300ML, 5GM/100ML, 5GM/50ML
- Privigen
- Thymoglobulin

PA Criteria	Criteria Details
Indications	All FDA-approved Indications, Some Medically accepted Indications.
Off-Label Uses	1) HIV, 2) Allogeneic bone marrow transplant (BMT), 3) Pregnancy-associated idiopathic thrombocytopenic pupura, 4) Myasthenia Gravis (MG), 5) Autoimmune Mucocutaneous Blistering Disease (AMBD), 6) Autoimmune Hemolytic Anemia, Warm Type (AHA-W), 7) Polymyositis and 8) Dermatomyositis
Exclusion Criteria	N/A

Required Medical Information	<p>1) Acute Idiopathic Thrombocytopenic Purpura: platelet less than 30,000 or need to increase platelet prior to major, invasive surgery. 2) Chronic ITP: duration of illness less than 6 months, no concurrent illness/disease explaining thrombocytopenia, platelets persistently below 20,000. 3) ITP in pregnancy: previous deliveries of children with autoimmune thrombocytopenia or platelets below 30,000 associated with bleeding before delivery, or platelets below 75,000 during the current pregnancy or history of splenectomy. 4) Chronic B-Cell Lymphocytic Leukemia with hypogammaglobulinemia: IgG below 600 and evidence of specific antibody deficiency and repeated bacterial infections. 5) HIV: CD4+ greater than 200/mm³, and clinically symptomatic. 6) BMT: hematologic neoplasm, seropositive for CMV prior to transplant, severe hypogammaglobulinemia defined as IgG less than 400 within the first 100 days post transplant, and seronegative donor. 7) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) including Guillain-Barre Syndrome: Difficulty with venous access for plasmaphoresis, or rapidly progressive form of disease with symptoms less than 2 weeks or deteriorating ability to ambulate, or deteriorating PFTs. 8) Autoimmune Mucocutaneous Blistering Disease (AMBD): Diagnosis of pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid or epidermolysis bullous acquisita. 9) Autoimmune Hemolytic Anemia, Warm Type: Predominance of IgG antibodies or comorbid hepatomegaly or hepatosplenomegaly. 10) Polymyositis and Dermatomyositis: associated with severe disability. 11) Acute Myasthenia Gravis (AMG): a) Myasthenic exacerbation defined by difficulty swallowing, acute respiratory failure, or major functional disability or b) presurgical treatment. 12) Multifocal motor neuropathy (For Gammagard only): medical record documentation of treatment response such as improvement in functional ability such as grip strength.</p>
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Acute ITP, ITP in pregnancy, HIV, BMT, AMBD, AMG, 3 months: All other diagnoses: Lifetime

Other Criteria	<p>1) For primary immunodeficiencies only, IVIG may be covered in the home under Medicare Part B if coverage guidelines are met. 2) Chronic ITP requires failure of prednisone. 3) AMG requires failure of two of the following: pyridostigmine, prednisone, azathioprine, or methotrexate. 4) AMBD requires a) failure of prednisone and at least one of the following: methotrexate, azathioprine, cyclosporine or cyclophosphamide or b) evidence of rapid disease progression and urgent administration of IVIG is medically necessary. 5) Polymyositis and Dermatomyositis require failure of prednisone and at least one of the following: methotrexate, azathioprine, cyclosporine or cyclophosphamide.</p>
-----------------------	--

IQIRVO

Products Affected

- Iqirvo

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) Confirmation of a diagnosis of primary biliary cholangitis. 2) documentation of an inadequate treatment response to ursodeoxycholic acid (UDCA), or documented contraindication to UDCA. Renewal: 1) documentation of reduction in alkaline phosphatase (ALP) from baseline. 2) Continued use of ursodeoxycholic acid (UDCA) unless there is documentation of intolerance.
Age Restrictions	Age of at least 18 years or older.
Prescriber Restrictions	Prescribed by, or in consultation with a gastroenterologist or hepatologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

IRON CHELATOR

Products Affected

- Deferasirox

- Deferiprone
- Ferriprox SOLN

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	For chronic iron overload due to blood transfusions (deferiprone and deferasirox) Initial: documentation of elevated sodium ferritin levels. For non-transfusion-dependent thalassemia syndromes (deferasirox only) Initial: 1) liver iron concentrations at least 5 milligrams of iron per gram of liver dry weight and 2) serum ferritin greater than 300 mcg/L. For transfusional iron overload in patients with sickle cell disease or other anemias (deferiprone only), initial: documentation of elevated sodium ferritin levels. Renewal criteria for all indications: reduction in total body iron, evidenced by decreased ferritin levels.
Age Restrictions	N/A
Prescriber Restrictions	Hematologist
Coverage Duration	12 months
Other Criteria	For chronic iron overload due to blood transfusions, Initial: Failure of deferoxamine or reason why deferoxamine cannot be used.

ISOTRETINOIN

Products Affected

- Accutane
- Amnesteem
- Claravis CAPS 10MG
- Isotretinoin CAPS 10MG, 20MG, 30MG, 40MG
- Myorisan
- Zenatane

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Females who are pregnant or who may become pregnant and are not using at least two forms of contraception.
Required Medical Information	Medical record documentation of negative pregnancy test and use of reliable methods of birth control in females of child-bearing age.
Age Restrictions	Age at least 12 years.
Prescriber Restrictions	Dermatologist
Coverage Duration	20 weeks
Other Criteria	Documentation of failure of at least a 4 week trial of a) one oral antibiotic (e.g., tetracycline, doxycycline, minocycline, or erythromycin) and b) topical tretinoin.

JOENJA

Products Affected

- Joenja

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) Medical record confirmation of a diagnosis of activated phosphoinositide 3-kinase delta (PI3K δ) syndrome (APDS). 2) Weight of at least 45kg or greater.
Age Restrictions	At least 12 years of age
Prescriber Restrictions	Prescribed by, or in consultation with an immunologist, hematologist, oncologist, allergist or geneticist.
Coverage Duration	Lifetime
Other Criteria	N/A

JOURNAVX

Products Affected

- Journavx

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Documentation of moderate to severe acute pain and that treatment is intended to be 14 days or less.
Age Restrictions	18 years of age or older.
Prescriber Restrictions	N/A
Coverage Duration	14 days
Other Criteria	Failure of, contraindication to, or intolerance to: 1) an NSAID, and 2) a short-acting opioid. In patients with a history of substance use disorder: Failure of, contraindication to, or intolerance to an NSAID.

JUXTAPID

Products Affected

- Juxtapid CAPS 10MG, 20MG, 30MG, 5MG

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial criteria: diagnosis of homozygous familial hypercholesterolemia. Renewal criteria: reduction in LDL-C.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Failure of or intolerance to: 1) ezetimibe and 2) rosuvastatin or atorvastatin.

JYNARQUE

Products Affected

- Jynarque TABS

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Evidence of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) as defined by 1) a confirmed glomerular filtration rate (GFR) decline of at least 5 mL/min per year over 1 year and/or 2.5 mL/min per year over a period of 5 years or 2) a total kidney volume increase of at least 5% per year confirmed by at least 3 repeated ultrasound or MRI measurements taken at least 6 months apart, or 3) Mayo Classification 1C to 1E.
Age Restrictions	N/A
Prescriber Restrictions	Nephrologist
Coverage Duration	Lifetime
Other Criteria	N/A

KALYDECO

Products Affected

- Kalydeco

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial criteria: medical record documentation of a diagnosis of cystic fibrosis with genetic confirmation of a mutation in the CFTR gene that is responsive to Kalydeco (ivacaftor). Renewal criteria: medical record documentation of treatment response such as an improvement in FEV1, reduction in pulmonary exacerbation, or improvement in respiratory symptoms.
Age Restrictions	N/A
Prescriber Restrictions	Pulmonologist
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

KERENDIA

Products Affected

- Kerendia TABS 10MG, 20MG

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	1) eGFR less than 25 mL/min/1.73m ² or 2) serum potassium greater than 5 mEq/L.
Required Medical Information	Medical record documentation of 1) a diagnosis of chronic kidney disease associated with type 2 diabetes and 2) eGFR of at least 25 mL/min/1.73m ² .
Age Restrictions	Age at least 18 years
Prescriber Restrictions	Prescribed by, or in consultation with a nephrologist or a cardiologist
Coverage Duration	Lifetime
Other Criteria	N/A

KEVEYIS

Products Affected

- Dichlorphenamide

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Renewal criteria: medical record documentation of a reduction in the number, frequency or duration of paralytic attacks.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

KINERET

Products Affected

- Kineret

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Rheumatoid Arthritis (RA) Renewal: Improved functioning and/or improvement in tender joint count and swollen joint count. 2) Neonatal onset multi-system inflammatory disease, renewal: improvement in symptoms or laboratory markers. 3) Deficiency of Interleukin-1 Receptor Antagonist (DIRA) renewal: documentation of a positive clinical response, such as low disease activity, or improvement in signs and symptoms.
Age Restrictions	N/A
Prescriber Restrictions	RA: Prescribed by or in consultation with a rheumatologist
Coverage Duration	RA Initial: 6 mo. Renewal: 12 mo. Neonatal Onset Multi-system Inflammatory Disease, DIRA: 12 mo.
Other Criteria	RA initial: failure of two of the following: Enbrel, adalimumab (Humira or adalimumab-adbm), Simponi, Actemra, Orencia, Rinvoq, or Xeljanz (IR or XR). All require prior authorization.

KORLYM

Products Affected

- Mifepristone TABS 300MG

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	1) Not covered for use in patients with type 2 diabetes mellitus that is not associated with Cushing's syndrome. 2) Not covered in pregnant females.
Required Medical Information	Initial criteria: Documentation of failure of surgical treatment or the patient is not a candidate for surgery. Renewal criteria: documentation of a reduction in HbA1c or has reached target HbA1c.
Age Restrictions	N/A
Prescriber Restrictions	Endocrinologist
Coverage Duration	Initial: 6 months. Renewal: Lifetime.
Other Criteria	1) Documentation of failure of a) insulin therapy and b) one of the following: metformin, a sulfonylurea and a thiazolidinedione.

KYNMOBI

Products Affected

- Kynmobi

- Kynmobi Titration Kit

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Renewal: Documentation that the patient's off time has been reduced with Kynmobi.
Age Restrictions	N/A
Prescriber Restrictions	Neurologist
Coverage Duration	Initial: 3 months. Renewal: Lifetime
Other Criteria	Initial: Documentation of failure of maximum tolerable doses of oral levodopa/carbidopa and one of the following: selegiline, ropinirole, pramipexole, tolcapone and entacapone.

LAMPIT

Products Affected

- Lampit

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of a diagnosis of Chagas disease caused by T. cruzi confirmed by detection of T. cruzi trypomastigotes on microscopy, detection of T. cruzi DNA by PCR assay, or 2 positive diagnostic serologic tests using two different techniques and antigens showing IgG antibodies to T. cruzi.
Age Restrictions	0 to 18 years of age.
Prescriber Restrictions	Infectious disease specialist or cardiologist.
Coverage Duration	60 days.
Other Criteria	N/A

LEUPROLIDE

Products Affected

- Eligard
- Leuprolide Acetate INJ 1MG/0.2ML, 22.5MG
- Lupron Depot (1-month)
- Lupron Depot (3-month)
- Lupron Depot (4-month)
- Lupron Depot (6-month)
- Lupron Depot-ped (1-month)
- Lupron Depot-ped (3-month)

PA Criteria	Criteria Details
Indications	All FDA-approved Indications, Some Medically accepted Indications.
Off-Label Uses	Gender dysphoria (GD)
Exclusion Criteria	N/A
Required Medical Information	Endometriosis (EM): requires laparoscopic confirmation of diagnosis.
Age Restrictions	Central Precocious Puberty (CPP): for females, age 1 to 11 years. For males, age 1 to 12 years.
Prescriber Restrictions	Prescribed by or in consultation with a hematologist, oncologist, obstetrician/gynecologist, urologist, or endocrinologist.
Coverage Duration	Anemia due to leiomyoma: 3 mo. EM, CPP, uterine leiomyoma: 6 mo. GD: 12 mo. Cancer: Lifetime
Other Criteria	N/A

LEVOLEUCOVORIN

Products Affected

- Levoleucovorin INJ 50MG
- Levoleucovorin Calcium

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Oncologist, rheumatologist, or gastroenterologist
Coverage Duration	12 months
Other Criteria	The following criteria applies to members who newly start on the drug: Medical record documentation of failure of leucovorin or reason why leucovorin cannot be used.

LIBERVANT

Products Affected

- Libervant

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Age 2 to 5 years
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

LIDOCAINE PATCHES

Products Affected

- Lidocaine PTCH 5%

PA Criteria	Criteria Details
Indications	All FDA-approved Indications, Some Medically accepted Indications.
Off-Label Uses	1) Diabetic peripheral neuropathy, 2) Cancer neuropathic pain, 3) Chronic back pain, 4) Osteoarthritis of hip or knee.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime.
Other Criteria	N/A

LIRAGLUTIDE

Products Affected

- Liraglutide INJ 6MG/ML

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of a diagnosis of type 2 diabetes.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

LITHIUM SOLUTION

Products Affected

- Lithium

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime.
Other Criteria	The following criteria only applies to members who newly start on the drug: Medical record documentation of an inability to swallow solid dosage forms.

LIVDELZI

Products Affected

- Livdelzi

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) Confirmation of a diagnosis of primary biliary cholangitis. 2) documentation of an inadequate treatment response to ursodeoxycholic acid (UDCA), or documented contraindication to UDCA. Renewal: 1) documentation of reduction in alkaline phosphatase (ALP) from baseline. 2) Continued use of ursodeoxycholic acid (UDCA) unless there is documentation of intolerance.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a gastroenterologist or hepatologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

LIVMARLI

Products Affected

- Livmarli SOLN

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of pruritis associated with Alagille syndrome OR cholestatic pruritis due to progressive familial intrahepatic cholestasis (PFIC). Renewal: Medical record documentation of clinical benefit, such as a decrease in pruritis, or improvement in quality of life.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

LIVTENCITY

Products Affected

- Livtency

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of 1) a history of solid organ transplant or hematopoietic stem cell transplantation, and 2) cytomegalovirus infection/disease.
Age Restrictions	Age at least 12 years
Prescriber Restrictions	Prescribed by, or in consultation with an infectious disease specialist, transplant specialist or oncologist.
Coverage Duration	8 weeks
Other Criteria	Failure of valganciclovir, ganciclovir, cidofovir or foscarnet.

LODOCO

Products Affected

- Lodoco

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Documentation of established atherosclerotic cardiovascular disease or multiple risk factors for cardiovascular disease.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a cardiologist or lipid specialist
Coverage Duration	Lifetime
Other Criteria	Failure of or intolerance to two statins, such as atorvastatin or rosuvastatin.

LOKELMA

Products Affected

- Lokelma

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial criteria: medical lab documentation of hyperkalemia. Renewal criteria: reduction in serum potassium from baseline.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

LUCEMYRA

Products Affected

- Lofexidine Hydrochloride

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	14 days
Other Criteria	N/A

LUMIZYME

Products Affected

- Lumizyme

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of 1) Clinical symptoms and biochemical testing indicates alpha-1,4-glucosidase deficiency, and 2) Objective, measurable treatment goals. Renewal: Medical record documentation of stabilization of disease progression.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Dosing consistent with product label: 20 mg/kg IV every 2 wk.

LUPKYNIS

Products Affected

- Lupkynis

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Receiving standard therapy including corticosteroids and immunosuppressants. Renewal: medical record documentation of 1) treatment response such as stabilization of eGFR or no worsening of disease activity and 2) continued use of background immunosuppressant therapy.
Age Restrictions	N/A
Prescriber Restrictions	Nephrologist or rheumatologist
Coverage Duration	12 months.
Other Criteria	Failure of Benlysta (requires prior authorization).

LYBALVI

Products Affected

- Lybalvi

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Patients using opioids or undergoing acute opioid withdrawal.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: Failure of two of the following: risperidone, aripiprazole, quetiapine IR and ER, ziprasidone, or asenapine (requires step therapy for new starts).

MAVYRET

Products Affected

- Mavyret

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) Detectable HCV RNA (viral load), 2) Documentation of treatment history including response to previous treatment (treatment naive, previous relapser, partial responder or null responder), and 3) Documentation of presence or absence of cirrhosis.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Criteria will be applied consistent with current AASLD/IDSA guidance
Other Criteria	N/A

MAYZENT

Products Affected

- Mayzent

- Mayzent Starter Pack

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist.
Coverage Duration	Lifetime
Other Criteria	Documentation that Mayzent is being requested for monotherapy and is not intended to be used in combination with other multiple sclerosis agents.

MEBENDAZOLE

Products Affected

- Emverm

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record confirmation of an infection caused by <i>Ancylostoma duodenale</i> (common hookworm), <i>Necator americanus</i> (American hookworm), <i>Enterobius vermicularis</i> (pinworm), <i>Trichuris</i> , (whipworm), or <i>Ascaris lumbricoides</i> (common roundworm).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 month
Other Criteria	N/A

MERCAPTOPURINE SUSPENSION

Products Affected

- Mercaptopurine SUSP

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: Documentation of an inability to swallow solid dosage forms.

METYROSINE

Products Affected

- Metyrosine

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Documentation of scheduled surgical resection or if no surgical intervention planned, documentation of contraindication to surgery or malignant pheochromocytoma.
Age Restrictions	N/A
Prescriber Restrictions	Endocrinologist, Oncologist or Nephrologist
Coverage Duration	12 months
Other Criteria	N/A

MIPLYFFA

Products Affected

- Miplyffa

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: a) confirmation of a diagnosis of Niemann-Pick disease type C (NPC) by genetic testing, b) documentation of neurologic symptoms due to NPC, and c) documentation that Miplyffa will be prescribed in combination with miglustat.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist or neurologist.
Coverage Duration	Lifetime
Other Criteria	N/A

MODAFINIL

Products Affected

- Modafinil TABS

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Renewal: documentation of significant improvement in daytime sleepiness and functioning.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 3 months. Renewal: lifetime.
Other Criteria	N/A

MOTTEGRITY

Products Affected

- Prucalopride

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Documentation of fewer than 3 spontaneous bowel movements per week.
Age Restrictions	Age at least 18 years
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

MOUNJARO

Products Affected

- Mounjaro

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of a diagnosis of type 2 diabetes.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

MOVANTIK

Products Affected

- Movantik

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Opioid-induced constipation in adults with chronic non-cancer pain: documentation of fewer than 3 spontaneous bowel movements per week.
Age Restrictions	Age at least 18 years.
Prescriber Restrictions	N/A
Coverage Duration	Lifetime.
Other Criteria	N/A

MULPLETA

Products Affected

- Mulpleta

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Platelets less than 50k.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a gastroenterologist, hematologist, hepatologist or surgeon.
Coverage Duration	7 days
Other Criteria	Documentation of upcoming procedure.

MULTAQ

Products Affected

- Multaq

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	NYHA Class IV heart failure. Symptomatic heart failure with recent decompensation requiring hospitalization.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Cardiologist
Coverage Duration	Lifetime
Other Criteria	Documentation of failure of or intolerance to amiodarone.

MYALEPT

Products Affected

- Myalept

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial criteria: 1) Laboratory test confirming leptin deficiency and 2) Documentation of complications of leptin deficiency such as hyperglycemia, diabetes, hypertriglyceridemia. Renewal criteria: Laboratory test results showing improvement in HbA1c, glucose and triglycerides from baseline.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Dosing consistent with the FDA approved labeling.

MYCAPSSA

Products Affected

- Mycapssa

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation showing: 1) a diagnosis of acromegaly, 2) response and tolerance to treatment with octreotide or lanreotide, and 3) that it is not appropriate to continue treatment with injection or depot. Renewal: documentation of IGF-1 normalization or symptom improvement.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

MYFEMBREE

Products Affected

- Myfembree

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Endometriosis (EM): requires laparoscopic confirmation of diagnosis.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an ob/gyn specialist
Coverage Duration	24 months
Other Criteria	Failure of or contraindication to oral contraceptives.

NAGLAZYME

Products Affected

- Naglazyme

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of 1) Diagnostic confirmation by such as elevation of glycosaminoglycans (GAG) in the urine or deficiency in galactosamine-4-sulfatase enzyme activity, or genetic test confirmation, and 2) Objective, measurable treatment goals. Renewal: Medical record documentation of stabilization of disease progression such as improvement in 12-minute walk test, rate of stair climbing, reduction in urinary GAG levels, or reduction in liver or spleen size.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Dosing consistent with product label: 1mg/kg IV once weekly.

NEMLUVIO

Products Affected

- Nemludio

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	A) Prurigo nodularis (PN): Initial: medical record confirmation of a diagnosis of prurigo nodularis. Renewal: medical record documentation of a clinical response, such as an improvement in pruritis, a reduction in nodular lesions, or an improvement in functioning. B) Atopic dermatitis (AD): initial: body surface area involvement = 10% at baseline. 2) AD renewal criteria: medical record documentation of a positive treatment response such as a reduction in body surface area involvement, improvement in itching, improvement in functional ability, reduction in the Investigator Global Assessment or Eczema Area and Severity Index from baseline.
Age Restrictions	AD: 12 years of age and older. PN: 18 years of age and older.
Prescriber Restrictions	Prescribed by, or in consultation with a dermatologist.
Coverage Duration	Initial: 6 months Renewal: 12 months
Other Criteria	AD Initial: For patients 12 years of age or older: 1) failure of one of the following very high potency topical steroids: augmented betamethasone, clobetasol or halobetasol and 2) failure of tacrolimus ointment, OR documentation that topical prescription therapies are not appropriate or are contraindicated.

NERLYNX

Products Affected

- Nerlynx

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of the diagnosis.
Age Restrictions	N/A
Prescriber Restrictions	Must be prescribed by or in consultation with an oncologist or in certain conditions a hematologist or endocrinologist
Coverage Duration	12 months
Other Criteria	Drug must be prescribed for a FDA approved indication. If not prescribed for a FDA approved indication, the off-label use of the drug must be for a medically accepted indication that is supported by AHFS (American Hospital Formulary Service) Drug Information, NCCN (National Comprehensive Cancer Network) guidelines, Micromedex DrugDex or peer reviewed medical literature in accordance with Chapter 15 of the Medicare Benefit Policy Manual.

NITAZOXANIDE

Products Affected

- Nitazoxanide TABS

PA Criteria	Criteria Details
Indications	All FDA-approved Indications, Some Medically accepted Indications.
Off-Label Uses	Cryptosporidiosis in HIV infected patients
Exclusion Criteria	N/A
Required Medical Information	For diagnosis of cryptosporidiosis in HIV infected patients: documentation that the patient is on antiretroviral therapy (ART) or if the patient is not on ART then ART is being initiated.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Cryptosporidiosis and Giardiasis: 3 days. Cryptosporidiosis, HIV: 14 days.
Other Criteria	For suspension: documentation that the tablet is not indicated for the member's age, or of an inability to take solid oral dosage forms.

NITYR

Products Affected

- Nityr

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of diagnostic confirmation of HT1 including laboratory testing (e.g. the presence of succinylacetone and tyrosyl compounds in urine or elevated plasma concentrations of tyrosine and methionine). Renewal: Improvement in urine succinylacetone (SA), liver function tests, alpha-fetoprotein, and serum tyrosine and phenylalanine levels.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

NOXAFIL

Products Affected

- Noxafil PACK
- Posaconazole
- Posaconazole Dr

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Candidiasis: 1 month. Aspergillosis: 3 months. Prophylaxis of invasive fungal infections: 6 months.
Other Criteria	For oropharyngeal candidiasis or prophylaxis of invasive fungal infections in a patient who has received a hematopoietic stem-cell transplant or has chemotherapy-induced neutropenia due to hematologic malignancy: failure of fluconazole or itraconazole. For suspension only: documentation of an inability to swallow solid oral dosage forms.

NUCALA

Products Affected

- Nucala

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) For severe asthma with eosinophilic phenotype: Initial criteria: a) Medical record documentation of diagnosis and b) Blood eosinophil levels greater than 150 cells/mcL at baseline or greater than or equal to 300 cells/mcL. Renewal criteria: documentation of or claims history showing a reduction in the use of oral steroids or reduction in asthma symptoms. 2) For eosinophilic granulomatosis with polyangiitis: Initial criteria: a) diagnosis confirmed by documentation of asthma, blood eosinophil level of 10% or an absolute count of greater than 1000 cells/mm ³ , and systemic vasculitis involving two or more extra-pulmonary organs. Renewal criteria: documentation of response to treatment such as achievement of remission, decrease in the use of steroids, decrease in the rate of relapses or improvement in asthma symptoms. 3) For hypereosinophilic syndrome (HES): Initial criteria: Medical record documentation showing that the diagnosis has a duration of at least 6 months, and does not have an identifiable nonhematologic secondary cause. Renewal: documentation of reduction in flares, or other clinical benefit from Nucala. 4) For the treatment of nasal polyps: Initial: a) documentation that Nucala is being used as add-on therapy, and b) documentation of an inadequate response to nasal corticosteroids. Renewal: Documentation of clinical benefit from Nucala.
Age Restrictions	Age at least 6 years for asthma with eosinophilic phenotype.
Prescriber Restrictions	Prescribed by or in consultation with a rheumatologist, pulmonologist, allergist, immunologist, vasculitis specialist, hematologist. EENT or otolaryngologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	For severe asthma with eosinophilic phenotype: Failure of an inhaled corticosteroid and a long-acting beta agonist.

NUEDEXTA

Products Affected

- Nuedexta

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	1) Complete atrioventricular block without implanted pacemaker or is at high risk for complete AV block.2) Concomitant use with drugs containing quinidine, quinine, mefloquine, drugs that prolong the QT interval and are metabolized by CYP2D6 (thioridazine and pimozide), monoamine oxidase inhibitors. 3) Heart failure. 4) Prolonged QT interval, congenital long QT syndrome or history suggesting torsades de pointes.
Required Medical Information	Renewal criteria: documentation of clinical benefit such as improvement in the Center for Neurologic Study Lability Scale or reduction in the number of laughing and crying episodes.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: Lifetime.
Other Criteria	N/A

NULOJIX

Products Affected

- Nulojix

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Documentation that Epstein-Barr virus status is positive.
Age Restrictions	N/A
Prescriber Restrictions	Nephrologist or transplant specialist
Coverage Duration	Lifetime
Other Criteria	To prevent or treat an organ transplant rejection, Part B versus D determination will be made to determine coverage. If the drug is to be covered by Part D and the patient is newly started on Nulojix, documentation of failure of tacrolimus and cyclosporine. Nulojix should be used in combination with basiliximab induction, mycophenolate mofetil and corticosteroids.

NUPLAZID

Products Affected

- Nuplazid CAPS
- Nuplazid TABS 10MG

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: Medical record documentation of failure of or intolerance to clozapine or reason why clozapine cannot be used.

NURTEC

Products Affected

- Nurtec

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Episodic migraine, initial: medical record documentation of 4-14 headache days per month. Episodic migraine, renewal: documentation of treatment response such as a decrease in the number of migraine days, less migraine episodes, decreased abortive medication usage, or emergency room visits related to migraine.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Episodic migraine, initial: 6 months. Episodic renewal: 12 months. Acute migraine: lifetime
Other Criteria	1) Episodic migraine, initial: failure of propranolol and topiramate. 2) Acute migraine treatment: Failure of two triptans such as eletriptan, sumatriptan, naratriptan, rizatriptan, or zolmitriptan. If triptans are contraindicated or there is a history of intolerance to a triptan: failure of or intolerance to: 1) naproxen and 2) one other NSAID such as ibuprofen, diclofenac, flurbiprofen or celecoxib.

OCALIVA

Products Affected

- Ocaliva

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Used in combination with ursodeoxycholic acid (UDCA) unless there is documentation of intolerance. Renewal: 1) Documentation of a reduction in alkaline phosphatase (ALP) from baseline. 2) Continued use of ursodeoxycholic acid (UDCA) unless there is documentation of intolerance.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a gastroenterologist, hepatologist or GI specialist
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Initial: Failure to achieve an alkaline phosphatase (ALP) level of less than 1.67 times the upper limit of normal after at least 12 months of ursodeoxycholic acid (UDCA), or documented contraindication to UDCA.

OCREVUS

Products Affected

- Ocrevus
- Ocrevus Zunovo

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	N/A

OMNIPOD

Products Affected

- Omnipod 5 Dexcom G7g6 Intro Kit (gen 5)
- Omnipod 5 Dexcom G7g6 Pods (gen 5)
- Omnipod 5 G7 Intro Kit (gen 5)
- Omnipod 5 G7 Pods (gen 5)
- Omnipod 5 Libre2 Plus G6 Intro Gen 5
- Omnipod 5 Libre2 Plus G6 Pods
- Omnipod Classic Pdm Starter Kit (gen 3)
- Omnipod Classic Pods (gen 3)
- Omnipod Dash Intro Kit (gen 4)
- Omnipod Dash Pdm Kit (gen 4)
- Omnipod Dash Pods (gen 4)

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	For all: a diagnosis of diabetes. The following criteria apply to those age 21 and older: 1) the member completed a comprehensive diabetes education program, and has been on a program of multiple daily injections of insulin (i.e., at least 3 injections per day), with frequent self-adjustments of insulin doses for at least 6 months prior to initiation of the insulin pump, and has documented frequency of glucose self-testing an average of at least 4 times per day during the 2 months prior to initiation of the insulin pump, and meets one or more of the following criteria while on the multiple daily injection regimen: a) Glycosylated hemoglobin level (HbA1c) greater than 7.0%, b) History of recurring hypoglycemia, c) Wide fluctuations in blood glucose before mealtime, d) Dawn phenomenon with fasting blood sugars frequently exceeding 200 mg/dl, or e) History of severe glycemic excursions. OR 2) the member has been on a pump prior to enrollment in Medicare and has documented frequency of glucose self-testing an average of at least 4 times per day during the month prior to Medicare enrollment.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime

Other Criteria	N/A
-----------------------	-----

OPFOLDA

Products Affected

- Opfolda

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) medical record documentation of late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) not improving on current enzyme replacement therapy, 2) weight of at least 40kg, and 3) documentation that Opfolda will be used in combination with cipagluosidase alfa-atga.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

OPIPZA

Products Affected

- Opienza

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: documentation of an inability to swallow solid oral dosage forms.

OPIUM TINCTURE

Products Affected

- Opium

- Opium Tincture TINC 1%

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Failure of or contraindication to diphenoxylate/atropine and loperamide.

OPSUMIT

Products Affected

- Opsumit

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Pregnancy
Required Medical Information	Documentation of World Health Organization (WHO) functional class II-IV.
Age Restrictions	N/A
Prescriber Restrictions	Pulmonologist or Cardiologist
Coverage Duration	Lifetime
Other Criteria	Failure of or contraindication to 1) sildenafil or tadalafil and 2) bosentan or ambrisentan. All require prior authorization.

ORAL IMMUNOTHERAPY

Products Affected

- Grastek
- Odactra
- Ragwitek

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	For Grastek: documentation of a positive skin test or pollen specific IgE antibodies to Timothy grass or cross-reactive grass pollens. For Odactra, documentation of a positive skin test to licensed house dust mite allergen extracts or positive in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites.
Age Restrictions	Age 65 years of age or younger
Prescriber Restrictions	Allergist or Immunologist
Coverage Duration	Lifetime
Other Criteria	Failure of or contraindication to 1) an oral or nasal antihistamine (e.g., cetirizine, levocetirizine, loratadine, azelastine nasal spray) and 2) an intranasal corticosteroid (e.g., fluticasone or flunisolide nasal spray)

ORAL RIBAVIRIN

Products Affected

- Ribavirin CAPS

- Ribavirin TABS 200MG

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Detectable HCV RNA (viral load), 2) Documentation of treatment history including response to previous treatment (treatment naïve, previous relapser, partial responder or null responder), and 3) Documentation of presence or absence of cirrhosis.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Criteria will be applied consistent with current AASLD/IDSA guidance
Other Criteria	Ribavirin will be approved consistent with FDA approved labeling or AASLD/IDSA guidelines as part of treatment regimens consisting of ledipasvir/sofosbuvir, sofosbuvir/velpatasvir, and Pegasys if criteria for these drugs are met. For non-formulary drugs such as Sovaldi or Daklinza approved based on the prescriber's supporting statement that all formulary drugs would not be as effective or safe as the non-formulary drug, ribavirin will be approved as requested consistent with FDA approved labeling or AASLD/IDSA guidelines.

ORAL TRANSMUCOSAL FENTANYL

Products Affected

- Fentanyl Citrate Oral Transmucosal

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Not approved for use of acute or postoperative pain and for opioid non-tolerant patients.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Oncologist or Pain Specialist
Coverage Duration	12 months
Other Criteria	Documentation of 1) Failure of two short-acting opioids (eg, oxycodone, morphine sulfate, etc) or an inability to swallow, dysphagia, esophagitis, mucositis, or uncontrollable nausea/vomiting AND 2) Patient is on or will be on a long-acting narcotic (eg, methadone, morphine sulfate ER, oxycodone ER, fentanyl), or the patient is on intravenous, subcutaneous, or spinal (intrathecal, epidural) narcotics (eg, morphine sulfate, hydromorphone, fentanyl citrate).

ORENCIA

Products Affected

- Orenzia

- Orenzia Clickject

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) Renewal: Improved functioning and/or improvement in tender joint count and swollen joint count. 2) Psoriatic Arthritis (PsA) Renewal: Improved functioning and/or decreased in the number of tender, swollen joints and reduction in skin lesions and/or has disease stability. 3) Prophylaxis of acute graft versus host disease (aGVHD): a) documentation that Orenzia will be used with a calcineurin inhibitor and methotrexate, and b) documentation that the patient will be undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor.
Age Restrictions	JIA: age at least 6 years for Orenzia IV and age at least 2 years for Orenzia Subcutaneous Injection
Prescriber Restrictions	RA, JIA: rheumatologist. PsA: dermatologist or rheumatologist. aGVHD: hematologist, oncologist or transplant specialist.
Coverage Duration	RA, JIA, PsA initial: 6 months. Renewal: 12 months. aGVHD: 28 days
Other Criteria	RA initial: failure of methotrexate and at least one other DMARD such as leflunomide, sulfasalazine, or hydroxychloroquine. JIA initial: failure of an 8-week trial of methotrexate.

ORFADIN

Products Affected

- Nitisinone

- Orfadin SUSP

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of diagnostic confirmation of HT1 including laboratory testing (e.g. the presence of succinylacetone and tyrosyl compounds in urine or elevated plasma concentrations of tyrosine and methionine). Renewal: Improvement in urine succinylacetone (SA), liver function tests, alpha-fetoprotein, and serum tyrosine and phenylalanine levels.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Dosing consistent with product label: initial 1 mg/kg/day (divided into 2 doses) titrated to achieve suppression of SA, maximum 2 mg/kg/day. For Orfadin Suspension: Documentation of an inability to swallow solid dosage forms.

ORGOVYX

Products Affected

- Orgovyx

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of an FDA approved or medically accepted indication.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with Oncologist or Urologist
Coverage Duration	Lifetime
Other Criteria	N/A

ORIAHNN

Products Affected

- Oriahnn

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an ob/gyn specialist.
Coverage Duration	24 months
Other Criteria	Failure of or contraindication to: 1) oral contraceptives and 2) tranexamic acid.

ORILISSA

Products Affected

- Orilissa

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Endometriosis (EM): requires laparoscopic confirmation of diagnosis.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an ob/gyn specialist
Coverage Duration	EM: 24 months. EM with dyspareunia: 6 months. EM with moderate hepatic impairment: 6 months.
Other Criteria	N/A

ORKAMBI

Products Affected

- Orkambi

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial criteria: Medical record documentation of a diagnosis of cystic fibrosis homozygous for the F508del mutation confirmed using an FDA-cleared cystic fibrosis mutation test. Renewal criteria: Medical record documentation of treatment response such as an improvement in FEV1, reduction in pulmonary exacerbation, or improvement in respiratory symptoms.
Age Restrictions	N/A
Prescriber Restrictions	Pulmonologist
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	For Orkambi Pack (Suspension): documentation of an inability to swallow solid dosage forms.

ORLADEYO

Products Affected

- Orladeyo

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Documentation of hereditary angioedema Type 1 and II confirmed by genetic testing, or complement studies of C4, C1INH antigenic and C1INH functional levels supporting the diagnosis. For hereditary angioedema Type III, documentation of diagnosis confirmed by genetic testing, normal complement studies combined with clinical features of angioedema or family history. Renewal: Documentation of reduction in the number of angioedema attacks, significant improvement in the severity and duration of attacks, or documentation of functional improvement.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist, allergist or an immunologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Failure of, intolerance to, or contraindication to two of the following: Cinryze, Haegarda, Takzyro. All require prior authorization.

OTEZLA

Products Affected

- Otezla

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Bechet's syndrome (BS) initial: medical record documentation of oral ulcer's caused by Bechet's syndrome. BS renewal: medical record documentation of reduction in severity of oral ulcers or improvement in symptoms. 2) Plaque psoriasis (PsO) initial: involvement of more than 2% of body surface area or hand, foot, face, or genital involvement. PsO renewal: improvement in affected BSA, plaque severity and/or functioning. 3) Psoriasis with arthropathy (PsA) renewal: improved functioning and/or greater improvement in tender joint count and swollen joint count.
Age Restrictions	N/A
Prescriber Restrictions	BS: rheumatologist. PsO: dermatologist. PsA: rheumatologist or dermatologist
Coverage Duration	Initial: 6 months. Renewal: 12 months
Other Criteria	PsO Initial: failure of 1) one topical agent such as a corticosteroid (i.e. betamethasone or clobetasol), calcipotriene, tazarotene (requires prior authorization), or tacrolimus and 2) methotrexate or cyclosporine.

OXBRYTA

Products Affected

- Oxbryta

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Renewal: documentation of improvement in hemoglobin from baseline.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Failure of hydroxyurea.

OXERVATE

Products Affected

- Oxervate

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Documentation of an active ocular infection or inflammation not related to neurotrophic keratitis in affected eye, or ocular disease requiring topical treatment in the affected eye.
Required Medical Information	Medical record documentation of neurotrophic keratitis.
Age Restrictions	Age at least 2 years.
Prescriber Restrictions	Ophthalmologist
Coverage Duration	8 weeks
Other Criteria	N/A

OXYCODONE ER

Products Affected

- Oxycodone Hcl Er T12A 10MG, 20MG, 40MG, 80MG
- Oxycodone Hydrochloride Er T12A 10MG, 20MG, 40MG
- Oxycontin T12A

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	Failure of sustained release morphine sulfate and not receiving concurrent therapy with another long-acting opioid, such as fentanyl or sustained release morphine sulfate.

OZEMPIC

Products Affected

- Ozempic INJ 2MG/3ML, 4MG/3ML, 8MG/3ML

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of a diagnosis of type 2 diabetes.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

PALIFERMIN

Products Affected

- Kepivance INJ 6.25MG

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Oncologist
Coverage Duration	7 days
Other Criteria	N/A

PALIPERIDONE ER INJECTION

Products Affected

- Invega Hafyera
- Invega Trinza

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	The following criteria applies to members who newly start on the drug. 1) For Invega Hafyera: medical record documentation or evidence from claims history that Invega Sustenna has been used for 4 months OR that Invega Trinza has been used for 3 months. 2) For Invega Trinza: medical record documentation or evidence from claims history that Invega Sustenna has been used for 4 months.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

PALYNZIQ

Products Affected

- Palynziq

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Phenylalanine level (Phe) at or above 600 micromol/L. Renewal: Reduction in Phe levels.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 3 months. Renewal: Lifetime
Other Criteria	N/A

PANRETIN

Products Affected

- Panretin

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of cutaneous lesions associated with AIDS-related Kaposi's sarcoma.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

PARENTERAL BISPHOSPHONATES

Products Affected

- Pamidronate Disodium INJ 30MG/10ML, 6MG/ML, 90MG/10ML
- Zoledronic Acid INJ 4MG/100ML, 4MG/5ML, 5MG/100ML

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	For hypercalcemia of malignancy: albumin-corrected serum calcium above 12mg/dL.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	1) For the diagnosis of osteoporosis: failure of two oral bisphosphonates such as ibandronate and alendronate or reason why bisphosphonates cannot be used. Risedronate is available after failure of ibandronate and alendronate. 2) For end stage renal disease (ESRD) patients on dialysis, Part B versus Part D determination will be made to determine if the drug prescribed will be used for an ESRD-related condition. For ESRD-related conditions, the drug will be covered under Part B and provided by the dialysis center.

PARICALCITOL

Products Affected

- Paricalcitol

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Hypercalcemia and vitamin D toxicity.
Required Medical Information	1) Stage 3 Chronic Kidney Disease (CKD): a) GFR 30-59, b) iPTH at least 70 pg/mL, c) serum calcium less than 9.5 mg/dL, d) serum phosphorus less than or equal to 4.6 mg/dL. 2) Stage 4 CKD: a) GFR 15-29, b) iPTH greater than 110 pg/mL, c) serum calcium less than 9.5 mg/dL, d) serum phosphorus less than or equal to 4.6 mg/dL.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	1) Failure of or intolerance to calcitriol or reason why calcitriol cannot be used. 2) For end stage renal disease (ESRD) patients, Part B versus Part D determination will be made to determine if the drug prescribed will be used for an ESRD-related condition. For ESRD-related conditions, the drug will be covered under Part B and provided by the dialysis center.

PAROXETINE SUSPENSION

Products Affected

- Paroxetine Hydrochloride SUSP

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: Documentation of 1) An inability to take solid oral dosage forms and 2) Failure of or contraindication to sertraline solution.

PEGASYS

Products Affected

- Pegasys

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) For the treatment of hepatitis B (HBV): a) Compensated cirrhosis and HBV DNA greater than 2000 IU/ml or b) If HBeAg positive, HBV DNA at least 20,000 IU/ml and serum ALT is persistently elevated after 3-6 months or liver biopsy shows at least moderate inflammation or significant fibrosis or c) If HBeAg negative, HBV DNA greater than 2000 IU/ml and serum ALT is persistently elevated after 3-6 months or liver biopsy shows at least moderate inflammation or fibrosis. 2) For the treatment of hepatitis C (HCV): Detectable HCV RNA (viral load), 2) Documentation of treatment history including response to previous treatment (treatment naive, previous relapser, partial responder or null responder), and 3) Documentation of presence or absence of cirrhosis.
Age Restrictions	N/A
Prescriber Restrictions	Gastroenterologist, infectious disease specialist, Hepatitis C specialist or hepatologist
Coverage Duration	HBV 12 mo. HCV: 48 weeks
Other Criteria	For the treatment of Hepatitis C, pegylated interferon is no longer standard of care. Refer to criteria for Mavyret, sofosbuvir/velpatasvir, ledipasvir/sofosbuvir, and Vosevi.

PENBRAYA

Products Affected

- Penbraya

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Age between 10 years and 25 years.
Prescriber Restrictions	N/A
Coverage Duration	2 doses in 6 months
Other Criteria	N/A

PENTAMIDINE

Products Affected

- Pentamidine Isethionate INJ

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with an infectious disease specialist, a transplant specialist, an oncologist, or a hematologist.
Coverage Duration	21 days
Other Criteria	N/A

PIMECROLIMUS

Products Affected

- Pimecrolimus

PA Criteria	Criteria Details
Indications	All FDA-approved Indications, Some Medically accepted Indications.
Off-Label Uses	Primary cutaneous lymphomas
Exclusion Criteria	N/A
Required Medical Information	For treatment of primary cutaneous lymphomas: documentation of mycosis fungoides.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a dermatologist or oncologist
Coverage Duration	Lifetime
Other Criteria	For treatment of atopic dermatitis, initial: failure of 1) tacrolimus ointment and 2) if older than 12 years of age: a high potency steroid such as clobetasol.

PLERIXAFOR

Products Affected

- Plerixafor

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Oncologist and hematologist
Coverage Duration	4 days
Other Criteria	Use in combination with a granulocyte colony stimulating factor.

PRALUENT

Products Affected

- Praluent

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	A) For secondary prevention for patients with established atherosclerotic cardiovascular disease (ASCVD): LDL-C greater than 55 mg/dL. B) Primary heterozygous familial hypercholesterolemia (HeFH) initial: 1) LDL-C greater than 100 mg/dL without ASCVD, or greater than 55 mg/dL with ASCVD. C) Primary hypercholesterolemia initial: LDL-C greater than 100 mg/dL without ASCVD, or greater than 55 mg/dL with ASCVD. D) Homozygous familial hypercholesterolemia (HoFH) initial: diagnosis confirmed by a) genetic testing or b) documentation of either untreated LDL-C greater than 500 mg/dL or treated LDL-C greater than 300 mg/dL, AND either xanthoma before 10 years of age or evidence of heterozygous familial hypercholesterolemia in both parents. Renewal criteria for all indications: 1) Continuance of treatment with statins unless contraindicated or the patient is unable to tolerate and 2) LDL reduction.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a cardiologist, endocrinologist or lipid specialist
Coverage Duration	Initial: 6 months. Renewal: Lifetime.
Other Criteria	For all indications: Medical record documentation of failure of, documented contraindications, or intolerance or significant side effects on one high-intensity statin therapy such as atorvastatin 40mg-80mg or rosuvastatin 20mg-40mg for 12 weeks. Contraindications and significant side effects to statins include evidence of rhabdomyolysis or persistent myalgia or myositis.

PRENATAL VITAMINS

Products Affected

- Pnv Prenatal Plus Multivitamin + Dha
- Prenatal TABS 120MG; 0; 200MG; 10MCG; 2MG; 12MCG; 27MG; 1MG; 20MG; 10MG; 1200MCG; 3MG; 1.84MG; 10MG; 25MG

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Male gender
Required Medical Information	N/A
Age Restrictions	Prior authorization is not required for patients under the age of 51. Prior authorization is required for patients 51 years of age and older.
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

PRETOMANID

Products Affected

- Pretomanid

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Drug-sensitive tuberculosis, latent infection due to Mycobacterium tuberculosis, extra-pulmonary infection due to Mycobacterium tuberculosis, or MDR-TB that is not treatment-intolerant or nonresponsive to standard therapy.
Required Medical Information	Medical record documentation of 1) Extensively drug resistant pulmonary tuberculosis confirmed by culture and drug sensitivity, 2) Pretomanid will be used in combination with Sirturo and linezolid.
Age Restrictions	N/A
Prescriber Restrictions	Infectious Disease or tuberculosis (TB) specialist
Coverage Duration	26 weeks
Other Criteria	N/A

PREVYMIS

Products Affected

- Prevymis INJ
- Prevymis TABS

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Documentation of 1) the patient is receiving or will receive an allogenic hematopoietic stem cell transplant and is at risk for cytomegalovirus (CMV) infection because of the patient's CMV-seropositive status or the donor's status. OR 2) that the patient is receiving or will receive a kidney transplant and is at high risk of CMV infection.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	200 days
Other Criteria	N/A

PROMACTA

Products Affected

- Promacta
- Eltrombopag Olamine

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	For chronic immune (idiopathic) thrombocytopenic purpura (ITP): 1) Initial criteria: Medical record documentation of platelet count less 30,000 per mm ³ . 2) Renewal criteria: maintenance of platelet counts between 30,000 per mm ³ and 150,000 per mm ³ or an increase in platelet counts from baseline with resolution of bleeding episodes. For thrombocytopenia in patients with chronic Hepatitis C: 1) Initial criteria: a) Platelets less than 75,000 per mm ³ . b) Request to treat thrombocytopenia to allow initiation of interferon-based therapy. 2) Renewal criteria: medical record documentation that platelets have increased since initiating Promacta. For the treatment of aplastic anemia (AA): 1) Initial criteria: platelets counts less than or equal to 30,000 per mm ³ . 2) Renewal criteria: maintenance of platelet counts between 30,000 per mm ³ and 150,000 per mm ³ or an increase in platelet counts from baseline.
Age Restrictions	Age at least 1 year.
Prescriber Restrictions	For ITP: Hematologist or Oncologist. For hepatitis C, thrombocytopenia: Hematologist, GI specialist, Hepatologist, Infectious Disease specialist or Oncologist. For aplastic anemia: Hematologist or Oncologist.
Coverage Duration	ITP: Initial 6wk, Renew 6mo. HepC, thrombo: Initial 3mo, Renew 12mo. AA: Initial 4mo, Renew 12mo.
Other Criteria	The following criteria only applies to chronic immune (idiopathic) thrombocytopenia: documentation of disease refractory to the following: systemic corticosteroids, immunoglobulin replacement or splenectomy. For suspension: documentation of an inability to swallow solid oral dosage forms.

PULMONARY FIBROSIS AGENTS

Products Affected

- Ofev

- Pirfenidone

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	A) Idiopathic pulmonary fibrosis, initial criteria: medical record documentation of the diagnosis of idiopathic pulmonary fibrosis based on the presence of a usual interstitial pneumonia pattern on high-resolution computed tomography or surgical lung biopsy. B) Systemic sclerosis-associated interstitial lung disease, initial, (Ofev only): medical record documentation of systemic sclerosis-associated interstitial lung disease. Renewal criteria (all diagnoses): medical record documentation of a decrease in the decline in force vital capacity (FVC).
Age Restrictions	N/A
Prescriber Restrictions	Pulmonologist
Coverage Duration	12 months
Other Criteria	N/A

PYRUKYND

Products Affected

- Pyrukynd

- Pyrukynd Taper Pack

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: medical record documentation of a diagnosis of hemolytic anemia with pyruvate kinase deficiency confirmed by genetic testing. Renewal: documentation of a reduction in transfusion requirements from baseline.
Age Restrictions	Age of at least 18 years
Prescriber Restrictions	Prescribed by or in consultation with a hematologist, oncologist, or genetic specialist
Coverage Duration	6 months.
Other Criteria	N/A

QBREXZA

Products Affected

- Qbrexza

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Renewal criteria: medical record documentation of an improvement in symptoms.
Age Restrictions	Age at least 9
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

QUININE SULFATE

Products Affected

- Quinine Sulfate CAPS 324MG

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	7 days
Other Criteria	N/A

RADICAVA

Products Affected

- Edaravone
- Radicava
- Radicava Ors
- Radicava Ors Starter Kit

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Must be prescribed by or in consultation with a neurologist or a specialist in Amyotrophic Lateral Sclerosis (ALS)
Coverage Duration	12 months
Other Criteria	N/A

RALDESY

Products Affected

- Raldesy

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs.
Required Medical Information	1) Medical record documentation of a diagnosis of major depressive disorder.
Age Restrictions	Age of at least 18 years.
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: documented inability to swallow solid oral dosage forms.

RAVICTI

Products Affected

- Ravicti

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Diagnosis confirmed by DNA testing. Renewal: Medical record documentation of stabilization of disease progression such as stabilization of neurologic impairments or seizures.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Failure of sodium phenylbutyrate powder (requires prior authorization).

REGRANEX

Products Affected

- Regranex

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Neoplasm at the application site.
Required Medical Information	Renewal: documentation of a reduction in ulcer size by approximately 30% after 10 weeks of treatment.
Age Restrictions	N/A
Prescriber Restrictions	Surgeon, Podiatrist, Endocrinologist or Infectious Disease Specialist
Coverage Duration	Initial: 3 months. Renewal: 2 months.
Other Criteria	N/A

RELISTOR

Products Affected

- Relistor

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Known or suspected mechanical gastrointestinal obstruction.
Required Medical Information	1) For the treatment of opioid-induced constipation in patients with advanced illness receiving palliative care: a) Receiving palliative care for advanced illness and b) Receiving chronic opioid therapy. 2) For the treatment of opioid-induced constipation in patients with chronic noncancer pain: a) documentation of less than 3 spontaneous bowel movements per week b) Receiving chronic opioid therapy for at least one month.
Age Restrictions	Age at least 18 years
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	For the treatment of opioid-induced constipation in patients receiving palliative care and using injections, dosing consistent with product label: a) 38 kg to less than 62 kg, 8 mg/dose. b) 62 kg to 114 kg, 12 mg/dose. c) Less than 38 kg or greater than 114 kg, 0.15/kg/dose.

RELYVRIO

Products Affected

- Relyvrio

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of a diagnosis of amyotrophic lateral sclerosis (ALS).
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or ALS specialist.
Coverage Duration	Lifetime
Other Criteria	N/A

REPATHA

Products Affected

- Repatha

- Repatha Pushtronex System
- Repatha Sureclick

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	A) For secondary prevention for patients with established atherosclerotic cardiovascular disease (ASCVD): LDL-C greater than 55 mg/dL. B) Primary heterozygous familial hypercholesterolemia (HeFH) initial: 1) LDL-C greater than 100 mg/dL without ASCVD, or greater than 55 mg/dL with ASCVD. C) Primary hypercholesterolemia initial: LDL-C greater than 100 mg/dL without ASCVD, or greater than 55 mg/dL with ASCVD. D) Homozygous familial hypercholesterolemia (HoFH) initial: diagnosis confirmed by a) genetic testing or b) documentation of either untreated LDL-C greater than 500 mg/dL or treated LDL-C greater than 300 mg/dL, AND either xanthoma before 10 years of age or evidence of heterozygous familial hypercholesterolemia in both parents. Renewal criteria for all indications: 1) Continuance of treatment with statins unless contraindicated or the patient is unable to tolerate and 2) LDL reduction.
Age Restrictions	N/A
Prescriber Restrictions	Cardiologist, Endocrinologist or Lipid Specialist
Coverage Duration	Initial: 6 months. Renewal: Lifetime.
Other Criteria	For all indications: Medical record documentation of failure of, documented contraindications, or intolerance or significant side effects on one high-intensity statin therapy such as atorvastatin 40mg-80mg or rosuvastatin 20mg-40mg for 12 weeks. Contraindications and significant side effects to statins include evidence of rhabdomyolysis or persistent myalgia or myositis.

REVCovi

Products Affected

- Revcovi

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: laboratory result confirmation of a diagnosis of adenosine deaminase severe combined immune deficiency (ADASCID). Renewal: medical record documentation of a clinical response to Revcovi, and that monitoring recommended per the FDA labeling is being completed.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with an immunologist.
Coverage Duration	12 months
Other Criteria	N/A

REYVOW

Products Affected

- Reyvow

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	Failure of two triptans such as eletriptan, sumatriptan, naratriptan, rizatriptan, or zolmitriptan. If triptans are contraindicated: failure of 1) naproxen and 2) one other NSAID such as ibuprofen, diclofenac, flurbiprofen or celecoxib.

REZDIFFRA

Products Affected

- Rezdiffra

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: a) Medical record documentation of noncirrhotic nonalcoholic steatohepatitis (NASH). 2) Documentation of moderate to advanced liver fibrosis, Stage F2 or F3.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a hepatologist or gastroenterologist
Coverage Duration	Lifetime
Other Criteria	N/A

REZUROCK

Products Affected

- Rezurock

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Medical record documentation of a diagnosis of chronic graft vs host disease.
Age Restrictions	12 years of age or older
Prescriber Restrictions	Prescribed by, or in consultation with an oncologist, hematologist, or transplant specialist.
Coverage Duration	Lifetime
Other Criteria	For patients age 18 and older: Failure of 1) Jakafi and 2) Imbruvica. Both require prior authorization. For patients age 12 to 17: Failure of Jakafi.

RINVOQ

Products Affected

- Rinvoq

- Rinvoq Lq

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Rheumatoid arthritis (RA) initial: documentation of an inadequate response or intolerance to one or more TNF inhibitors (such as Humira or Enbrel). RA renewal: improved functioning and/or improvement in tender joint count and swollen joint count. 2) Psoriatic arthritis (PsA) initial: documentation of an inadequate response or intolerance to one or more TNF inhibitor (such as Humira, Enbrel, or Simponi). PsA renewal: improved functioning and/or improvement in tender joint count and swollen joint count. 3) Atopic dermatitis (AD) initial: body surface area involvement of at least 10% at baseline. AD renewal: medical record documentation of a positive treatment response such as a reduction in body surface area involvement, improvement in itching, or improvement in functional ability, reduction in the Investigator Global Assessment or Eczema Area and Severity Index from baseline. 4) Ulcerative colitis (UC) or Crohn's disease (CD): initial: documentation of an inadequate response or intolerance to one or more TNF inhibitor (such as Humira or Simponi). UC or CD renewal: medical record documentation of treatment response such as decrease in symptoms, fistulas or bloody stools per day, elimination of signs of toxicity, or clinical remission. 5) Ankylosing spondylitis (AS) renewal: improved functioning and/or signs and symptoms of AS. 6) Non-radiographic axial spondyloarthritis renewal: improved functioning and/or improvement in signs and symptoms of non-radiographic axial spondyloarthritis. 7) Polyarticular juvenile idiopathic arthritis (pJIA): initial: documentation of an inadequate response or intolerance to one or more TNF inhibitor (such as adalimumab). pJIA renewal: improved functioning and/or improvement in tender joint count and swollen joint count. 8) Giant cell arteritis (GCA), renewal: documentation of clinical remission or a reduction in giant cell arteritis signs and symptoms from baseline.
Age Restrictions	N/A

Prescriber Restrictions	RA, pJIA, AS, non-radiographic axial spondyloarthritis, GCA: prescribed by or in consultation with a rheumatologist. PsA: prescribed by or in consultation with a dermatologist or rheumatologist. AD: prescribed by or in consultation with a dermatologist, allergist or immunologist. UC or CD: prescribed by or in consultation with a gastroenterologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Rheumatoid arthritis initial: failure of one of the following: methotrexate, leflunomide, sulfasalazine, or hydroxychloroquine. Atopic dermatitis initial: Failure of or contraindication to 1) one of the following very high potency topical steroids: augmented betamethasone, clobetasol or halobetasol and 2) tacrolimus ointment. Ankylosing spondylitis and non-radiographic axial spondyloarthritis, initial: failure of one non-steroidal anti-inflammatory drug such as meloxicam, ibuprofen, naproxen or diclofenac. pJIA initial: failure of an 8 week trial of methotrexate.

RITUXIMAB

Products Affected

- Riabni
- Rituxan
- Ruxience
- Truxima

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Rheumatoid Arthritis (RA) renewal: medical record documentation of a 20% or greater improvement in tender joint count and swollen joint count or a reduction in specific, objective pain symptoms and/or improved functioning.
Age Restrictions	Age at least 18 years.
Prescriber Restrictions	Oncologist, Rheumatologist or Dermatologist.
Coverage Duration	NHL, CLL, WG, MPA and pemphigus vulgaris: Lifetime. RA Initial: 6 months. RA Renewal: 12 months.
Other Criteria	N/A

RIVFLOZA

Products Affected

- Rivfloza

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Confirmation of primary hyperoxaluria type 1 (PH1) with elevated urinary oxalate excretion and genetic testing. Renewal: medical record documentation of reduction in urinary oxalate excretion.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a nephrologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

ROZLYTREK PELLETS

Products Affected

- Rozlytrek PACK

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of the diagnosis.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with an oncologist.
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to new starts only. Initial: Documentation of an inability to swallow solid oral dosage forms. Drug must be prescribed for a FDA approved indication or a medically accepted indication that is supported by AHFS (American Hospital Formulary Service) Drug Information or Micromedex for non-cancer indications, and supported by NCCN Compendium, Clinical Pharmacology, Lexi-Drugs, and acceptable medical journals for cancer indications.

RSV VACCINE

Products Affected

- Arexvy
- Mresvia

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Prior authorization does not apply to members age 50 years or older for Arexvy, and does not apply to members age 60 years or older for Mresvia.
Age Restrictions	Minimum age of 50 years for Arexvy and 60 years for Mresvia.
Prescriber Restrictions	N/A
Coverage Duration	1 month for 1 dose
Other Criteria	N/A

RUFINAMIDE SUSPENSION

Products Affected

- Rufinamide SUSP

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: documentation of an inability to take solid oral dosage forms.

RYBELSUS

Products Affected

- Rybelsus TABS 14MG, 3MG, 7MG

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of a diagnosis of type 2 diabetes.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

RYTARY

Products Affected

- Rytary

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Prescribed by or in consultation with a neurologist or movement disorder specialist.
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	Failure of carbidopa/levodopa ER tablets.

SANDOSTATIN LAR

Products Affected

- Octreotide Acetate INJ 10MG, 20MG, 30MG

- Sandostatin Lar Depot

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) For the treatment of acromegaly: a) Initial: medical record documentation of failure of surgery, radiation or bromocriptine or reason or reason why surgery, radiation or bromocriptine are not options. b) Renewal: documentation of IGF-1 normalization or symptom improvement. 2) Renewal criteria for all other conditions: reduction in symptoms such as stool frequency.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For the treatment of acromegaly, metastatic carcinoid tumors and vasoactive intestinal peptide tumors: documentation of response to and tolerance to octreotide immediate release injection.

SAPHNELO

Products Affected

- Saphnelo

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Severe active CNS lupus or used in combination with IV cyclophosphamide
Required Medical Information	Initial criteria: 1) Medical record documentation of a diagnosis of systemic lupus erythematosus (SLE) and is auto-antibody positive as defined as Antinuclear antibody (ANA titer) greater than or equal to 1:80 or anti-double stranded DNA antibody (Anti-dsDNA) greater than or equal to 30 IU/ml. 2) Receiving standard therapy including NSAIDs, antimalarials, corticosteroids or immunosuppressants. Renewal criteria: medical record documentation of treatment response such as an improvement in the SELENA-SLEDAI score or no worsening of disease activity.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a rheumatologist
Coverage Duration	Initial: 6 months. Renewal: 12 months
Other Criteria	N/A

SAPROPTERIN

Products Affected

- Javygtor PACK 500MG
- Javygtor TABS
- Sapropterin Dihydrochloride

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Renewal: Documentation of response to therapy.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 3 months. Renewal: Lifetime.
Other Criteria	N/A

SAVELLA

Products Affected

- Savella

- Savella Titration Pack

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of a diagnosis of fibromyalgia.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	Failure of two of the following: pregabalin, duloxetine, or amitriptyline.

SCOPOLAMINE

Products Affected

- Scopolamine PT72 1MG/3DAYS

PA Criteria	Criteria Details
Indications	All FDA-approved Indications, Some Medically accepted Indications.
Off-Label Uses	Excessive salivation prophylaxis
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Post-op nausea and vomiting and motion sickness: 1 month. Excessive salivation: 12 months.
Other Criteria	For the treatment of motion sickness: failure of or intolerance to meclizine.

SECUADO

Products Affected

- Secuado

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	Documentation of failure of, intolerance to, or contraindication to asenapine sublingual tablets (requires step therapy for new starts).

SIGNIFOR

Products Affected

- Signifor

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Renewal criteria: decrease in urinary free cortisol or improvement in signs or symptoms.
Age Restrictions	N/A
Prescriber Restrictions	Endocrinologist
Coverage Duration	Initial: 3 months. Renewal: Lifetime.
Other Criteria	N/A

SIKLOS

Products Affected

- Siklos

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of sickle cell anemia with crisis.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

SILDENAFIL

Products Affected

- Sildenafil Citrate SUSR
- Sildenafil Citrate TABS 20MG

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Concurrent therapy with nitrates.
Required Medical Information	Documentation of New York Heart Association (NYHA) Functional Class II-IV.
Age Restrictions	N/A
Prescriber Restrictions	Pulmonologist or Cardiologist
Coverage Duration	Lifetime
Other Criteria	For oral suspension: documentation of a reason why sildenafil tablets cannot be used such as failure, inability to swallow oral dosage form, or contraindication that is also not a contraindication to the suspension.

SIMPONI

Products Affected

- Simponi

- Simponi Aria

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Rheumatoid arthritis (RA) renewal: improved functioning and/or improvement in tender joint count and swollen joint count. 2) Psoriasis with arthropathy (PsA) renewal: improved functioning and/or greater improvement in tender joint count and swollen joint count. 3) Ankylosing spondylitis (AS) renewal: improved functioning and/or signs and symptoms of AS. 4) Ulcerative Colitis (UC) renewal: medical record documentation of treatment response such as decrease in bloody stools per day, elimination of signs of toxicity, or clinical remission.
Age Restrictions	N/A
Prescriber Restrictions	Rheumatoid arthritis, ankylosing spondylitis: rheumatologist. Psoriatic arthritis: dermatologist or rheumatologist. Ulcerative colitis: gastroenterologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Rheumatoid arthritis initial: failure of one of the following: methotrexate, leflunomide, sulfasalazine, or hydroxychloroquine. AS initial: failure of one oral nonsteroidal anti-inflammatory drug such as meloxicam, ibuprofen, naproxen or diclofenac.

SIRTURO

Products Affected

- Sirturo

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of 1) multi-drug resistant pulmonary tuberculosis confirmed by culture and drug sensitivity and must be resistant to at least isoniazid and rifampin, 2) Other effective regimens cannot be offered.
Age Restrictions	N/A
Prescriber Restrictions	Infectious Disease or tuberculosis (TB) specialist
Coverage Duration	24 weeks
Other Criteria	N/A

SKYCLARYS

Products Affected

- Skyclarys

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of Friedreich's ataxia (FA or FRDA) confirmed by genetic testing. Renewal: medical record documentation of a slowing of progression or clinical benefit.
Age Restrictions	Age at least 16 years or older
Prescriber Restrictions	Prescribed by, or in consultation with a neurologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

SKYRIZI

Products Affected

- Skyrizi INJ 150MG/ML, 180MG/1.2ML, 360MG/2.4ML, 600MG/10ML
- Skyrizi Pen

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Plaque psoriasis (PsO) initial: involvement of at least 3% of body surface area or hand, foot, face, scalp, or genital involvement. PsO renewal: improvement in affected body surface area, plaque severity and/or functioning. 2) Psoriatic arthritis (PsA) renewal: improved functioning and/or greater improvement in tender joint count and swollen joint count. C) Crohn's disease (CD) renewal criteria: a decrease in symptoms, reduction in enterocutaneous fistulas or clinical remission. 4) Ulcerative colitis (UC) renewal: medical record documentation of treatment response such as decrease in bloody stools per day, elimination of signs of toxicity, or clinical remission.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with 1) a dermatologist for PsO, 2) dermatologist or rheumatologist for PsA. CD or UC: Prescribed by, or in consultation with a gastroenterologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Plaque psoriasis, initial: failure of 1) one topical agent such as a corticosteroid (i.e. betamethasone or clobetasol), calcipotriene, tazarotene (requires prior authorization), or tacrolimus and 2) methotrexate or cyclosporine.

SOFOSBUVIR/VELPATASVIR

Products Affected

- Epclusa PACK
- Sofosbuvir/velpatasvir

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) Detectable HCV RNA (viral load), 2) Documentation of treatment history including response to previous treatment (treatment naive, previous relapser, partial responder or null responder), and 3) Documentation of presence or absence of cirrhosis.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Criteria will be applied consistent with current AASLD/IDSA guidance
Other Criteria	Criteria will be applied consistent with current AASLD/IDSA guidance.

SOHONOS

Products Affected

- Sohonos

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Medical record documentation of a diagnosis of fibrodysplasia ossificans progressiva (FOP), confirmed by ACVR1 R206H mutation.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

SOLTAMOX

Products Affected

- Soltamox

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Concomitant coumarin-type anticoagulant therapy or in women with a history of deep vein thrombosis or pulmonary embolus.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: Documentation of an inability to take solid oral dosage forms.

SOMATROPINS

Products Affected

- Genotropin
- Genotropin Miniquick
- Humatrope INJ 12MG, 24MG, 6MG
- Norditropin Flexpro
- Nutropin Aq Nuspin 10
- Nutropin Aq Nuspin 20
- Nutropin Aq Nuspin 5
- Omnitrope
- Saizen
- Saizenprep Reconstitutionkit
- Zorbtive

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	1) In patients with Prader-Willi syndrome, patients who are severely obese, have a history of upper airway obstruction, sleep apnea or severe respiratory impairment. 2) Not approved for the treatment of acute critical illness, respiratory failure or patients with an underlying intracranial tumor.
Required Medical Information	1) Growth Hormone Deficiency (GHD): a) short stature (SS) defined by one of the following:(i) height more than 3 standard deviations (SD) below mean for age and gender or (ii) height below the 3rd percentile for age and gender or (iii) height more than 2 SD below mean and growth velocity (GV) below the 25th percentile for age and gender or (iv) growth velocity less than 2 SD below the mean for age and gender AND b) laboratory results consistent with growth hormone deficiency. 2) Idiopathic SS: short stature as defined under GHD. 3) Prader-Willi syndrome: confirmed by genetic testing or decreased muscle tone by exam. 4) Turner's Syndrome and short-stature homeobox-containing gene (SHOX) deficiency: confirmation of diagnosis by genetic testing. 5) Small for gestational age (SGA) with no catch-up growth by age 2 to 4 years: height remains less than 2 SD below the mean for age and gender. 6) Adult-Onset GHD: a) Pituitary, hypothalamic disease, or GHD as a result of tumor, irradiation, surgery or trauma AND b) laboratory results consistent with growth hormone deficiency. 7) Childhood-Onset Adult GHD: a) laboratory results consistent with growth hormone deficiency. Renewal for all: documentation of improved quality of life or clinical benefit.
Age Restrictions	SBS: Age at least 18 years

Prescriber Restrictions	Endocrinologist, Gastroenterologist, or Nephrologist
Coverage Duration	SBS: 4 weeks. All other diagnoses: 12 months.
Other Criteria	N/A

SOMATULINE DEPOT

Products Affected

- Lanreotide Acetate

- Somatuline Depot

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	1) For the treatment of acromegaly and Carcinoid Syndrome: failure of octreotide or reason why octreotide cannot be used. 2) The following criteria applies to members who newly start on the drug for gastroenteropancreatic neuroendocrine tumors: failure of octreotide or reason why octreotide cannot be used.

SOMAVERT

Products Affected

- Somavert

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Baseline liver function tests are not greater than 3 times the upper limit of normal.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

SOTYLIZE

Products Affected

- Sotylize

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	Medical record documentation of an inability to take solid oral dosage forms.

SPRAVATO

Products Affected

- Spravato 56mg Dose
- Spravato 84mg Dose

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	The following criteria applies to members who newly start on the drug: 1) For treatment resistant major depressive disorder: medical record documentation of failure of separate 6 week trials of two different antidepressants . 2) For treatment of depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior: documentation that Spravato will be used in conjunction with an oral antidepressant.
Age Restrictions	N/A
Prescriber Restrictions	Psychiatrist
Coverage Duration	Lifetime
Other Criteria	N/A

SPRITAM

Products Affected

- Levetiracetam TB3D
- Spritam TB3D 1000MG, 500MG, 750MG

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Evidence from documentation or claims history that Spritam is not being used as monotherapy for myoclonic seizures or primary generalized tonic-clonic seizures.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime.
Other Criteria	The following criteria applies to members who newly start on the drug: 1) For the treatment of partial-onset seizures, failure of the following: a) levetiracetam tablets or oral solution and b) one of the following: carbamazepine tablet/chew tablet/suspension, oxcarbazepine tablet/suspension, phenytoin capsule/chew tablet/suspension, topiramate, divalproex, felbamate tablet/suspension, tiagabine, lamotrigine tablet/chew tablet/oral disintegrating tablet, gabapentin tablet/capsule/solution, lacosamide tablet/suspension or zonisamide. 2) For the treatment of primary generalized tonic-clonic seizures, failure of the following: a) levetiracetam tablets or oral solution and b) one of the following: topiramate, lamotrigine tablet/chew tablet/oral disintegrating tablet, phenytoin capsule/chew tablet/suspension, lacosamide tablet/suspension or carbamazepine tablet/chew tablet/suspension. 3) For the treatment of myoclonic seizures. failure of the following: a) levetiracetam tablets or oral solution and b) one of the following: divalproex, lamotrigine tablet/chew tablet/oral disintegrating tablet or topiramate.

STAMARIL

Products Affected

- Stamaril

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of planned travel to a country at risk for yellow fever. Renewal: Documentation that it has been at least 10 years since the previous dose, or that a booster is recommended to travel to a specific country.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 month for 1 dose
Other Criteria	N/A

STRENSIQ

Products Affected

- Strensiq

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Diagnosis confirmed by genetic testing, low serum activity of alkaline phosphatase or elevated pyridoxine.
Age Restrictions	N/A
Prescriber Restrictions	Endocrinologist, Geneticist or Metabolic Specialist
Coverage Duration	Lifetime
Other Criteria	N/A

SUCRAID

Products Affected

- Sucraid

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) Diagnosis confirmed by one of the following: a) acidic stool pH less than 6, b) increase in breath hydrogen of greater than 10 ppm when challenged with sucrose or c) genetic testing showing sucrase deficiency and 2) Objective, measurable treatment goals are provided. Renewal: medical record documentation of treatment response such as improvement in growth and development or decrease in diarrhea, flatulence or abdominal pain.
Age Restrictions	N/A
Prescriber Restrictions	Gastroenterologist, Endocrinologist, Metabolic Specialist
Coverage Duration	Initial: 3 months. Renewal: 12 months.
Other Criteria	Dosing consistent with product label: Weight greater than 15kg: 17,000 IU per meal or snack. Weight less than 15kg: 8,500 IU per meal or snack.

SYMDEKO

Products Affected

- Symdeko

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial criteria: Medical record documentation of a diagnosis of cystic fibrosis homozygous for the F508del mutation or has a mutation that is responsive to the drug confirmed using an FDA-cleared cystic fibrosis mutation test. Renewal criteria: Medical record documentation of treatment response such as an improvement in FEV1, reduction in pulmonary exacerbation, or improvement in respiratory symptoms.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

SYMPAZAN

Products Affected

- Sympazan

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Sympazan must be used as adjunctive treatment.
Age Restrictions	Age at least two.
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: 1) For Lennox-Gastaut, petit mal variant, failure of a) clonazepam and b) one of the following: valproate, topiramate, lamotrigine, felbamate or rufinamide. 2) For Lennox-Gastaut, other seizure types, failure of two of the following: clonazepam, valproate, topiramate, lamotrigine, felbamate or rufinamide. 3) For all indications, documentation of an inability to swallow solid and liquid dosage forms (tablets and suspension).

SYMPROIC

Products Affected

- Symproic

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Documentation of fewer than 3 spontaneous bowel movements per week.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime.
Other Criteria	N/A

SYNAGIS

Products Affected

- Synagis INJ 100MG/ML, 50MG/0.5ML

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Current age less than 12 months at the start of the RSV season and gestational age is less than 29 weeks and 0 days. 2) Preterm infants who develop chronic lung disease (CLD) of prematurity: a) gestational age is less than 32 weeks and 0 days gestation, b) greater than 21% oxygen requirement for at least 28 days and c) one of the following: current age less than 12 months or current age 12 to 24 months and there is continued need for supplemental oxygen, chronic corticosteroids, or diuretic therapy during the 6 month period prior to the start of the RSV season. 3) Current age less than 12 months with hemodynamically significant congenital heart disease and one of the following: a) acyanotic heart disease who is receiving medication to control CHF and will require cardiac surgical procedures or b) moderate to severe pulmonary hypertension. 4) Current age less than or equal to 12 months with congenital abnormalities of the airway or neuromuscular disease that impairs the ability to clear secretions from the upper airways. 5) Age less than 24 months who will be profoundly immunocompromised during RSV season (such as chemotherapy, or post solid organ or stem cell transplant.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Max of 5 doses

Other Criteria	<p>For patients less than 24 months and with chronic lung disease or hemodynamically significant congenital heart disease, Synagis will be covered for a maximum of 2 seasons. The maximum number of doses depends on the diagnosis or for preterm infants based on gestational age. Synagis season typically starts on November 1st and ends March 31st. Requests are reviewed for November administration unless the CDC surveillance indicates that the season has started earlier. The season will be extended after March 31st until the CDC surveillance report for the region indicates the season is over. A maximum of 5 doses, 1 dose per month, will be approved during the RSV season unless gestational age is between 32 and 34 weeks and 6 days where Synagis will be approved until the patient reaches 90 days of age.</p>
-----------------------	---

SYNAREL

Products Affected

- Synarel

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Endometriosis (EM): requires laparoscopic confirmation of diagnosis.
Age Restrictions	Central precocious puberty: Female age less than 11 years, Male age less than 12 years. Endometriosis: age at least 18 years.
Prescriber Restrictions	EM: Prescribed by or in consultation with ob/gyn specialist or endocrinologist. Central precocious puberty: Prescribed by or in consultation with pediatric endocrinologist or endocrinologist.
Coverage Duration	Endometriosis: 6 months. Central precocious puberty: female until age 11 and male until age 12.
Other Criteria	N/A

TADALAFIL

Products Affected

- Alyq

- Tadalafil TABS 20MG

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Concurrent use of nitrates.
Required Medical Information	Documentation of New York Heart Association (NYHA) Class II or III.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or cardiologist
Coverage Duration	Lifetime
Other Criteria	N/A

TADALAFIL BPH

Products Affected

- Tadalafil TABS 5MG

PA Criteria	Criteria Details
Indications	Some FDA-approved Indications Only.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of a diagnosis of benign prostatic hyperplasia (BPH). Renewal: medical record documentation of an improvement in symptoms of BPH.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: Lifetime.
Other Criteria	Initial: failure of 1) an alpha blocker such as tamsulosin or alfuzosin and 2) an alpha reductase inhibitor such as finasteride or dutasteride.

TADLIQ

Products Affected

- Tadliq

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of an inability to swallow oral tablets or capsules.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a cardiologist or pulmonologist.
Coverage Duration	Lifetime
Other Criteria	N/A

TAKHZYRO

Products Affected

- Takhzyro

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Documentation of hereditary angioedema Type 1 and II confirmed by genetic testing or complement studies of C4, C1INH antigenic and C1INH functional levels supporting the diagnosis. For hereditary angioedema Type III, documentation of diagnosis confirmed by genetic testing, normal complement studies combined with clinical features of angioedema or family history. Renewal criteria for long term prevention: Documentation of a reduction in the number of angioedema attacks, significant improvement in the severity and duration of attacks or clinical documentation of functional improvement.
Age Restrictions	Age at least 2 years.
Prescriber Restrictions	Hematologist, allergist or immunologist.
Coverage Duration	Long term prevention initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

TALTZ

Products Affected

- Taltz

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Plaque psoriasis (PsO) initial: involvement of at least 3% of body surface area or hand, foot, face, scalp, or genital involvement. PsO renewal: improvement in affected body surface area, plaque severity and/or functioning. 2) Psoriatic arthritis renewal: improvement in functioning and/or decreased in number of tender, swollen joints and reduction in skin lesions and/or has disease stability. 3) Ankylosing spondylitis (AS) renewal: improved functioning and/or signs and symptoms of AS. 4) active non-radiographic axial spondyloarthritis (axSPA) renewal: improved functioning and/or signs and symptoms of active non-radiographic axial spondyloarthritis.
Age Restrictions	N/A
Prescriber Restrictions	Plaque psoriasis: dermatologist. Psoriatic arthritis: dermatologist or rheumatologist. Ankylosing spondylitis, and axSPA: rheumatologist
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	PsA initial: failure of two of the following: Enbrel, adalimumab (Humira or adalimumab-adbm), Simponi, Orencia, Otezla, Cosentyx, Skyrizi, Stelara, Rinvoq, or Xeljanz (IR or XR). All require prior authorization. PsO initial: failure of two of the following: Enbrel, adalimumab (Humira or adalimumab-adbm), Otezla, Cosentyx, Skyrizi, or Stelara. All require prior authorization. AS initial: failure of two of the following: Enbrel, Humira or adalimumab-adbm, Simponi, Cosentyx, or Xeljanz (IR or XR). All require prior authorization. axSPA initial: failure of Cosentyx with prior authorization.

TARPEYO

Products Affected

- Tarpeyo

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of primary immunoglobulin A nephropathy at risk of rapid disease progression.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a nephrologist.
Coverage Duration	9 months
Other Criteria	Failure of or intolerance to prednisone.

TAVALISSE

Products Affected

- Tavalisse

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial criteria: Medical record documentation of platelet count less than 20,000 per mm ³ or less than 30,000 per mm ³ with symptoms of bleeding. Renewal criteria: Medical record documentation of maintenance of platelet counts of at least 30,000 per mm ³ or an increase in platelet counts from baseline with resolution of bleeding episodes.
Age Restrictions	N/A
Prescriber Restrictions	Hematologist or Oncologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months
Other Criteria	For chronic immune (idiopathic) thrombocytopenia: documentation of an insufficient response to a previous treatment such as: steroids, IVIG, Promacta, or Rituxan.

TAVNEOS

Products Affected

- Tavneos

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: documentation of microscopic polyangiitis or granulomatosis with polyangiitis, a positive test for anti-PR3 or anti-MPO, documentation that Tavneos will be used in combination with standard therapy (including corticosteroids), and at least 1 major item, 3 non-major items, or 2 renal items of proteinuria and hematuria on the Birmingham Vasculitis Activity Score (BVAS). Renewal: Documentation of clinical remission, improved BVAS score or improved functioning and/or symptoms.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a rheumatologist or nephrologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

TAZORAC

Products Affected

- Tazarotene CREA 0.1%
- Tazarotene GEL

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Pregnancy
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	1) For acne vulgaris: documentation of failure of topical tretinoin. 2) For psoriasis vulgaris: documentation of failure of a mid-to-high potency topical corticosteroid (eg. triamcinolone, betamethasone, fluocinonide, or clobetasol) and topical calcipotriene.

TEGSEDI

Products Affected

- Tegsedi

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial criteria: Transthyretin variant by genotyping, documented amyloid deposit by biopsy. Renewal criteria: medical record documentation of improvement in pain or functioning.
Age Restrictions	18 years or older
Prescriber Restrictions	Neurologist
Coverage Duration	Initial: 6 months. Renewal: Lifetime.
Other Criteria	N/A

TERIFLUNOMIDE

Products Affected

- Teriflunomide

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	Documentation that teriflunomide is being requested for monotherapy and is not intended to be used in combination with other multiple sclerosis agents.

TERIPARATIDE

Products Affected

- Bonsity

- Teriparatide

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Patients at increased baseline risk for osteosarcoma (including those with Paget's disease of bone, open epiphyses, or prior external beam or implant radiation therapy involving the skeleton).
Required Medical Information	1) Postmenopausal female with either a) evidence of recent radiographic osteoporotic fracture while on a bisphosphonate or b) high risk or very high risk of osteoporotic fracture. 2) Male with primary or hypogonadal osteoporosis and either a) evidence of history of osteoporotic fracture or b) multiple risk factors for osteoporotic fractures such as BMD less than -2.5 SD, low BMI, history of hip fracture in 1st degree relative, tall stature, and chronic daily use of tobacco. 3) Female or male with steroid-induced osteoporosis and both: a) steroid use for greater than 3 months at a dose of 5mg per day prednisone (or equivalent) and b) BMD T-score less than -2.5. Renewal for all indications: for use longer than 2 years, documentation of high risk of fracture.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Failure of or contraindication to an oral bisphosphonate, unless considered very high risk for fracture.

TESTOSTERONE-SYSTEMIC

Products Affected

- Methitest

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	1) Men with carcinoma of the breast. 2) Men with known or suspected carcinoma of the prostate.
Required Medical Information	1) For members newly started on the drug for the treatment of primary or secondary hypogonadism: a) total testosterone level less than 300 ng/dL or b) free testosterone level below the normal range for age and gender. 2) Delayed puberty: Skeletal age of at least 12 or chronological age of at least 14.
Age Restrictions	N/A
Prescriber Restrictions	For metastatic breast cancer: oncologist
Coverage Duration	Delayed puberty: 6 months. All other diagnoses: lifetime.
Other Criteria	For treatment of secondary hypogonadism: failure of testosterone cypionate and topical testosterone gel.

TETRABENAZINE

Products Affected

- Tetrabenazine

PA Criteria	Criteria Details
Indications	All FDA-approved Indications, Some Medically accepted Indications.
Off-Label Uses	1) Tardive dyskinesia and 2) Tourette's Syndrome.
Exclusion Criteria	1) Patients who are actively suicidal or with untreated or inadequately treated depression. 2) Patients with impaired hepatic function. 3) Patients taking monoamine oxidase inhibitors. 4) Patients taking reserpine. At least 20 days should elapse after stopping reserpine before starting tetrabenazine.
Required Medical Information	Initial criteria: If the request is for doses greater than 50 mg per day, medical record documentation of CYP2D6 genotyping is required. Renewal criteria: Medical record documentation of a clinical response such as improvement in chorea, ability to perform activities of daily living, reduction in falls, and increase in quality of life.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 3 months. Renewal: 12 months.
Other Criteria	N/A

THALOMID

Products Affected

- Thalomid

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Erythema Nodosum Leprosum (ENL) Renewal criteria: documentation of response to treatment.
Age Restrictions	N/A
Prescriber Restrictions	MM: Oncologist or Hematologist. ENL: Dermatologist. Infectious Disease: Infectious Disease Specialist
Coverage Duration	Cancer: Lifetime. ENL: 12 months.
Other Criteria	N/A

TICOVAC

Products Affected

- Ticovac

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of planned travel to an endemic country. Renewal for fourth dose: documentation of continued risk after 3 years from initial doses.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 12 months. Renewal: 1 month.
Other Criteria	N/A

TIGECYCLINE

Products Affected

- Tigecycline

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Complicated infection of skin and/or subcutaneous tissue: Culture and sensitivity indicates resistance to vancomycin plus aztreonam. 2) Complicated infectious disease of abdomen: Culture and sensitivity indicates resistance to imipenem/cilastin. 3) Community acquired pneumonia: a) Severity of infection necessitates IV treatment and a) Culture and sensitivity indicates resistance to i) a beta-lactam, such as cefotaxime, ceftriaxone plus azithromycin or clarithromycin and ii) fluoroquinolone such as levofloxacin or moxifloxacin.
Age Restrictions	Age at least 18 years
Prescriber Restrictions	Infectious disease specialist
Coverage Duration	14 days
Other Criteria	N/A

TIROSINT SOLUTION

Products Affected

- Tirosint-sol

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	Documentation of an inability to take solid oral dosage forms.

TOLVAPTAN

Products Affected

- Tolvaptan TBPk

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Autosomal dominant polycystic kidney disease, initial: evidence of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD), defined by either a confirmed glomerular filtration rate (GFR) decline of at least 5 mL/min per year over 1 year and/or 2.5 mL/min per year over a period of 5 years OR a total kidney volume increase of at least 5% per year confirmed by at least 3 repeated ultrasound or MRI measurements taken at least 6 months apart. 2) Hypervolemic or euvoletic hyponatremia, initial: documentation of serum sodium less than 125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a nephrologist for ADPKD, or nephrologist, cardiologist or endocrinologist for hyponatremia.
Coverage Duration	ADPKD: Lifetime. Hyponatremia: 30 days.
Other Criteria	N/A

TOPICAL ANTIVIRALS

Products Affected

- Acyclovir CREA
- Acyclovir OINT
- Penciclovir CREA

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	1) Applies to acyclovir ointment only: for genital herpes or patient who are immunocompromised with non-life-threatening mucocutaneous herpes simplex infection, failure of oral acyclovir. 2) For penciclovir: for recurrent herpes simplex labialis (oral herpes), failure of topical acyclovir cream.

TREPROSTINIL

Products Affected

- Treprostinil

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Documentation of New York Heart Association (NYHA) Class II to IV.
Age Restrictions	N/A
Prescriber Restrictions	Pulmonologist or Cardiologist
Coverage Duration	Lifetime
Other Criteria	Failure of or contraindication to 1) sildenafil or tadalafil and 2) bosentan or ambrisentan. All require prior authorization.

TRIKAFTA

Products Affected

- Trikafta

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial criteria: Medical record documentation of a diagnosis of cystic fibrosis with at least one F508del mutation or has a mutation that is responsive to the drug confirmed using an FDA-cleared cystic fibrosis mutation test. Renewal criteria: Medical record documentation of treatment response such as an improvement in FEV1, reduction in pulmonary exacerbation, or improvement in respiratory symptoms.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

TRINTELLIX

Products Affected

- Trintellix

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: Failure of 1) a selective serotonin reuptake inhibitor (SSRI): such as fluoxetine, paroxetine, citalopram, escitalopram, sertraline, AND 2) venlafaxine or duloxetine.

TRULICITY

Products Affected

- Trulicity

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of a diagnosis of type 2 diabetes.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

TRUMENBA

Products Affected

- Trumenba

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Age 10-25 years
Prescriber Restrictions	N/A
Coverage Duration	Series of 3 doses in 6 months.
Other Criteria	N/A

TRYNGOLZA

Products Affected

- Tryngolza

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) Documentation of a diagnosis of Familial Chylomicronemia Syndrome (FCS) confirmed by a genetic test. Renewal: 1) a reduction in triglycerides from baseline, and 2) documentation of clinical improvement such as episodes of acute pancreatitis.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a lipid specialist, endocrinologist, cardiologist, gastroenterologist, or pancreatologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

TRYVIO

Products Affected

- Tryvio

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of 1) blood pressure that is not adequately controlled on multiple blood pressure lowering medications and 2) that Tryvio will be prescribed in combination with other blood pressure lowering medications. Renewal: documentation of reduction in blood pressure from baseline.
Age Restrictions	Age of at least 18 years
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist, nephrologist or endocrinologist
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Initial: Failure of at least two of the following: 1) a beta blocker such as metoprolol, carvedilol, atenolol, 2) a calcium channel blocker such as amlodipine, nifedipine, diltiazem, verapamil, 3) an angiotensin receptor blocker or ACE inhibitor such as losartan or lisinopril, 4) a diuretic such as hydrochlorothiazide.

TYMLOS

Products Affected

- Tymlos

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Patients at increased baseline risk for osteosarcoma (including those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, open epiphyses, or prior external beam or implant radiation therapy involving the skeleton).
Required Medical Information	1) For Postmenopausal females: a) evidence of recent radiographic osteoporotic fracture while on a bisphosphonate or b) high risk or very high risk of osteoporotic fracture. 2) For males: a) documentation of high risk of fracture or b) failure of or intolerance to other osteoporosis therapy.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	24 months. Use is not recommended for longer.
Other Criteria	1) Failure of or contraindication to an oral bisphosphonate, unless considered very high risk for fracture. 2) If there is prior history of a parathyroid hormone analog, cumulative use is not greater than 2 years. If there is prior history then coverage will be allowed to provide a maximum of 24 months of treatment during a lifetime.

TYSABRI

Products Affected

- Tysabri

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	History of or existing progressive multifocal leukoencephalopathy.
Required Medical Information	Crohn's disease: 1) Baseline CRP greater than 2.87mg/L and 2) if the patient is currently on oral corticosteroids, requires documentation of a steroid taper plan. Renewal criteria for Crohn's disease: documentation of a) reduction in CDAI or number of disease flares and/or improved quality of life, b) If previously on oral steroids, steroid has been successfully discontinued, and c) no history of serious infection or evidence of liver toxicity since the previous authorization. MS renewal: documented benefit since initiation of Tysabri such as delay in the accumulation of physical disability and/or reduction in the frequency of clinical exacerbations and no symptoms suggestive of PML (e.g. progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes).
Age Restrictions	Age at least 18 years
Prescriber Restrictions	Neurologist or gastroenterologist
Coverage Duration	12 months
Other Criteria	1) 2) Crohn's disease: failure of infliximab and Humira. 2) Multiple sclerosis: failure of interferon-beta (Avonex, Rebif, Betaseron), Copaxone, Gilenya or Tecfidera with documentation of all of the following a) continuation of clinical relapses b) CNS lesion progression on MRI or worsening disability and c) not on combination therapy with Avonex, Rebif, Betaseron, Copaxone, Glatopa, Extavia, Gilenya or Tecfidera.

UBRELVY

Products Affected

- Ubrelyvy

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	Failure of two triptans such as eletriptan, sumatriptan, naratriptan, rizatriptan, or zolmitriptan. If triptans are contraindicated: failure of 1) naproxen and 2) one other NSAID such as ibuprofen, diclofenac, flurbiprofen or celecoxib.

USTEKINUMAB

Products Affected

- Steqeyma

- Wezlana

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Psoriasis with arthropathy (PsA) renewal: improved functioning and/or improvement in tender joint count and swollen joint count. 2) Plaque psoriasis (PsO) initial: involvement of at least 3% of body surface area or hand, foot, face, scalp, or genital involvement.) PsO renewal: improvement in affected body surface area, plaque severity and/or functioning. 3) Crohn's Disease (CD) renewal: medical record documentation of a decrease in symptoms, reduction in enterocutaneous fistulas or clinical remission. 4) Ulcerative colitis (UC) renewal: medical record documentation of treatment response such as decrease in bloody stools per day, elimination of signs of toxicity, and/or clinical remission.
Age Restrictions	N/A
Prescriber Restrictions	Psoriatic arthritis: rheumatologist or dermatologist. Plaque psoriasis: dermatologist. Crohn's Disease and Ulcerative Colitis: gastroenterologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Plaque psoriasis, initial criteria: failure of 1) one topical agent such as a corticosteroid (i.e. betamethasone or clobetasol), calcipotriene, tazarotene (requires prior authorization), or tacrolimus (requires prior authorization) and 2) methotrexate or cyclosporine.

UZEDY

Products Affected

- Uzedy

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: failure of risperidone intramuscular injection (generic Risperdal Consta).

VARIZIG

Products Affected

- Varizig INJ 125UNIT/1.2ML

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 month
Other Criteria	N/A

VAXCHORA

Products Affected

- Vaxchora

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Medical record documentation of a plan to travel to a cholera-affected area.
Age Restrictions	Age 2 through 64 years of age.
Prescriber Restrictions	N/A
Coverage Duration	1 month for 1 dose
Other Criteria	N/A

VELTASSA

Products Affected

- Veltassa

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial criteria: medical lab documentation of hyperkalemia. Renewal criteria: reduction in serum potassium from baseline.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

VENTAVIS

Products Affected

- Ventavis

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Documentation of New York Heart Association (NYHA) Class III to IV.
Age Restrictions	N/A
Prescriber Restrictions	Pulmonologist or cardiologist
Coverage Duration	Lifetime
Other Criteria	Failure of or contraindication to 1) sildenafil or tadalafil and 2) bosentan or ambrisentan. All require prior authorization.

VEOZAH

Products Affected

- Veozah

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of moderate to severe vasomotor symptoms due to menopause. Renewal: documentation of a reduction in severity of vasomotor symptoms.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: Lifetime.
Other Criteria	1) Failure of paroxetine. 2) Failure of, or contraindication to estradiol.

VERKAZIA

Products Affected

- Verkazia

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Renewal: documentation of an improvement in symptoms of vernal keratoconjunctivitis.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an ophthalmologist
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

VERQUVO

Products Affected

- Verquvo

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of 1) ejection fraction of less than 45%, 2) NYHA class II-IV, 3) a recent decompensation requiring hospitalization or a need for outpatient IV diuretics.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist.
Coverage Duration	Lifetime
Other Criteria	N/A

VERSACLOZ

Products Affected

- Versacloz

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: Documentation of an inability to use clozapine oral disintegrating tablets.

VESICARE LS

Products Affected

- Vesicare Ls

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of a diagnosis of neurogenic detrusor overactivity.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

VIBERZI

Products Affected

- Viberzi

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	1) Alcoholism, alcohol abuse, alcohol addiction, or consumption of more than 3 alcoholic drinks daily. 2) Known or suspected biliary duct obstruction. 3) History of or current chronic or severe constipation. 4) Severe hepatic impairment. 5) Known or suspected mechanical gastrointestinal obstruction. 6) History of pancreatitis. 7) Sphincter of Oddi disease or dysfunction. 8) Structural disease of the pancreas such as pancreatic duct obstruction.
Required Medical Information	Initial: Medical record documentation of irritable bowel syndrome with diarrhea. Documented symptoms of loose or watery stools at least greater than or equal to 25% of stools. Renewal: Medical record documentation of a significant reduction in diarrhea frequency and abdominal pain and/or improvement in quality of life during the 12 week trial.
Age Restrictions	Age at least 18 years
Prescriber Restrictions	N/A
Coverage Duration	Initial: 12 weeks. Renewal: Lifetime.
Other Criteria	Failure of loperamide and dicyclomine.

VIGABATRIN

Products Affected

- Vigabatrín
- Vigadrone
- Vigafyde
- Vigpoder

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Complex Partial Seizures (CPS) Initial: Requires use with another anticonvulsant as combination therapy.
Age Restrictions	Infantile Spasm: age less than 2 years
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug for the treatment of Complex Partial Seizures: Failure of adjunctive treatment with at least two of the following: topiramate, felbamate, gabapentin, lamotrigine, tiagabine, levetiracetam, oxcarbazepine, zonisamide or lacosamide.

VIIBRYD

Products Affected

- Viibryd Starter Pack
- Vilazodone Hydrochloride

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Concomitant use of a MAOI or within 14 days after discontinuing a MAOI.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: Documentation of failure of 1) a selective serotonin reuptake inhibitor such as paroxetine, fluoxetine, citalopram, escitalopram or sertraline and 2) venlafaxine or duloxetine.

VIJOICE

Products Affected

- Vioice

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: a) medical record documentation of a mutation in the PIK3CA gene. b) documentation of the need for systemic therapy. Renewal: documentation of a reduction in lesion size or significant improvement in symptoms.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a genetic specialist
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

VORICONAZOLE

Products Affected

- Voriconazole INJ

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Until end of plan year
Other Criteria	N/A

VOSEVI

Products Affected

- Vosevi

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) Detectable HCV RNA (viral load), 2) Documentation of treatment history including response to previous treatment (treatment naive, previous relapser, partial responder or null responder) with a NS5A inhibitor for genotype 1 to 6 and/or sofosbuvir without an NS5A inhibitor for genotype 1a and genotype 3 and 3) Documentation of presence or absence of cirrhosis.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Criteria will be applied consistent with current AASLD/IDSA guidance
Other Criteria	N/A

VOWST

Products Affected

- Vowst

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Documentation of at least 1 recurrent episode of c. difficile infection (CDI) with a positive stool test and 2) documentation that Vowst will be initiated within 2-4 days following completion of an antibiotic course of treatment for CDI.
Age Restrictions	At least 18 years of age.
Prescriber Restrictions	N/A
Coverage Duration	3 days
Other Criteria	N/A

VOXZOGO

Products Affected

- Voxzogo

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) diagnosis of achondroplasia confirmed by genetic testing with a mutation in the fibroblast growth factor receptor type 3 (FGFR3) gene, and 2) open epiphyses. Renewal: medical record documentation of open epiphyses.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with an endocrinologist.
Coverage Duration	12 months
Other Criteria	N/A

VOYDEYA

Products Affected

- Voydeya

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: confirmation of a diagnosis of paroxysmal nocturnal hemoglobinuria via flow cytometry. Renewal criteria: medical record documentation of clinical benefit, such as increase in hemoglobin level from baseline.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with a hematologist or an oncologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

VPRIV

Products Affected

- Vpriv

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) Diagnosis confirmed by one of the following: a) biochemical assay of glucocerebrosidase activity in WBCs or skin fibroblasts is less than or equal to 30% of normal activity, b) genotyping revealing 2 pathogenic mutations of the glucocerebrosidase gene. 2) Severity of disease results in one or more of the following conditions: a) moderate to severe anemia, b) thrombocytopenia with bleeding tendency, c) bone disease, d) significant hepatomegaly or splenomegaly. 3) Objective, measurable treatment goals are provided. Renewal: 1) Medical record documentation of stabilization of disease progression, such as a) improvement in hematologic markers, such as increased hgb/hct and/or platelet counts, b) reduction in spleen or liver volume, c) reduction in biochemical markers, such as chitotrisidase, ACE, acid phosphatase tartrate resistant (TRAP), d) reduction in skeletal markers, such as DEXA scan, bone pain, bone age (for patient age 14 years or less).
Age Restrictions	Age 4 years and older
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Dosing consistent with product label: 60 units/kg every other week. Range 15-60 units/kg.

VYNDAQEL

Products Affected

- Vyndamax
- Vyndaqel

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation confirming the diagnosis of either wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTRwt-CM or hATTR-CM).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist.
Coverage Duration	Lifetime
Other Criteria	N/A

WAINUA

Products Affected

- Wainua

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: medical record documentation of genetic mutation in the TTR gene and Stage 1 or 2 familial amyloid polyneuropathy (FAP). Renewal: documentation of improvement in pain or functioning.
Age Restrictions	Age at least 18 years old.
Prescriber Restrictions	Prescribed by or in consultation with a neurologist.
Coverage Duration	Initial: 6 months. Renewal: Lifetime.
Other Criteria	N/A

WAKIX

Products Affected

- Wakix

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Renewal criteria: medical record documentation of a significant improvement in daytime sleepiness and functioning.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 3 months. Renewal: Lifetime.
Other Criteria	Narcolepsy, excessive daytime sleepiness (not required for narcolepsy/cataplexy): Failure of or intolerance to: 1) methylphenidate, dextroamphetamine or amphetamine/detroamphetamine, AND 2) modafinil (requires PA).

WEGOVY

Products Affected

- Wegovy

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	For reducing the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease, initial: 1) Medical record documentation of established cardiovascular disease (such as prior stroke, myocardial infarction, or peripheral arterial disease). 2) Body mass index of at least 25 kg/m2.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	Not covered for treatment of diabetes. Covered options for type 2 diabetes include Ozempic, Mounjaro, Trulicity, Victoza, Byetta and Bydureon, and Rybelsus (all require PA).

WINREVAIR

Products Affected

- Winrevair

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Documentation of WHO Group 1 pulmonary arterial hypertension diagnosed by right heart catheterization. Renewal: Documentation of clinical improvement or disease stability such as increased exercise capacity, improvement in WHO functional class, or decreased clinical worsening events.
Age Restrictions	At least 18 years of age or older.
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or cardiologist
Coverage Duration	Initial: 12 months. Renewal: Lifetime.
Other Criteria	Trial of, or contraindication to: 1) sildenafil or tadalafil and 2) bosentan, ambrisentan or macitentan. All require prior authorization.

XARELTO SUSPENSION

Products Affected

- Xarelto SUSR

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	Documentation of an inability to swallow oral tablets.

XCOPRI

Products Affected

- Xcopri

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: Failure of two of the following: carbamazepine, oxcarbazepine, phenytoin, topiramate, divalproex, felbamate, tiagabine, lamotrigine, gabapentin, zonisamide, lacosamide and levetiracetam.

XDEMZY

Products Affected

- Xdemzy

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record confirmation of blepharitis caused by demodex mites.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an optometrist or ophthalmologist.
Coverage Duration	6 weeks
Other Criteria	N/A

XELJANZ

Products Affected

- Xeljanz

- Xeljanz Xr

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) Rheumatoid arthritis (RA) initial: documentation of an inadequate response or intolerance to one or more TNF inhibitors (such as Humira, Enbrel, or Simponi). RA renewal: improved functioning and/or improvement in tender joint count and swollen joint count. 2) Psoriasis with arthropathy (PsA) initial: documentation of an inadequate response or intolerance to one or more TNF inhibitor (such as Humira, Enbrel, or Simponi). PsA renewal: improved functioning and/or improvement in tender joint count and swollen joint count. 3) Ulcerative Colitis (UC) initial: documentation of an inadequate response or intolerance to one or more TNF inhibitor (such as Humira or Simponi). UC renewal: medical record documentation of treatment response such as decrease in bloody stools per day, elimination of signs of toxicity, or clinical remission. 4) Active polyarticular course juvenile idiopathic arthritis (pcJIA) initial: documentation of an inadequate response or intolerance to one or more TNF inhibitor (such as Humira, Enbrel, or Simponi). pcJIA renewal: improved functioning and/or improvement in tender joint count and swollen joint count. 5) Ankylosing spondylitis (AS) initial: documentation of an inadequate response or intolerance to one or more TNF inhibitor (such as Humira, Enbrel, or Simponi). AS renewal: improvement in functioning and/or improvement in signs and symptoms of AS.
Age Restrictions	N/A
Prescriber Restrictions	Psoriatic arthritis: dermatologist or rheumatologist. Rheumatoid arthritis, juvenile idiopathic arthritis and ankylosing spondylitis: rheumatologist. Ulcerative colitis: gastroenterologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.

Other Criteria	Rheumatoid arthritis initial: failure of one of the following: methotrexate, leflunomide, sulfasalazine, or hydroxychloroquine. AS initial: failure of one oral nonsteroidal anti-inflammatory drug such as meloxicam, ibuprofen, naproxen or diclofenac. pcJIA initial: failure of an 8 week trial of methotrexate. For oral solution only: documentation of an inability to swallow solid oral dosage forms, or documentation that the tablets are not indicated for the member's age.
-----------------------	--

XENLETA

Products Affected

- Xenleta

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of culture and susceptibility of pathogen.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an infectious disease specialist.
Coverage Duration	MRSA: 10 days. Non-MRSA: 5 days.
Other Criteria	Documentation of allergy to, drug interaction to or drug resistance to two of the following: 1) linezolid and 2) moxifloxacin or levofloxacin.

XERMELO

Products Affected

- Xermelo

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial Criteria: 1) Carcinoid syndrome with 4 or more daily bowel movements despite the use of a somatostatin analog such as octreotide for at least 3 months and 2) concurrent use of a somatostatin analog. Renewal Criteria: Documentation of clinical response to therapy defined as a reduction from baseline in bowel movement frequency.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 3 months. Renewal: 12 months.
Other Criteria	N/A

XGEVA

Products Affected

- Xgeva

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Preexisting hypocalcemia and pregnancy.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	1) For bone metastasis associated with solid tumors and prevention of skeletal related events in patients with multiple myeloma: documentation of failure of zoledronic acid or there is a contraindication to zoledronic acid that is not a contraindication to denosumab. 2) For the treatment of hypercalcemia of malignancy: failure of one IV bisphosphonate including zoledronic acid or pamidronate.

XOLAIR

Products Affected

- Xolair

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	1) For the treatment of allergic asthma: Initial: a) Positive skin prick test or in-vitro specific IgE test (such as RAST, MAST, FAST, ELISA) to one or more perennial allergens, b) Total serum IgE of 30 -1,300 IU/mL for pediatric patients age 6-12 or 30 -700 IU/ml for age 12 and above, c) Documentation supporting poor asthma control such as multiple asthma exacerbations resulting in repeated uses of health care services including urgent care, ED visits or hospitalizations and/or limitation in activities of daily living. Renewal: Documentation of a reduction in asthma exacerbations and frequency of office visits, ED or urgent care visits, hospitalizations and in the use/need for oral steroids and sustained clinical improvement from baseline. 2) For the treatment of chronic idiopathic urticaria: Initial: medical record documentation of urticaria for 6 weeks or longer. Renewal: documentation of clinical response to Xolair. 3) For the treatment of nasal polyps: Initial: a) documentation that Xolair is being used as add-on therapy, and b) documentation of an inadequate response to nasal corticosteroids. Renewal: Documentation of clinical benefit from Xolair. 4) For the treatment of IgE-mediated food allergy: initial: medical documentation of: a) IgE-mediate food allergy, b) allergic reaction to one more foods, and c) that Xolair will be used in conjunction with food allergen avoidance. Renewal: That Xolair continues to be used in conjunction with food allergen avoidance.
Age Restrictions	For chronic idiopathic urticaria: age at least 12 years. For allergic asthma, age at least 6 years.
Prescriber Restrictions	For allergic asthma: Pulmonologist or Immunologist. For chronic idiopathic urticaria: Allergist, Immunologist or Dermatologist. For IgE-mediated food allergy: Allergist or Immunologist.
Coverage Duration	Initial, all: 12 weeks. Renewal: asthma, nasal polyps, IgE allergy: 6 months. Urticaria: lifetime.

Other Criteria	<p>1) For the treatment of allergic asthma: failure of, intolerance to or contraindication to a high-dose inhaled corticosteroid and a long-acting beta agonist. 2) For the treatment of chronic idiopathic urticaria: failure of, intolerance to or contraindication to two formulary antihistamines for at least two weeks (failure defined as continued hives and itching). Formulary antihistamines include levocetirizine and desloratadine.</p>
-----------------------	---

XOLREMDI

Products Affected

- Xolremdi

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) medical record documentation of a diagnosis of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, confirmed by molecular genetic testing or a bone marrow biopsy. 2) baseline absolute neutrophil count and absolute lymphocyte count. Renewal: medical record documentation of an increase in absolute neutrophil count and absolute lymphocyte count from baseline.
Age Restrictions	12 years of age or older
Prescriber Restrictions	Prescribed by or in consultation with a hematologist, immunologist or dermatologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months
Other Criteria	N/A

XROMI

Products Affected

- Xromi

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of sickle cell anemia with crisis.
Age Restrictions	Age of at least 12 years.
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	For patients age 18 years and older: documentation of an inability to swallow solid oral dosage forms.

XURIDEN

Products Affected

- Xuriden

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Genetic testing indicating a deficiency in uridine 5'-monophosphate (UMP) synthase or above normal urine concentration of orotic acid. Renewal: evidence of hematologic improvements.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation of a endocrinologist or a metabolic specialist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

XYREM

Products Affected

- Sodium Oxybate

- Xyrem

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	1) Succinic semialdehyde dehydrogenase deficiency. 2) Concurrent treatment with sedative hypnotics.
Required Medical Information	Renewal criteria: medical record documentation of a significant improvement in daytime sleepiness and functioning.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 3 months. Renewal: Lifetime.
Other Criteria	Narcolepsy, excessive daytime sleepiness (not required for narcolepsy/cataplexy): Failure 1) modafinil and 2) one of the following: methylphenidate, amphetamine-dextroamphetamine, or dextroamphetamine.

XYWAV

Products Affected

- Xywav

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Renewal: Medical record documentation of a significant improvement in daytime sleepiness and functioning.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 3 months. Renewal: Lifetime.
Other Criteria	Narcolepsy, excessive daytime sleepiness (not required for narcolepsy/cataplexy or idiopathic hypersomnia): Failure of or intolerance to: 1) methylphenidate, dextroamphetamine or amphetamine/dextroamphetamine, AND 2) modafinil (requires PA).

YORVIPATH

Products Affected

- Yorvipath

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial criteria: Prior to initiation of therapy, 25-hydroxyvitamin D stores is within normal range and serum calcium (albumin adjusted) greater than or equal to 7.8 mg/dL. Renewal criteria: maintenance of serum calcium (albumin-corrected) concentration in the low-normal range.
Age Restrictions	Age at least 18 years
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist or nephrologist
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	N/A

ZAVESCA

Products Affected

- Miglustat

- Yargesa

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record documentation of 1) Diagnostic conformation by biochemical assay of decreased glucocerebrosidase activity in WBCs or skin fibroblasts, or genotyping revealing two pathogenic mutations of the glucocerebrosidase gene, and 2) Hgb at least 9g/dL and platelet at least 50 x109/L, and 3) Patient is unable to use enzyme replacement therapy due to allergy or poor venous access. Renewal: Medical record documentation of stabilization of disease progression such as 1) Improvement in hematologic markers such as increased Hgb/Hct and/or platelet counts or 2) Reduction in spleen or liver volume, or biochemical markers, such as chitotrisidase, ACE, acid phosphatase tartrate resistant (TRAP), or skeletal markers, such as DEXA scan, bone pain.
Age Restrictions	Age at least 18 years.
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	Dosing consistent with product label: 100mg up to three times a day.

ZEMAIRA/PROLASTIN

Products Affected

- Prolastin-c
- Zemaira

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) documented ZZ or Z/null AAT deficiency and 2) AAT serum level less than or equal to 11 micromoles/L or 50mg/dL and 3) moderate emphysema and/or FEV1 less than 80% and 4) the provider has outlined specific, measurable treatment goals such as slowing of FEV1 decline or lack of disease progression. Renewal: documentation patient is meeting treatment goals such as slowing FEV1 decline or lack of disease progression.
Age Restrictions	N/A
Prescriber Restrictions	Pulmonologist
Coverage Duration	Initial: 3 months. Renewal: 12 months.
Other Criteria	Initial: Medical record documentation of failure of or intolerance to Aralast or reason why Aralast cannot be used.

ZEPBOUND

Products Affected

- Zepbound

PA Criteria	Criteria Details
Indications	Some FDA-approved Indications Only.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: 1) Medical record documentation of moderate to severe sleep apnea confirmed by polysomnography. 2) BMI of greater than or equal to 30kg/m2.
Age Restrictions	18 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	Lifetime.
Other Criteria	N/A

ZILBRYSQ

Products Affected

- Zilbrysq

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Initial: Medical record confirmation of a diagnosis of generalized myasthenia gravis (gMG) and anti-acetylcholine receptor (AChR) antibody positive status. Renewal: medical record documentation of a clinical response, such as improvement in function.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist.
Coverage Duration	Initial: 6 months. Renewal: 12 months.
Other Criteria	Failure of 1) pyridostigmine, and 2) an immunomodulator such as azathioprine, mycophenolate or cyclosporine.

ZINPLAVA

Products Affected

- Zinplava

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Evidence that the patient is currently using standard antibacterial drug treatment according to the FDA approved label.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 dose per 180 days
Other Criteria	N/A

ZOKINVY

Products Affected

- Zokinvy

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Medical record documentation of a diagnosis of Hutchinson-Gilford progeria syndrome (HGPS), or processing-deficient progeroid laminopathies (PLs) confirmed by genetic testing.
Age Restrictions	N/A
Prescriber Restrictions	Specialist in genetics or metabolic disorders
Coverage Duration	12 months
Other Criteria	N/A

ZONISADE

Products Affected

- Zonisade

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	The following criteria applies to members who newly start on the drug: documentation of an inability to take solid oral dosage forms.

ZTALMY

Products Affected

- Ztalmy

PA Criteria	Criteria Details
Indications	Some FDA-approved Indications Only.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	The following criteria applies to members who newly start on the drug: Medical record documentation confirming a diagnosis of cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

ZURZUVAE

Products Affected

- Zurzuvae

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Current pregnancy.
Required Medical Information	Medical record documentation of a diagnosis of postpartum depression.
Age Restrictions	At least 18 years of age or older.
Prescriber Restrictions	N/A
Coverage Duration	14 days
Other Criteria	N/A

ZYPREXA RELPREVV

Products Affected

- Zyprexa Relprevv

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	The following criteria applies to members who newly start on the drug: currently taking oral olanzapine and prescriber wishes to switch to the injection to improve compliance.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Lifetime
Other Criteria	N/A

PART B VERSUS PART D

Products Affected

- Abelcet
- Acetylcysteine SOLN
- Acyclovir Sodium INJ 50MG/ML
- Albuterol Sulfate NEBU 0.083%, 0.63MG/3ML, 1.25MG/3ML, 2.5MG/0.5ML
- Aminosyn II INJ 993MG/100ML; 1018MG/100ML; 700MG/100ML; 738MG/100ML; 500MG/100ML; 300MG/100ML; 660MG/100ML; 1000MG/100ML; 1050MG/100ML; 172MG/100ML; 270MG/100ML; 298MG/100ML; 722MG/100ML; 530MG/100ML; 400MG/100ML; 200MG/100ML; 500MG/100ML
- Aminosyn-pf 7% INJ 32.5MEQ/L; 490MG/100ML; 861MG/100ML; 370MG/100ML; 576MG/100ML; 270MG/100ML; 220MG/100ML; 534MG/100ML; 831MG/100ML; 475MG/100ML; 125MG/100ML; 300MG/100ML; 570MG/100ML; 347MG/100ML; 50MG/100ML; 360MG/100ML; 125MG/100ML; 44MG/100ML; 452MG/100ML
- Amphotericin B INJ
- Amphotericin B Liposome
- Arformoterol Tartrate
- Azathioprine INJ
- Azathioprine TABS
- Bleomycin Sulfate INJ 30UNIT
- Budesonide SUSP
- Cladribine
- Clinimix 4.25%/dextrose 10%
- Clinimix 4.25%/dextrose 5%
- Clinimix 5%/dextrose 15%
- Clinimix 5%/dextrose 20%
- Clinimix E 2.75%/dextrose 5% INJ 570MG/100ML; 316MG/100ML; 33MG/100ML; 5GM/100ML; 515MG/100ML; 132MG/100ML; 165MG/100ML; 201MG/100ML; 159MG/100ML; 51MG/100ML; 110MG/100ML; 454MG/100ML; 154MG/100ML; 261MG/100ML; 187MG/100ML; 138MG/100ML; 217MG/100ML; 112MG/100ML; 116MG/100ML; 50MG/100ML; 11MG/100ML; 160MG/100ML
- Clinimix E 4.25%/dextrose 10%
- Clinimix E 4.25%/dextrose 5%
- Clinimix E 5%/dextrose 15%
- Clinimix E 5%/dextrose 20%
- Clinisol Sf 15%
- Clinolipid
- Cromolyn Sodium NEBU
- Cyclophosphamide CAPS
- Cyclophosphamide TABS
- Cyclosporine CAPS
- Cyclosporine Modified
- Cytarabine INJ 100MG/ML, 20MG/ML
- Cytarabine Aqueous
- Depo-medrol INJ 20MG/ML
- Engerix-b
- Everolimus TABS 0.25MG, 0.5MG, 0.75MG, 1MG
- Ganciclovir INJ 500MG
- Gengraf CAPS 100MG, 25MG
- Gengraf SOLN
- Heplisav-b
- Imovax Rabies (h.d.c.v.)
- Intralipid INJ 20GM/100ML
- Ipratropium Bromide INHALATION SOLN 0.02%
- Ipratropium Bromide/albuterol Sulfate
- Jylamvo
- Levalbuterol NEBU

- Levalbuterol Hcl NEBU
0.31MG/3ML, 1.25MG/3ML
- Levalbuterol Hydrochloride
- Methylprednisolone TABS
- Methylprednisolone Sodium Succinate
- Methylprednisolone Sodiumsuccinate
INJ 40MG
- Mycophenolate Mofetil CAPS
- Mycophenolate Mofetil INJ
- Mycophenolate Mofetil SUSR
- Mycophenolate Mofetil TABS
- Mycophenolic Acid Dr
- Myhibbin
- Nutrilipid
- Ondansetron Hcl SOLN
- Ondansetron Hcl TABS 24MG
- Ondansetron Hydrochloride ORAL
SOLN
- Ondansetron Hydrochloride TABS
- Ondansetron Odt TBDP 4MG, 8MG
- Plenamine INJ 147.4MEQ/L;
2.17GM/100ML; 1.47GM/100ML;
434MG/100ML; 749MG/100ML;
1.04GM/100ML; 894MG/100ML;
749MG/100ML; 1.04GM/100ML;
1.18GM/100ML; 749MG/100ML;
1.04GM/100ML; 894MG/100ML;
592MG/100ML; 749MG/100ML;
250MG/100ML; 39MG/100ML;
960MG/100ML
- Prednisone SOLN
- Prednisone TABS 10MG, 1MG,
2.5MG, 20MG, 50MG, 5MG
- Prehevbrio
- Premasol INJ 52MEQ/L;
1760MG/100ML; 880MG/100ML;
34MEQ/L; 1760MG/100ML;
372MG/100ML; 406MG/100ML;
526MG/100ML; 492MG/100ML;
492MG/100ML; 526MG/100ML;
356MG/100ML; 356MG/100ML;
390MG/100ML; 34MG/100ML;
152MG/100ML
- Prograf PACK
- Prosol
- Pulmozyme SOLN 2.5MG/2.5ML
- Rabavert
- Recombivax Hb
- Sirolimus SOLN
- Sirolimus TABS
- Solu-medrol INJ 500MG
- Tacrolimus CAPS
- Tobramycin NEBU 300MG/5ML
- Travasol INJ 52MEQ/L;
1760MG/100ML; 880MG/100ML;
34MEQ/L; 1760MG/100ML;
372MG/100ML; 406MG/100ML;
526MG/100ML; 492MG/100ML;
492MG/100ML; 526MG/100ML;
356MG/100ML; 500MG/100ML;
356MG/100ML; 390MG/100ML;
34MG/100ML; 152MG/100ML
- Trexall
- Trophamine INJ 0.54GM/100ML;
1.2GM/100ML; 0.32GM/100ML; 0; 0;
0.5GM/100ML; 0.36GM/100ML;
0.48GM/100ML; 0.82GM/100ML;
1.4GM/100ML; 1.2GM/100ML;
0.34GM/100ML; 0.48GM/100ML;
0.68GM/100ML; 0.38GM/100ML;
5MEQ/L; 0.025GM/100ML;
0.42GM/100ML; 0.2GM/100ML;
0.24GM/100ML; 0.78GM/100ML
- Vinblastine Sulfate INJ 1MG/ML
- Vincasar Pfs
- Vincristine Sulfate INJ 1MG/ML
- Xatmep

Details

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

INDEX

A

Abelcet	367	Aliqopa.....	39
Abilify Mycite	1	Alosetron.....	13
Abilify Mycite Maintenance Kit	1	Alosetron Hydrochloride	13
Abilify Mycite Starter Kit	1	Alunbrig	39
Abiraterone Acetate.....	39	Alyftrek.....	14
Abirtega.....	39	Alyq.....	285
Abraxane	39	Ambrisentan.....	15
Accutane.....	136	Aminosyn II	367
Acetylcysteine	367	Aminosyn-pf 7%.....	367
Actemra	2	Amnesteem	136
Actemra Actpen	2	Amphotericin B.....	367
Acthar	3	Amphotericin B Liposome.....	367
Acthar Hp	3	Apokyn.....	16
Actimmune	5	Apomorphine Hydrochloride	16
Acyclovir	304	Aprepitant	86
Acyclovir Sodium	367	Aqneursa	17
Adalimumab	6	Aralast	18
Adalimumab-aaty 1-pen Kit.....	6	Aralast Np	18
Adalimumab-aaty 2-pen Kit.....	6	Aranesp Albumin Free.....	96
Adalimumab-aaty 2-syringe Kit.....	6	Arcalyst.....	19
Adalimumab-aaty Cd/uc/hs Starter	6	Arexvy.....	249
Adalimumab-adbm.....	6	Arformoterol Tartrate.....	367
Adalimumab-adbm Crohns/uc/hs Starter	6	Arikayce.....	20
Adalimumab-adbm Psoriasis/uveitis Starter	6	Aristada	21
Adalimumab-adbm Starter Package For Crohns Disease/uc/hs	6	Aristada Initio	21
Adalimumab-adbm Starter Package For Psoriasis/uveitis	6	Armodafinil.....	22
Adbry.....	8	Astagraf.....	23
Adempas.....	9	Astagraf XL	23
Agamree	10	Atgam.....	131
Aimovig.....	11	Attruby	24
Akeega.....	39	Augtyro	39
Albuterol Sulfate	367	Austedo	25
Aldurazyme	12	Auvelity.....	26
Alecensa	39	Avastin	39
		Avmapki Fakzynja Co-pack	39
		Avsola	127
		Ayvakit.....	39

Azathioprine 367

B

Balversa 39

Bavencio 39

Beleodaq 39

Bendamustine Hydrochloride 39

Benlysta 27

Benznidazole 28

Besremi 39

Betaine Anhydrous 65

Bexarotene 39

Bexsero 29

Bivigam 131

Bleomycin Sulfate 367

Bonsity 296

Bortezomib 39

Bosentan 30

Bosulif 39

Botox 31

Botulinum Toxin 31

Braftovi 39

Briviact 32

Bronchitol 33

Brukinsa 39

Budesonide 367

Buphenyl 34

Buprenorphine 35

Buprenorphine Patch 35

Busulfan 39

Bydureon Bcise 101

Byetta 101

Bylvay 36

Bylvay (pellets) 36

C

Cablivi 37

Cabometyx 39

Calquence 39

Camzyos 38

Cancer Drugs 39

Caplyta 43

Caprelsa 39

Carbaglu 44

Carglumic Acid 44

Carmustine 39

Cayston 45

Cerdelga 46

Cerezyme 47

Chenodal 48

Cholbam 49

Cimzia 50

Cimzia Starter Kit 50

Cinryze 52

Citalopram 40mg 53

Citalopram Hydrobromide 53

Cladribine 367

Claravis 136

Clinimix 4.25%/dextrose 10% 367

Clinimix 4.25%/dextrose 5% 367

Clinimix 5%/dextrose 15% 367

Clinimix 5%/dextrose 20% 367

Clinimix E 2.75%/dextrose 5% 367

Clinimix E 4.25%/dextrose 10% 367

Clinimix E 4.25%/dextrose 5% 367

Clinimix E 5%/dextrose 15% 367

Clinimix E 5%/dextrose 20% 367

Clinisol Sf 15% 367

Clinolipid 367

Clobazam 54

Clofarabine 39

Cobenfy 55

Cobenfy Starter Pack 55

Colony Stimulating Factors 56

Cometriq 39

Copiktra 39

Corlanor 57

Cortrophin 3, 58

Cosentyx 59

Cosentyx Sensoready Pen 59

Cosentyx Unoready 59

Cotellic 39

Crenessity 61

Cresemba 62

Cromolyn Sodium 367

Ctexli 63

Cuvrior	64
Cyclophosphamide	367
Cyclosporine	367
Cyclosporine Modified.....	367
Cyramza	39
Cystadane	65
Cystadrops	66
Cystaran.....	66
Cysteamine	66
Cytarabine	367
Cytarabine Aqueous	367

D

Dacarbazine	39
Dactinomycin	39
Dalfampridine	67
Dalfampridine Er.....	67
Danziten	39
Darzalex	39
Darzalex Faspro	39
Dasatinib	39
Daunorubicin Hydrochloride	39
Daurismo	39
Daybue	68
Deferasirox	135
Deferiprone	135
Deflazacort	69
Dengvaxia	70
Depo-medrol	367
Diacomit.....	71
Dichlorphenamide	143
Diclofenac 3% Gel	72
Diclofenac Sodium.....	72, 73
Diclofenac Sodium Solution	73
Dificid	74
Docetaxel.....	39
Dojolvi.....	75
Doptelet.....	76
Doxorubicin Hcl.....	39
Doxorubicin Hydrochloride	39
Doxorubicin Hydrochloride Liposomal	39
Drizalma	77
Drizalma Sprinkle	77

Dronabinol	78
Droxidopa	79
Dupixent.....	80
Duvyzat	82

E

Edaravone	233
Egrifta	83
Egrifta Sv	83
Elaprase.....	84
Eligard.....	148
Elmiron	85
Eltrombopag Olamine.....	228
Emend	86
Emgality	87
Empliciti.....	39
Emsam.....	88
Emverm.....	165
Enbrel.....	89
Enbrel Mini	89
Enbrel Sureclick.....	89
Endari.....	90
Engerix-b.....	367
Enspryng	91
Entyvio	92
Entyvio Pen.....	92
Eohilia	93
Epclusa.....	266
Epidiolex	94
Eprontia.....	95
Erbitux.....	39
Eribulin Mesylate.....	39
Erivedge	39
Erleada	39
Erlotinib Hydrochloride	39
Erythropoiesis-stimulating Agents.....	96
Eslicarbazepine	98
Eslicarbazepine Acetate	98
Evenity	99
Everolimus	39, 367
Evrysdi	100
Exenatide.....	101
Exkivity.....	39

Exondys	102
Exondys 51	102

F

Fabhalta	103
Fabrazyme	104
Fasenra	105
Fasenra Pen	105
Fentanyl Citrate Oral Transmucosal	199
Ferriprox	135
Fetzima	106
Fetzima Titration Pack	106
Filspari	107
Filsuvez	108
Fingolimod	109
Fingolimod Hydrochloride	109
Fintepla	110
Firdapse	111
Firmagon	39
Flebogamma Dif	131
Fluorouracil	39
Folotylin	39
Fotivda	39
Fruzaqla	39
Fulphila	56
Fulvestrant	39
Fycompa	112
Fynetra	56

G

Galafold	113
Gamastan	131
Gammagard Liquid	131
Gammagard S/d Iga Less Than 1mcg/ml	131
Gammaked	131
Gammaplex	131
Gamunex-c	131
Ganciclovir	367
Gardasil	114
Gardasil 9	114
Gattex	115
Gavreto	39
Gefitinib	39

Gemtesa	116
Gengraf	367
Genotropin	269
Genotropin Miniquick	269
Gilenya	109
Gilotrif	39
Gomekli	39
Granisetron	117
Granisetron Hcl	117
Granisetron Hydrochloride	117
Granix	56
Grastek	197

H

Haegarda	118
Heplisav-b	367
Hetlioz	119
Hetlioz Lq	119
Humatrope	269
Humira	6
Humira Pediatric Crohns Disease Starter Pack	6
Humira Pen	6
Humira Pen-cd/uc/hs Starter	6
Humira Pen-pediatric Uc Starter Pack	6
Humira Pen-ps/uv Starter	6
Hyftor	120

I

Ibrance	39
Ibtrozi	121
Icatibant	122
Icatibant Acetate	122
Iclusig	39
Idarubicin Hcl	39
Idarubicin Hydrochloride	39
Idhifa	39
Imatinib Mesylate	39
Imbruvica	39
Imfinzi	39
Imkeldi	123
Imovax Rabies (h.d.c.v.)	367
Impavido	124
Inbrija	125

Increlex	126
Inflectra	127
Infliximab	127
Ingrezza	129
Inlyta	39
Inqovi	40
Inrebic	130
Intralipid	367
Intravenous Immune Globulin	131
Invega Hafyera	213
Invega Trinza	213
Ipratropium Bromide	367
Ipratropium Bromide/albuterol Sulfate	367
Iqirvo	134
Iron Chelator	135
Isotretinoin	136
Itovebi	40
Ivabradine Hydrochloride	57
Iwilfin	40

J

Jakafi	40
Javygtor	255
Jaypirca	40
Jevtana	40
Joenja	137
Journavx	138
Juxtapid	139
Jylamvo	367
Jynarque	140

K

Kalydeco	141
Kepivance	212
Kerendia	142
Keveyis	143
Keytruda	40
Kineret	144
Kisqali	40
Kisqali Femara 200 Dose	40
Kisqali Femara 400 Dose	40
Kisqali Femara 600 Dose	40
Korlym	145

Koselugo	40
Krazati	40
Kynmobi	146
Kynmobi Titration Kit	146
Kyprolis	40

L

Lampit	147
Lanreotide Acetate	271
Lapatinib Ditosylate	40
Lazcluze	40
Lenalidomide	40
Lenvima 10 Mg Daily Dose	40
Lenvima 12mg Daily Dose	40
Lenvima 14 Mg Daily Dose	40
Lenvima 18 Mg Daily Dose	40
Lenvima 20 Mg Daily Dose	40
Lenvima 24 Mg Daily Dose	40
Lenvima 4 Mg Daily Dose	40
Lenvima 8 Mg Daily Dose	40
Leukine	56
Leuprolide	148
Leuprolide Acetate	148
Levalbuterol	367
Levalbuterol Hcl	368
Levalbuterol Hydrochloride	368
Levetiracetam	275
Levoleucovorin	149
Levoleucovorin Calcium	149
L-glutamine	90
Libervant	150
Libtayo	40
Lidocaine	151
Lidocaine Patches	151
Liraglutide	152
Lithium	153
Lithium Solution	153
Livdelzi	154
Livmarli	155
Livtency	156
Lodoco	157
Lofexidine Hydrochloride	159
Lokelma	158

Lonsurf	40
Lorbrena	40
Lucemyra.....	159
Lumakras	40
Lumizyme	160
Lumoxiti	40
Lupkynis.....	161
Lupron Depot (1-month)	148
Lupron Depot (3-month)	148
Lupron Depot (4-month)	148
Lupron Depot (6-month)	148
Lupron Depot-ped (1-month)	148
Lupron Depot-ped (3-month)	148
Lybalvi	162
Lynparza.....	40
Lytgobi	40

M

Mavyret	163
Mayzent.....	164
Mayzent Starter Pack	164
Mebendazole	165
Mekinist.....	40
Mektovi	40
Melphalan Hydrochloride	40
Mercaptopurine	166
Mercaptopurine Suspension	166
Methitest.....	297
Methylprednisolone.....	368
Methylprednisolone Sodium Succinate.....	368
Methylprednisolone Sodiumsuccinate	368
Metyrosine.....	167
Mifepristone	145
Miglustat	357
Miplyffa.....	168
Mitomycin	40
Modafinil.....	169
Motegrity	170
Mounjaro	171
Movantik	172
Mresvia.....	249
Mulpleta	173
Multaq	174

Mutamycin	40
Myalept	175
Mycapssa.....	176
Mycophenolate Mofetil.....	368
Mycophenolic Acid Dr	368
Myfembree.....	177
Myhibbin.....	368
Mylotarg.....	40
Myorisan	136

N

Naglazyme	178
Nelarabine	40
Nemluvio.....	179
Nerlynx	180
Neulasta.....	56
Nilotinib Hydrochloride.....	40
Ninlaro	40
Nipent.....	40
Nitazoxanide	181
Nitisinone.....	201
Nityr	182
Norditropin Flexpro	269
Noxafil	183
Nubeqa	40
Nucala	184
Nuedexta	185
Nulojix	186
Nuplazid.....	187
Nurtec.....	188
Nutrilipid.....	368
Nutropin Aq Nuspin 10.....	269
Nutropin Aq Nuspin 20.....	269
Nutropin Aq Nuspin 5.....	269
Nyvepria.....	56

O

Ocaliva	189
Ocrevus	190
Ocrevus Zunovo.....	190
Octagam	131
Octreotide Acetate	253
Odactra.....	197

Odomzo	40
Ofev	229
Ogsiveo	40
Ojemda	40
Ojjaara	40
Omnipod.....	191
Omnipod 5 Dexcom G7g6 Intro Kit (gen 5).....	191
Omnipod 5 Dexcom G7g6 Pods (gen 5)	191
Omnipod 5 G7 Intro Kit (gen 5)	191
Omnipod 5 G7 Pods (gen 5).....	191
Omnipod 5 Libre2 Plus G6 Intro Gen 5.....	191
Omnipod 5 Libre2 Plus G6 Pods	191
Omnipod Classic Pdm Starter Kit (gen 3).....	191
Omnipod Classic Pods (gen 3).....	191
Omnipod Dash Intro Kit (gen 4)	191
Omnipod Dash Pdm Kit (gen 4).....	191
Omnipod Dash Pods (gen 4)	191
Omnitrope	269
Ondansetron Hcl.....	368
Ondansetron Hydrochloride	368
Ondansetron Odt	368
Onureg.....	40
Opdivo.....	40
Opfolda.....	193
Opipza	194
Opium.....	195
Opium Tincture	195
Opsumit.....	196
Oral Immunotherapy	197
Oral Ribavirin.....	198
Oral Transmucosal Fentanyl	199
Orencia	200
Orencia Clickject.....	200
Orfadin	201
Orgovyx.....	202
Oriahnn.....	203
Orilissa	204
Orkambi.....	205
Orladeyo.....	206
Orserdu.....	40
Otezla	207
Oxaliplatin.....	40
Oxbryta.....	208

Oxervate.....	209
Oxycodone Er	210
Oxycodone Hcl Er.....	210
Oxycodone Hydrochloride Er	210
Oxycontin.....	210
Ozempic	211

P

Paclitaxel Protein-bound Particles	40
Palifermin.....	212
Paliperidone Er Injection	213
Palynziq.....	214
Pamidronate Disodium.....	216
Panretin	215
Parenteral Bisphosphonates	216
Paricalcitol	217
Paroxetine Hydrochloride	218
Paroxetine Suspension	218
Part B Versus Part D	367
Pazopanib Hydrochloride.....	40
Pegasys.....	219
Pemazyre.....	40
Pemetrexed.....	40
Pemetrexed Disodium.....	40
Penbraya.....	220
Penciclovir	304
Pentamidine.....	221
Pentamidine Isethionate	221
Perampanel.....	112
Perjeta	40
Pimecrolimus	222
Piqray 200mg Daily Dose.....	40
Piqray 250mg Daily Dose.....	40
Piqray 300mg Daily Dose.....	40
Pirfenidone.....	229
Plenamine.....	368
Plerixafor.....	223
Pnv Prenatal Plus Multivitamin + Dha	225
Pomalyst.....	40
Posaconazole.....	183
Posaconazole Dr.....	183
Praluent	224
Prednisone.....	368

Prehevbrio	368
Premasol	368
Prenatal.....	225
Prenatal Vitamins	225
Pretomanid	226
Prevymis.....	227
Privigen	131
Procrit	96
Prograf.....	368
Prolastin-c	358
Proleukin	40
Promacta.....	228
Prosol.....	368
Prucalopride	170
Pulmonary Fibrosis Agents	229
Pulmozyme.....	368
Pyrukynd	230
Pyrukynd Taper Pack	230

Q

Qbrexza	231
Qinlock.....	40
Quinine Sulfate.....	232

R

Rabavert	368
Radicava	233
Radicava Ors	233
Radicava Ors Starter Kit	233
Ragwitek	197
Raldesy	234
Ravicti	235
Recombivax Hb.....	368
Regranex	236
Relistor	237
Relyvrio.....	238
Repatha.....	239
Repatha Pushtronex System	239
Repatha Sureclick.....	239
Retacrit	96
Retevmo	40
Revcovi	240
Revlimid.....	40

Revuforj	40
Reyvow	241
Rezdifra	242
Rezlidhia	40
Rezurock	243
Riabni.....	246
Ribavirin	198
Rinvoq.....	244
Rinvoq Lq	244
Rituxan.....	246
Rituximab.....	246
Rivfloza.....	247
Rolvedon	56
Romidepsin	40
Romvimza	40
Rozlytrek.....	40, 248
Rozlytrek Pellets	248
Rsv Vaccine	249
Rubraca	40
Rufinamide.....	250
Rufinamide Suspension	250
Ruxience	246
Rybelsus.....	251
Rydapt	40
Rytary.....	252

S

Saizen.....	269
Saizenprep Reconstitutionkit	269
Sajazir	122
Sandostatin Lar	253
Sandostatin Lar Depot.....	253
Saphnelo.....	254
Sapropterin.....	255
Sapropterin Dihydrochloride	255
Savella.....	256
Savella Titration Pack	256
Scemblix	40
Scopolamine.....	257
Secuado	258
Signifor	259
Siklos	260
Sildenafil	261

Sildenafil Citrate	261
Simponi	262
Simponi Aria	262
Sirolimus	368
Sirturo	263
Skyclarys	264
Skyrizi	265
Skyrizi Pen	265
Sodium Oxybate	354
Sodium Phenylbutyrate	34
Sofosbuvir/velpatasvir	266
Sohonos	267
Soltamox	268
Solu-medrol	368
Somatropins	269
Somatuline Depot	271
Somavert	272
Sorafenib	40
Sorafenib Tosylate	40
Sotylyze	273
Spravato	274
Spravato 56mg Dose	274
Spravato 84mg Dose	274
Spritam	275
Stamaril	276
Steqeyma	315
Stimufend	56
Stivarga	40
Strensiq	277
Sucraid	278
Sunitinib Malate	40
Symdeko	279
Sympazan	280
Symproic	281
Synagis	282
Synarel	284
Synribo	40

T

Tabrecta	40
Tacrolimus	368
Tadalafil	285, 286
Tadalafil Bph	286
Tadliq	287
Tafinlar	40
Tagrisso	40
Takhzyro	288
Taltz	289
Talzenna	40
Tarpeyo	290
Tasigna	40
Tasimelteon	119
Tavalisse	291
Tavneos	292
Tazarotene	293
Tazorac	293
Tazverik	40
Tecentriq	40
Tecentriq Hybreza	41
Tegsedi	294
Temsirolimus	41
Tepmetko	41
Teriflunomide	295
Teriparatide	296
Testosterone-systemic	297
Tetrabenazine	298
Tevimbra	41
Thalomid	299
Thiotepa	41
Thymoglobulin	131
Tibsovo	41
Ticovac	300
Tigecycline	301
Tirosint Solution	302
Tirosint-sol	302
Tobramycin	368
Tolvaptan	303
Topical Antivirals	304
Toremifene Citrate	41
Tracleer	30
Travasol	368
Trelstar Mixject	41
Treprostinil	305
Tretinoin	41
Trexall	368
Trikafta	306

Trintellix.....	307
Trophamine	368
Trulicity.....	308
Trumenba	309
Truqap	41
Truseltiq	41
Truxima	246
Tryngolza	310
Tryvio.....	311
Tukysa	41
Turalio	41
Tymlos.....	312
Tysabri.....	313

U

Ubrelvy.....	314
Udenyca.....	56
Udenyca Onbody.....	56
Ustekinumab	315
Uzedy	316

V

Valchlor.....	41
Vanflyta.....	41
Varizig.....	317
Vaxchora	318
Vectibix	41
Veltassa	319
Venclexta.....	41
Venclexta Starting Pack	41
Ventavis.....	320
Veozah.....	321
Verkazia	322
Verquvo	323
Versacloz.....	324
Verzenio	41
Vesicare Ls.....	325
Viberzi.....	326
Vigabatrin.....	327
Vigadrone	327
Vigafyde.....	327
Vigpoder.....	327
Viibryd	328

Viibryd Starter Pack.....	328
Vijoice.....	329
Vilazodone Hydrochloride.....	328
Vinblastine Sulfate.....	368
Vincasar Pfs	368
Vincristine Sulfate	368
Vitrakvi	41
Vizimpro	41
Vonjo.....	41
Voranigo	41
Voriconazole.....	330
Vosevi	331
Vowst.....	332
Voxzogo.....	333
Voydeya	334
Vpriv	335
Vyndamax.....	336
Vyndaqel.....	336
Vyxeos	41

W

Wainua	337
Wakix	338
Wegovy.....	339
Welireg.....	41
Wezlana.....	315
Winrevair	340

X

Xalkori	41
Xarelto.....	341
Xarelto Suspension	341
Xatmep.....	368
Xcopri	342
Xdemvy.....	343
Xeljanz	344
Xeljanz Xr.....	344
Xenleta	346
Xeomin.....	31
Xermelo.....	347
Xgeva	348
Xolair	349
Xolremdi	351

Xospata.....	41
Xpovio.....	41
Xpovio 60 Mg Twice Weekly.....	41
Xpovio 80 Mg Twice Weekly.....	41
Xromi	352
Xtandi.....	41
Xuriden.....	353
Xyrem.....	354
Xywav	355

Y

Yargesa.....	357
Yervoy.....	41
Yondelis	41
Yonsa.....	41
Yorvipath.....	356

Z

Zaltrap	41
Zanosar	41
Zarxio	56

Zavesca	357
Zejula	41
Zelboraf.....	41
Zemaira	358
Zemaira/prolastin	358
Zenatane.....	136
Zepbound	359
Ziextenzo.....	56
Zilbrysq.....	360
Zinplava	361
Zokinvy	362
Zoledronic Acid	216
Zolinza	41
Zonisade.....	363
Zorbtive.....	269
Ztalmy	364
Zurzuvae	365
Zydelig	41
Zykadia	41
Zyprexa Relprevv.....	366